Athenex, Inc. (Form: 10-Q, Received: 05/09/2019 08:40:40)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Small reporting company

Emerging growth company

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38112

ATHENEX, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	43-1985966
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1001 Main Street, Suite 600 Buffalo, NY	14203
(Address of principal executive offices)	(Zip Code)

(716) 427-2950

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ATNX		The Nasdaq Global Select Market

As of May 1, 2019, the registrant had 67,065,698 shares of common stock, $0.001 par value per share, outstanding.

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements	1
	Condensed Consolidated Balance Sheets (Unaudited)	1
	Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	2
	Condensed Consolidated Statement of Stockholders’ Equity (Unaudited)	3
	Condensed Consolidated Statements of Cash Flows (Unaudited)	4
	Notes to Condensed Consolidated Financial Statements (Unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32
Item 4.	Controls and Procedures	33
PART II.	OTHER INFORMATION	34
Item 1.	Legal Proceedings	34
Item 1A.	Risk Factors	34
Item 6.	Exhibits	35
Signatures		36

PART I—FINANCI AL INFORMATION

Item 1. Condensed Consolidated Financial Statements.

ATHENEX, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(unaudited)

(In thousands, except share and per share data)

	March 31,			December 31,
	2019			2018
Assets
Current assets:
Cash and cash equivalents	$	71,003		$	49,794
Short-term investments		341			57,629
Accounts receivable, net of chargebacks and other deductions of $10,448 and $13,101, respectively, and allowance for doubtful accounts of $8 and $9, respectively		20,576			12,951
Inventories		25,191			28,787
Prepaid expenses and other current assets		33,569			21,658
Total current assets		150,680			170,819
Property and equipment, net		12,249			11,447
Goodwill		37,589			37,495
Intangible assets, net		10,361			10,848
Operating lease right-of-use assets, net		9,428			—
Deferred income tax assets		—			486
Total assets	$	220,307		$	231,095
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	20,389		$	12,997
Accrued expenses		42,571			37,718
Current portion of operating lease liabilities		3,067			—
Current portion of long-term debt		1,720			961
Total current liabilities		67,747			51,676
Long-term liabilities:
Deferred compensation		2,605			2,825
Deferred rent		—			2,022
Long-term operating lease liabilities		8,362			—
Long-term debt and finance lease obligations		46,012			45,803
Total liabilities		124,726			102,326
Commitments and contingencies (See Note 15)
Stockholders' equity:
Common stock, par value $0.001 per share, 250,000,000 shares authorized at March 31, 2019 and December 31, 2018; 68,718,618 and 68,668,986 shares issued at March 31, 2019 and December 31, 2018, respectively; 67,045,698 and 66,996,066 shares outstanding at March 31, 2019 and December 31, 2018, respectively		69			69
Additional paid-in capital		593,035			591,064
Accumulated other comprehensive income (loss)		415			(656	)
Accumulated deficit		(478,949	)		(443,716	)
Less: treasury stock, at cost; 1,672,920 shares at March 31, 2019 and December 31, 2018		(7,406	)		(7,406	)
Total Athenex, Inc. stockholders' equity		107,164			139,355
Non-controlling interests		(11,583	)		(10,586	)
Total stockholders' equity		95,581			128,769
Total liabilities and stockholders' equity	$	220,307		$	231,095

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATHENEX, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(In thousands, except share and per share data)

	Three Months Ended March 31,
	2019			2018
Revenue:
Product sales, net	$	25,163		$	12,605
License fees and consulting revenue		105			25,091
Grant revenue		39			140
Total revenue		25,307			37,836
Costs and operating expenses:
Cost of sales		19,902			11,326
Research and development expenses		24,475			21,303
Selling, general, and administrative expenses		15,188			13,080
Total costs and operating expenses		59,565			45,709
Operating loss		(34,258	)		(7,873	)
Interest expense (income)		1,472			(227	)
Loss before income tax expense (benefit)		(35,730	)		(7,646	)
Income tax expense (benefit)		500			(307	)
Net loss		(36,230	)		(7,339	)
Less: net loss attributable to non-controlling interests		(997	)		(41	)
Net loss attributable to Athenex, Inc.	$	(35,233	)	$	(7,298	)
Unrealized gain (loss) on investment, net of income taxes		3			(35	)
Foreign currency translation adjustment, net of income taxes		1,068			718
Comprehensive loss	$	(34,162	)	$	(6,615	)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (See Note 12)	$	(0.53	)	$	(0.12	)
Weighted-average shares used in computing net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (See Note 12)		67,011,432			61,655,294

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATHENEX, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(In thousands, except share data)

	Common Stock				Additional					Accumulated other			Treasury Stock						Total Athenex, Inc.			Non-			Total
	Shares		Amount		paid-in capital		Accumulated deficit			comprehensive income (loss)			Shares			Amount			stockholders' equity			controlling interests			stockholders' equity
Balance at January 1, 2018		59,894,362	$	60	$	423,805	$	(326,276	)	$	(146	)		(1,672,920	)	$	(7,406	)	$	90,037		$	685		$	90,722
Sale of common stock, net of costs and discounts of $4,611		4,765,000		4		68,051		—			—			—			—			68,055			—			68,055
Stock-based compensation cost		—		—		2,161		—			—			—			—			2,161			—			2,161
Restricted stock expense		—		—		540		—			—			—			—			540			—			540
Stock options and warrants exercised		289,487		1		1,262		—			—			—			—			1,263			—			1,263
Net loss		—		—		—		(7,298	)		—			—			—			(7,298	)		(41	)		(7,339	)
Other comprehensive income, net of tax		—		—		—		—			683			—			—			683			—			683
Balance at March 31, 2018 (unaudited)		64,948,849	$	65	$	495,819	$	(333,574	)	$	537			(1,672,920	)	$	(7,406	)	$	155,441		$	644		$	156,085

	Common Stock				Additional					Accumulated other			Treasury Stock						Total Athenex, Inc.			Non-			Total
	Shares		Amount		paid-in capital		Accumulated deficit			comprehensive income (loss)			Shares			Amount			stockholders' equity			controlling interests			stockholders' equity
Balance at January 1, 2019		68,668,986	$	69	$	591,064	$	(443,716	)	$	(656	)		(1,672,920	)	$	(7,406	)	$	139,355		$	(10,586	)	$	128,769
Stock-based compensation cost		—		—		1,693		—			—			—			—			1,693			—			1,693
Stock options and warrants exercised		49,632		—		278		—			—			—			—			278			—			278
Net loss		—		—		—		(35,233	)		—			—			—			(35,233	)		(997	)		(36,230	)
Other comprehensive income, net of tax		—		—		—		—			1,071			—			—			1,071			—			1,071
Balance at March 31, 2019 (unaudited)		68,718,618	$	69	$	593,035	$	(478,949	)	$	415			(1,672,920	)	$	(7,406	)	$	107,164		$	(11,583	)	$	95,581

The accompanying notes are an integral part of these condensed consolidated financial statements.

ATHENEX, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(unaudited)

(In thousands)

	Three Months Ended March 31,
	2019			2018
Cash flows from operating activities:
Net loss	$	(36,230	)	$	(7,339	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		879			868
Stock-based compensation expense		1,778			2,701
Amortization of debt discount		257			—
Deferred rent expense		—			168
Gain on disposal of assets		—			(62	)
Deferred income taxes		486			(321	)
Changes in operating assets and liabilities:
Receivables, net		(7,624	)		623
Prepaid expenses and other assets		(11,911	)		494
Inventories		3,596			(2,010	)
Accounts payable and accrued expenses		15,798			(7,848	)
Net cash used in operating activities		(32,971	)		(12,726	)
Cash flows from investing activities:
Purchase of property and equipment		(918	)		(1,177	)
Payments for licenses		(4,175	)		—
Purchases of short-term investments		—			(67,256	)
Sale of short-term investments		57,291			11,633
Net cash provided by (used in) investing activities		52,198			(56,800	)
Cash flows from financing activities:
Proceeds from sale of stock		—			72,666
Proceeds from issuance of debt		743			—
Costs incurred related to the sale of stock		—			(4,611	)
Proceeds from exercise of stock options		278			1,263
Repayment of finance lease obligations and long-term debt		(45	)		(337	)
Net cash provided by financing activities		976			68,981
Net increase (decrease) in cash and cash equivalents		20,203			(545	)
Cash and cash equivalents, beginning of period		49,794			39,284
Effect of exchange rate changes on cash and cash equivalents		1,006			478
Cash and cash equivalents, end of period	$	71,003		$	39,217
Supplemental cash flow disclosures
Interest paid	$	981		$	13
Non-cash investing and financing activities:
Accrued purchases of property and equipment	$	634		$	104
Right-of-use assets recognized in exchange for new operating lease obligations	$	583		$	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

Athenex, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (Unaudited)

1. Company and Nature of Business

Organization and Description of Business

Athenex, Inc. and subsidiaries (the “Company” or “Athenex”), originally under the name Kinex Pharmaceuticals LLC (“Kinex”), formed in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015.

Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The Company’s current clinical pipeline is derived from Orascovery, Src Kinase Inhibition, T-cell receptor-engineered T-cells (TCR-T), and Arginine deprivation therapy research platforms. The Company has assembled a leadership team and has established global operations in the U.S. and China across the pharmaceutical value chain to execute its mission to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. The Company’s primary activities since commencement have been conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, and conducting clinical trials. The Company also conducts commercial sales of specialty products through its wholly-owned subsidiary, Athenex Pharmaceutical Division (APD), under its Commercial Platform.

Follow-On Offering

In January 2018, the Company completed an underwritten public follow-on offering of 4,300,000 shares of its common stock. The Company granted the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock. In February 2018, the underwriters partially exercised their option, purchasing an additional 465,000 shares of common stock. All shares were offered by the Company at a price of $15.25 per share. Net proceeds were $68.1 million, after deducting underwriting discounts and commissions and offering expenses of $4.6 million.

Debt and Equity Offering

On July 3, 2018, the Company closed a privately placed debt and equity financing deal with Perceptive Advisors LLC and its affiliates (“Perceptive”) for gross proceeds of $100.0 million and received aggregate net proceeds of $97.1 million, net of fees and offering expenses. The Company entered into a 5-year senior secured loan for $50.0 million of this financing and issued 2,679,528 shares of its common stock at a purchase price of $18.66 per share for the remaining $50.0 million. The loan matures on the fifth anniversary from the closing date and bears interest at a floating per annum rate equal to London Interbank Offering Rates (“LIBOR”) (with a floor of 2.0%) plus 9.0%. The Company is required to make monthly interest-only payments with a bullet payment of the principal at maturity. The loan agreement contains specified financial maintenance covenants. In connection with the loan agreement, the Company granted Perceptive a warrant for the purchase of 425,000 shares of common stock at a purchase price of $18.66 per share. This was accounted for as a detachable warrant at its fair value and is recorded as an increase to additional paid-in-capital on the condensed consolidated statement of stockholders’ equity.

Significant Risks and Uncertainties

The Company has incurred operating losses since its inception and, as a result, as of March 31, 2019 and December 31, 2018 had an accumulated deficit of $478.9 million and $443.7 million, respectively. Operations have been funded primarily through the sale of common stock and, to a lesser extent, from convertible bond financing, senior secured loan, revenue, and grant funding. The Company will require significant additional funds to conduct clinical trials and to fund its operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company may be required to delay, modify, or terminate its research and development programs or reduce its planned commercialization efforts. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations, including additional public offerings; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans and might delay, modify, or terminate its research and development programs or reduce its planned commercialization efforts. Accordingly, there is substantial doubt regarding the Company’s ability to continue as a going concern.

These condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of the business. The Company’s recurring losses from operations and negative cash flows from operations have raised substantial doubt regarding its ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

The Company has a senior secured loan agreement which contains various covenants. A breach of any of these covenants could result in a default. If a default under this loan agreement is not cured or waived, the default could result in the acceleration of debt, which could require us to repurchase or repay the debt in full prior to the date it is otherwise due. If we default, the lender may seek repayment through our subsidiary guarantors or by executing on the security interest granted pursuant to the loan agreement.

Athenex is subject to a number of risks similar to other biopharmaceutical companies, including, but not limited to, the lack of available capital, possible failure of preclinical testing or clinical trials, inability to obtain marketing approval of product candidates, competitors developing new technological innovations, unsuccessful commercialization strategy and launch plans for our proprietary drug candidates, market acceptance of the Company’s products, and protection of proprietary technology. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate sufficient product revenue and might not, if ever, achieve profitability and positive cash flow.

2.	Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments ) considered necessary for a fair presentation of the results of the Company for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been fully eliminated in consolidation.

Results of the operations for the three months ended March 31, 2019 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission (“SEC”) on March 11, 2019.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, allowance for doubtful accounts, inventory reserves, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates.

Leases

The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, the Company will evaluate whether to account for the lease as either an operating or financing lease. Operating leases are included in right-of-use assets (“ROU assets”) and operating lease liabilities on the condensed consolidated balance sheet as of March 31, 2019. The Company’s finance leases are included in property and equipment, net and long-term debt and finance lease obligations on the condensed consolidated balance sheet. A majority of the Company’s operating leases are for real estate properties used in operations located in the U.S. and Asia. The Company’s finance leases are for manufacturing equipment in the U.S.

ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the operating lease liabilities as the Company’s leases generally do not provide an implicit r ate. The Company uses the stated rate per each lease agreement in determining the finance lease liabilities. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. Lease expense f or operating leases is recognized on a straight-line basis over the lease term.

The Company elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term leases.

Concentration of Credit Risk, Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and invests in highly liquid U.S. treasury notes, commercial paper and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility in China, and therefore is subject to foreign currency fluctuation.

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, " Leases (Topic 842), " which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use model that requires a lessee to recognize a ROU asset representing the right to use the underlying asset over the lease term and lease liability on the balance sheet for all leases with a term longer than 12 months. Lease obligations are to be measured at the present value of lease payments and accounted for using the effective interest method. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. For finance leases, the leased asset is depreciated on a straight-line basis and recorded separately from the interest expense in the income statement resulting in higher expense in the earlier part of the lease term. For operating leases, the depreciation and interest expense components are combined, recognized evenly over the term of the lease, and presented as a reduction to operating income. The ASU requires that assets and liabilities be presented or disclosed separately and classified appropriately as current and noncurrent. The ASU further requires additional disclosure of certain qualitative and quantitative information related to lease agreements. In July 2018, the FASB issued new guidance that provided for a new optional transition method that allows entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to opening retained earnings. Under this approach, comparative periods are not restated.

The Company adopted the new lease standard on January 1, 2019 and used the effective date as our date of initial application. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company (1) to not reassess whether any expired or existing contracts are or contain leases, (2) to not reassess the lease classification for any expired or existing leases, and (3) to not reassess initial direct costs for any existing leases. The Company also elected the single component practical expedient, which requires the Company, by class of underlying asset, not to allocate the total consideration to the lease and nonlease components based on their relative stand-alone selling prices. This single component practical expedient requires the Company to account for the lease component and nonlease component(s) associated with that lease as a single component if (i) the timing and pattern of transfer of the lease component and the nonlease component(s) associated with it are the same and (ii) the lease component would be classified as an operating lease if it were accounted for separately. In preparation for adoption of the standard, the Company implemented internal controls to enable the preparation of financial information. The standard had a material impact on our consolidated balance sheet, with no material impact on our consolidated statement of operations and comprehensive loss. On the adoption date, the Company recognized $9.8 million of operating lease ROU assets, $11.9 million of operating lease liabilities, and derecognized its existing deferred rent balance of $2.1 million.

In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ,” which expands the scope of Topic 718, “ Compensation – Stock Compensation ,” which only included share-based payments to employees, to include share-based payments issued to nonemployees for goods and services. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company will only need to remeasure liability-classified awards that have not yet been settled as of the date of adoption, and equity-classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted this standard on January 1, 2019 and the adoption of this ASU did not impact the Company’s condensed consolidated financial statements.

3. Inventories

Inventories consist of the following (in thousands):

	March 31, 2019		December 31, 2018
Raw materials and purchased parts	$	3,962	$	4,092
Work in progress		3,174		3,166
Finished goods		18,055		21,529
Total inventories	$	25,191	$	28,787

4. Intangible Assets, net

The Company’s identifiable intangible assets, net, consist of the following (in thousands):

	March 31, 2019
	Cost/Fair Value			Accumulated Amortization		Impairments		Net
Amortizable intangible assets:
Licenses	$	8,935		$	2,432	$	—	$	6,503
Polymed customer list		1,593			974		—		619
Polymed technology		3,712			1,125		—		2,587
Product rights		530			295		—		235
Indefinite-lived intangible assets:
CDE in-process research and development (IPR&D)		728			—		—		728
Effect of currency translation adjustment		(311	)		—		—		(311	)
Total intangible assets, net	$	15,187		$	4,826	$	—	$	10,361

	December 31, 2018
	Cost/Fair Value			Accumulated Amortization		Impairments		Net
Amortizable intangible assets
Licenses	$	8,935		$	2,060	$	—	$	6,875
Polymed customer list		1,593			938		—		655
Polymed technology		3,712			999		—		2,713
Product rights		530			263		—		267
Indefinite-lived intangible assets:
CDE in-process research and development (IPR&D)		1,026			—		298		728
Effect of currency translation adjustment		(390	)		—		—		(390	)
Total intangibles, net	$	15,406		$	4,260	$	298	$	10,848

As of March 31, 2019, licenses at cost include an Orascovery license of $0.4 million and licenses purchased from Gland Pharma Limited (“Gland”) of $4.3 million, and a license purchased from MAIA Pharmaceuticals, Inc. (“MAIA”) for $4.0 million. The Orascovery license with Hanmi Pharmaceuticals Co. Ltd. (“Hanmi”) was purchased directly from Hanmi and is being amortized on a straight-line basis over a period of 12.75 years, the remaining life of the license agreement at the time of purchase. The licenses purchased from Gland are being amortized on a straight-line basis over a period of 5 years, the remaining life of the license agreement at the time of purchase. The license purchased from MAIA is being amortized over a period of 7 years, the remaining life of the license agreement at the time of purchase.

The remaining intangible assets were acquired in connection with the acquisitions of Athenex Pharma Solutions (“APS” or “Athenex Pharma Solutions,” and formerly known as QuaDPharma), Polymed Therapeutics, Inc. (“Polymed”), and Comprehensive Drug Enterprises (“CDE”). Intangible assets are amortized using an economic consumption model over their useful lives. The APS customer list was being amortized on a straight-line basis over 7 years. The Polymed customer list and technology are amortized on a straight-line basis over 6 and 12 years, respectively. The CDE in-process research and development, (“IPR&D”), will not be amortized until the related projects are completed. IPR&D will be tested annually for impairment, unless conditions exist causing an earlier impairment test (e.g., abandonment of project). No impairment charges were recorded during the three months ended March 31, 2019. The weighted-average useful life for all intangible assets was 7.58 years as of March 31, 2019.

The Company recorded $ 0.5 million and $0.4 million of amortization expense for the three months ended March 31, 2019 and 201 8, respectively.

5. Fair Value Measurements

Financial instruments consist of cash and cash equivalents, short-term investments, an equity investment, accounts receivable, accounts payable, accrued liabilities, and debt. Short-term investments and the equity investment are stated at fair value. Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts.

ASC 820, Fair Value Measurements , establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under the ASC 820 are described as follows:

Level 1 —Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

Level 2 —Inputs to the valuation methodology include:

•

Quoted prices for similar assets or liabilities in active markets;

•

Quoted prices for identical or similar assets or liabilities in inactive markets;

•

Inputs other than quoted prices that are observable for the asset or liability;

•

Inputs that are derived principally from or corroborated by observable market data by correlation or other means; and

•

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 —Inputs to the valuation methodology are unobservable, supported by little or no market activity, and are significant to the fair value measurement.

Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 for any of the periods presented.

The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands):

	Fair Value Measurements at March 31, 2019 Using:
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale investment	$	341	$	341	$	—	$	—
Total assets	$	341	$	341	$	—	$	—

	Fair Value Measurements at December 31, 2018 Using:
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Financial assets included within cash and cash equivalents
Money market funds	$	25	$	25	$	—	$	—
Short-term investments - commercial paper		5,396		—		5,396		—
Financial assets included within short-term investments
Short-term investments - commercial paper		36,544		—		36,544		—
Short-term investments - corporate notes		16,699		—		16,699		—
Short-term investments - U.S. government bonds		3,998		—		3,998		—
Available-for-sale investment		388		388		—		—
Total assets	$	63,050	$	413	$	62,637	$	—

The Company classifies its money market funds within Level 1 because it uses quoted market prices to determine their fair value. The Company classifies its commercial paper, corporate notes, and U.S. government bonds within Level 2 because it uses quoted prices for similar assets or liabilities in active markets and each has a specified term and all Level 2 inputs are observable for substantially the full term of each instrument.

The Company owns 68,000 shares of PharmaEssentia, a company publicly traded on the Taiwan OTC Exchange. As of March 31, 2019 and December 31, 2018, the Company’s investment in PharmaEssentia was valued at the reported closing price. This investment is classified as a Level 1 investment.

6. Asset Acquisition

On June 29, 2018, the Company entered into a Share Subscription Agreement (“SSA”) for Axis Therapeutics (“Axis”), a subsidiary of the Company jointly owned by Athenex and Xiangxue Life Sciences Limited (“XLifeSc”). Under the SSA, Athenex contributed $30.0 million cash for a 55% ownership interest in Axis and XLifeSc contributed a license for IPR&D of certain immunotherapy technology for a 45% ownership interest in Axis. Also, on June 29, 2018, through a license agreement entered into between XLifeSc and Axis, XLifeSc granted Axis an exclusive, sublicensable worldwide (excluding mainland China) right and license to use its proprietary TCR-engineered T Cell therapy to develop and commercialize products for oncology indications (“TCR-T License”). Upon effectiveness of the TCR-T License and satisfaction of certain conditions of the license agreement, the Company issued 267,952 shares of its common stock equal to $5.0 million to XLifeSc as an upfront payment by Axis. On September 14, 2018, Athenex completed the $30.0 million cash injection to Axis and all the closing conditions under the SSA were fulfilled.

The Company has consolidated the financial statements of Axis into its condensed consolidated financial statements as of and for the three months ended March 31, 2019 and as of and for the year ended December 31, 2018 using the voting interest model. The nonmonetary exchange of 45% of the shares of Axis for the IPR&D from XLife has been accounted for as an asset acquisition that does not constitute a business under ASC 805. Therefore, the acquisition of IPR&D was expensed as research and development expense at its fair value. The Company determined that the fair value of the equity issued to XLifeSc was $24.5 million, considering the $30.0 million contribution made by the Company for its 55% ownership interest and the arms-length nature of the transaction. Accordingly, the Company recorded an expense of $24.5 million within research and development expenses on its consolidated statements of operations and comprehensive loss for the year ended December 31, 2018.

7. Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31,		December 31,
	2019		2018
Accrued wages and benefits	$	6,508	$	5,061
Accrued clinical expenses		1,888		2,653
Accrued operating expenses		3,646		8,128
Deferred revenue		131		190
Accrued R&D licensing fees		654		4,827
Accrued tax withholdings		192		—
Accrued selling fees and rebates		1,910		423
Accrued construction costs		27,642		16,436
Total accrued expenses	$	42,571	$	37,718

The accrued construction costs relate to the building of the manufacturing facility in Dunkirk, NY. Of this amount, the Company expects $27.1 million to be reimbursed by New York State. This amount is recorded within prepaid expenses and other current assets on the Company’s condensed consolidated balance sheet as of March 31, 2019.

8. Income Taxes

The Company did not record a provision for federal income taxes for the three months ended March 31, 2019 because it expects to generate a loss for the year ending December 31, 2019 and the Company’s net deferred tax assets continue to be fully offset by a valuation allowance. Tax expense to date is the result of recording a valuation allowance against the deferred tax asset related to foreign tax benefits on losses in the Peoples Republic of China (“PRC”).

9. Debt and Lease Obligations

Debt

The Company’s debt as of March 31, 2019 and December 31, 2018, consists of the following (in thousands):

	March 31,		December 31,
	2019		2018
Current portion of mortgage	$	792	$	779
Current portion of bank loan		743		—
Current portion of finance and capital lease obligation		185		182
Long-term portion of finance and capital lease obligation		374		422
Senior secured loan, net of debt discount and financing fees of $4,362 and $4,619, respectively		45,638		45,381
Total	$	47,732	$	46,764

The mortgage payments, assumed in connection with the acquisition of CDE, extend through July 30, 2019.

During 2018, the Company issued a senior secured loan with a principal value of $50.0 million and a maturity date of June 30, 2023. The loan bears interest at a floating per annum rate equal to LIBOR (with a floor of 2.0%) plus 9.0%. The Company is required to make monthly interest-only payments with a bullet payment of the principal at maturity.

During the first quarter of 2019, the Company was issued an unsecured, subordinated bank loan to fund operations in China. This loan has a principal value of $0.7 million, a maturity date of December 11, 2019, and bears interest at a fixed rate of 5.7% annually.

Lease Obligation s

The Company has operating leases for office and manufacturing facilities in several locations in the U.S. and Asia and has three finance leases for manufacturing equipment used in its facilities near Buffalo, NY. The components of lease expense are as follows (in thousands):

	Three Months Ended March 31, 2019
Operating lease cost	$	781
Finance lease cost:
Amortization of assets		12
Interest on lease liabilities		9
Total net lease cost	$	802

The Company has elected to exclude short-term leases from its operating lease ROU assets and lease liabilities. Lease costs for short-term leases were not material to the financial statements for the three months ended March 31, 2019. Variable lease costs for the three months ended March 31, 2019 were not material to the financial statements.

Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):

	March 31, 2019
Operating leases:
Operating lease ROU assets, net	$	9,428

Current operating lease liabilities	$	3,067
Long-term operating lease liabilities		8,362
Total operating lease liabilities	$	11,429

Finance leases:
Property and equipment, at cost	$	688
Accumulated amortization, net		(40	)
Property and equipment, net	$	648

Current obligations of finance leases	$	185
Long-term portion of finance leases		374
Total finance lease obligations	$	559

Weighted average remaining lease term (in years):
Operating leases		5.83
Finance leases		2.86

Weighted average discount rate:
Operating leases		13.0	%
Finance leases		5.9	%

Supplemental cash flow information related to leases is as follows (in thousands):

	Three Months Ended March 31, 2019
Cash paid for amount included in the measurements of lease liabilities:
Operating cash flows from operating leases	$	803
Operating cash flows from finance leases		9
Financing cash flows from finance leases		45

ROU assets recognized in exchange for new operating lease obligations	$	583

Future minimum payments and maturities of leases is as follows (in thousands):

Year ending December 31:	Operating Leases			Finance Leases
2019 (remaining nine months)	$	2,551		$	161
2020		2,968			214
2021		2,535			214
2022		2,356			20
2023		2,096			—
Thereafter		3,952			—
Total lease payments		16,458			609
Less: Imputed interest		(5,029	)		(50	)
Total lease obligations		11,429			559
Less: Current obligations		(3,067	)		(185	)
Long-term lease obligations	$	8,362		$	374

10. Related Party Transactions

During the three months ended March 31, 2019 and 2018, the Company entered into transactions with individuals and companies that have financial interests in the Company. Related party transactions included the following:

In 2015, CDE signed an agreement with Avalon BioMedical (Management) Limited and its subsidiaries (“Avalon”) under which Avalon would receive certain administrative services and would occupy space at CDE’s research location. Avalon would reimburse CDE for these administrative services as incurred and pay CDE a percentage of the total rent payment based on its staff headcount occupying the Hong Kong research and development facility (See Note 15— Commitments and Contingencies ). Members of the Company’s board and management collectively have a controlling interest in Avalon. The Company does not hold any interest in Avalon and does not have any obligations to absorb losses or any rights to receive benefits from Avalon. As of March 31, 2019 and December 31, 2018, Avalon held 786,061 shares of the Company’s common stock, which represented approximately 1% of the Company’s total issued shares for both periods. Balances due from Avalon recorded on the condensed consolidated balance sheets were not significant.

In June 2018, the Company entered into two in-licensing agreements with Avalon wherein the Company obtained certain intellectual property from Avalon in an effort to develop and commercialize the underlying products. Under these agreements the Company is required to pay upfront fees and future milestone payments and sales-based royalties. During the year ended December 31, 2018, the Company recorded $5.5 million of upfront fees, consisting of $3.5 million in cash and $2.0 million in equity, as research and development expense on its condensed consolidated statement of operations and comprehensive loss. During the three months ended March 31, 2019 and 2018, no fees were paid to Avalon in connection with the license agreements.

The Company receives consulting and licensing revenue from PharmaEssentia, a company in which Athenex has an investment classified as available-for-sale (see Note 5— Fair Value Measurements ). Revenue recorded and cost-sharing funds received from PharmaEssentia amounted to $0.3 million and $0.1 million for the three months ended March 31, 2019 and 2018, respectively.

The Company receives certain clinical development services from ZenRx Limited and its s ubsidiaries (“ZenRx”), a company for which one of our executive officers serves on the board of directors. In connection with such services, the Company made payments to ZenR x of $ 0.3 million and $0. 1 million for the three months ended March 31, 2019 and 201 8 , respectively . In April 2013, the Company entered into a license agreement with ZenRx pursuant to which the Company granted an exclusive, sublicensable license to use certain of our intellectual property to develop and commercialize Oratecan and Orax ol in Australia and New Zealand, and a non-exclusive license to manufacture a certain compound, but only for use in Oratecan and Oraxol. ZenRx is responsible for all development, manufacturing and commercialization, and the related costs and expenses, of a ny product candidates resulting from the agreement. No revenue was earned from this license agreement in the periods presented in these consolidated financial statements.

d .	Certain family members of executives perform consulting services to the Company. Such services were not significant to the condensed consolidated financial statements.

11. Stock-Based Compensation

Common Stock Option Plans

The Company has four equity compensation plans, adopted in 2017, 2013, 2007 and 2004 (the “Plans”) which authorize the grant of up to 16,000,000 shares of common stock to employees, directors, and consultants. Additionally, on June 14, 2017, the Company adopted its 2017 Employee Stock Purchase Plan (the “ESPP”), which authorizes the issuance of up to 1,000,000 shares of common stock for future issuances to eligible employees.

Stock Options

The total fair value of stock options vested and recorded as compensation expense during the three months ended March 31, 2019 and 2018 was $1.7 million and $2.2 million, respectively. As of March 31, 2019, $14.8 million of unrecognized cost related to non-vested stock options was expected to be recognized over a weighted-average period of approximately 1.7 years. T he total intrinsic value of options exercised was approximately $0.4 million and $3.4 million for the three months ended March 31, 2019 and 2018, respectively.

The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (in thousands, except stock option amounts and exercise price):

	Stock Options			Weighted- Average Exercise price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2018		10,687,650		$	8.51		6.87	$	44,688
Granted		760,000			13.17		—		—
Exercised		(49,632	)		5.60		—		—
Forfeited and expired		(122,985	)		13.86		—		—
Outstanding at March 31, 2019		11,275,033		$	8.78		6.36	$	39,154
Vested and exercisable at March 31, 2019		8,153,661		$	6.88		5.45	$	43,787

The Company determines the fair value of stock-based awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding a number of highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated:

	Three Months Ended			Three Months Ended
	March 31, 2019			March 31, 2018
Weighted average grant date fair value	$	8.03		$	9.43
Expected dividend yield		—	%		—	%
Expected stock price volatility		64	%		59	%
Risk-free interest rate		2.63	%		2.57	%
Expected life of options (in years)		6.3			5.6

Employee Stock Purchase Plan

The ESPP is available to eligible employees as defined in the plan document. Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from December 1, 2018 to June 30, 2019. The Company expects to offer 6-month offering periods after the current period. The 2017 Plans reserved 1,000,000 shares of common stock for issuance under the ESPP. Stock-based compensation related to the ESPP amounted to $0.1 million and $0 for the three months ended March 31, 2019 and 2018, respectively.

Stock-Based Compensation Cost

The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three months ended March 31, 2019 and 2018 (in thousands):

	Three Months Ended March 31,
	2019		2018
Stock options	$	1,693	$	2,161
Restricted stock expense		—		540
Employee stock purchase plan		85		—
Total stock-based compensation expense	$	1,778	$	2,701
Cost of sales	$	64	$	44
Research and development expenses		591		513
Selling, general, and administrative expenses		1,123		2,144
Total stock-based compensation expense	$	1,778	$	2,701

12. Net Loss per Share Attributable to Athenex, Inc. Common Stockholders

Basic net loss per share is calculated by dividing net loss attributable to Athenex, Inc. common stockholders by the weighted-average number of common shares issued, outstanding, and vested during the period. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share and common shares equivalents for the period using the treasury-stock method. For the purposes of this calculation, warrants to purchase common stock and stock options are considered common stock equivalents but are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

	Three Months Ended March 31,
	2019		2018
Stock options and other common stock equivalents		11,219,839		9,931,020
Unvested restricted shares		—		240,000
Total potential dilutive shares		11,219,839		10,171,020

13. Business Segment, Geographic, and Concentration Risk Information

The Company has three operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue (only applicable to two reportable segments). Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. Consequently, the Company has concluded each operating segment to be a reportable segment. The Company’s operating segments are as follows:

Oncology Innovation Platform —This operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. This segment focuses specifically on Orascovery and Src Kinase Inhibition research platforms, and TCR-T Immunotherapy and Arginine Deprivation Therapy. This segment performs research in the United States, Taiwan, Hong Kong, and mainland China.

Global Supply Chain Platform —This operating segment includes A PS and Polym ed. A PS is a contract manufacturing company that provides small to mid-scale Current Good Manufacturing Practices (“ cGMP ”) manufacturing of clinical and commercial products for pharmaceutical and biotech companies and for the internal supplies to the clini cal studies and commercial development of our proprietary drugs . APS also performs microbiological and analytical testing for raw material and form ulated products and has expanded and begun to manufacture and sell pharmaceutical products under Section 503B of the Compounding Quality Act within the Federal Food, Drug & Cosmetic Act. Polymed markets and sells active pharmaceutical ingredient (“ API ”) and medical devices in North America, Europe, and Asia from its locations in Texas and China. Polymed also deve lops new compounds and processing techniques, and manufactures API at Taihao, a cGMP facility in Chongqing, China.

Commercial Platform —This operating segment includes Athenex Pharmaceutical Division, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. This segment provides services and products to external customers based mainly in the United States.

The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the United States, Taiwan, Hong Kong, and mainland China. The Global Supply Chain Platform segment operates and holds long-lived assets located in the United States and China. The Commercial Platform segment operates and holds long-lived assets located in the United States. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer.

Segment information is as follows (in thousands):

	Three Months Ended March 31,
	2019			2018
Total revenue:
Oncology Innovation Platform	$	144		$	25,231
Global Supply Chain Platform		11,339			5,127
Commercial Platform		14,675			8,694
Total revenue for reportable segments		26,158			39,052
Intersegment revenue		(851	)		(1,216	)
Total consolidated revenue	$	25,307		$	37,836

Intersegment revenue eliminated in the above table reflects sales from the Global Supply Chain Platform to the Oncology Innovation Platform.

	Three Months Ended March 31,
	2019		2018
Total revenue by product group:
API sales	$	4,831	$	2,642
Medical device sales		—		585
Contract manufacturing revenue		251		241
Commercial product sales		20,081		9,137
License fees		—		25,091
Consulting revenue		105		—
Grant revenue		39		140
Total consolidated revenue	$	25,307	$	37,836

Intersegment revenue is recorded by the selling segment when it is realized or realizable and all revenue recognition criteria are met. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger.

	Three Months Ended March 31,
	2019			2018
Net (loss) income attributable to Athenex, Inc.:
Oncology Innovation Platform	$	(27,603	)	$	1,509
Global Supply Chain Platform		(767	)		(6,569	)
Commercial Platform		(6,863	)		(2,238	)
Total consolidated net loss attributable to Athenex, Inc.	$	(35,233	)	$	(7,298	)

	Three Months Ended March 31,
	2019		2018
Total depreciation and amortization:
Oncology Innovation Platform	$	189	$	156
Global Supply Chain Platform		311		467
Commercial Platform		379		245
Total consolidated depreciation and amortization	$	879	$	868

	March 31,		December 31,
	2019		2018
Total assets:
Oncology Innovation Platform	$	113,808	$	135,878
Global Supply Chain Platform		65,488		58,816
Commercial Platform		41,011		36,401
Total consolidated assets	$	220,307	$	231,095

	Three Months Ended March 31,
	2019		2018
Total revenue:
United States	$	20,335	$	9,901
Spain		—		25,000
India		777		962
Austria		2,173		1,243
China		386		648
United Kingdom		1,023		—
Other foreign countries		613		82
Total consolidated revenue	$	25,307	$	37,836

	March 31,		December 31,
	2019		2018
Total property and equipment, net:
United States	$	7,283	$	6,549
China		4,966		4,898
Total consolidated property and equipment, net	$	12,249	$	11,447

Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment.

	Three Months Ended March 31,
	2019			2018
Percentage of total revenue by customer:
Customer A		22	%		10	%
Customer B		21	%		4	%
Customer C		21	%		7	%
Customer D		—			66	%

	March 31,			December 31,
	2019			2018
Percentage of total accounts receivable by customer:
Customer A		32	%		18	%
Customer B		19	%		16	%
Customer C		10	%		—
Customer D		7	%		12	%

1 4 . Revenue Recognition

The Company records revenue in accordance with ASC, Topic 606 “ Revenue from Contracts with Customers .” Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the entity performs the following five steps: (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Following is a description of principal activities – separated by reportable segments – from which the Company generates its revenue (See Note 13 – Business Segment, Geographic, and Concentration Risk Information ).

Oncology Innovation Platform

License fees and consulting revenue

The Company out-licenses certain of its intellectual property (“IP”) and provides related consulting services to pharmaceutical companies in specific territories that allow the customer to use, develop, commercialize, or otherwise exploit the licensed IP. In accordance with Topic 606, the Company analyzes each of its out-licensing contracts with customers to identify each of the performance obligations within the contract. Each out-license contains multiple performance obligations. The Company has determined that each of its out-license agreements with customers are classified as functional licenses and are capable of being distinct, because the IP that is licensed carries standalone value and is not expected to be altered through the life of the agreement. Therefore, for each of its out-licensing agreements, the Company has determined that the execution of the license and delivery of the IP to the licensee is a distinct performance obligation. As such, the Company records revenue at a point-in-time for its out-licensing if any of the transaction price is allocated to the obligation, including up-front licensing fee payments. The Company’s classification of each out-license as such requires significant judgment to be used by management. The Company considers the economic and regulatory characteristics of the licensed IP to determine if it has standalone value on the date of the licensing, which would make the licensing distinct and dictate that the Company recognizes any transaction price allocated to the license performance obligation at a point-in-time. Revenue recognized at a point-in-time for the execution of a distinct licensing of IP amounted to $0 and $25.0 million for the three months ended March 31, 2019 and 2018, respectively.

Other performance obligations included in the Company’s out-licensing agreements include reaching milestone development and regulatory events by performing research and development activities over the licensed IP. The Company did not reach any milestone events during the three months ended March 31, 2019 or 2018. If the Company reaches any further milestone payments, the Company plans to record the associated milestone payment as revenue at a point-in-time. Certain out-licensing agreements include performance obligations to manufacture and provide drug product in the future when the licensed product is approved for commercial sale. To date, the Company has not satisfied any of these performance obligations as none of its drugs have been approved by the regulatory agencies in any of the licensed territories.

In addition to the multiple performance obligations, the Company’s out-licensing agreements include variable pricing. After the performance obligations are identified, the Company determines each portion of the transaction price, which generally includes upfront fees, milestone payments, and royalty payments. The Company begins by allocating the payments set forth in the agreement to the performance obligation to which the consideration is related. Then, the Company considers whether or not that transaction price is fixed, variable, or subject to return. If any portion of the transaction price is constrained by more than one performance obligation, the Company allocated that portion of the transaction price to the performance obligation that will be satisfied later and will not recognize revenue until it is fully satisfied and the constraint on the transaction price no longer exists. There are no other significant methods employed to allocate the transaction price to performance obligations in a contract. The Company exercises significant judgment when allocating the variable transaction prices to the proper performance obligations, considering if any of those payments are refundable or are contingent on any future events. The Company did not use any other significant judgments related to out-licensing revenue during the three months ended March 31, 2019 and 2018.

Grant revenue

The Company receives grant award funding to support its continuing research and development efforts. The Company considers these grants to be operating revenue as they support the Company’s primary operating activities. Revenue is recognized when the underlying performance obligation is satisfied, which is generally when all grant eligibility criteria are met at a point-in-time. Grant revenue is not significant to the condensed consolidated financial statements.

Global Supply Chain Platform

The Company’s Global Supply Chain Platform manufactures API for use internally in its research and development and clinical studies and for sale to pharmaceutical customers globally. The Company also generates revenue on this platform, by providing small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies and selling pharmaceutical products under 503B regulations set forth by the FDA.

Revenue earned by the Global Supply Platform is recognized when the Company has satisfied its performance obligation, which is the shipment or the delivery of drug products. The underlying contracts for these sales are generally purchase orders and the Company recognizes revenue at a point-in-time. Any remaining performance obligations related to product sales are the result of customer deposits and are reflected in the deferred revenue contract liability balance.

Commercial Platform

The Company’s Commercial Platform generates revenue by distributing specialty products through independent pharmaceutical wholesalers. The wholesalers then sell to an end-user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end-user and the Company. Sales are initially recorded at the list price sold to the wholesaler. Because these prices will be reduced for the end-user, the Company records a contra asset in accounts receivable and a reduction to revenue at the time of the sale, using the difference between the list price and the estimated end-user contract price. Upon the sale by the wholesaler to the end-user, the wholesaler will chargeback the difference between the original list price and price at which the product was sold to the end-user and such chargeback is offset against the initial estimated contra asset. The significant estimates inherent in the initial chargeback provision relate to wholesale units pending chargeback and to the ultimate end-user contract selling price. The Company bases the estimate for these factors on product-specific sales and internal chargeback processing experience, as well as estimated wholesaler inventory stocking levels. As of March 31, 2019 and December 31, 2018, the Company’s total provision for chargebacks and other deductions totaled $9.0 million and $11.8 million, respectively, included as a reduction of accounts receivable. The Company’s total expense for chargebacks and other deductions was $17.5 million and $5.0 million for the three months ended March 31, 2019 and 2018, respectively.

The Company offers cash discounts, which approximate 2.0% of the gross sales price, as an incentive for prompt customer payment, and, consistent with industry practice, the Company’s return policy permits customers to return products within a window of time before and after the expiration of product dating. The Company expects that its wholesale customers will make prompt payments to take advantage of the cash discounts, and expects customers to use their right of return. Therefore, at the time of sale, product revenue and accounts receivable are reduced by the full amount of the discount offered and the return expected. The Company considers payment performance and historical return rates and adjusts the accrual to reflect actual experience. As of March 31, 2019 and December 31, 2018, the Company’s accrual for cash discounts and return accrual included as a reduction of accounts receivable were not material to the condensed consolidated financial statements.

The Company also offers contractual allowances, generally rebates or administrative fees, to certain wholesale customers, group purchasing organizations (“GPOs”), and end-user customers, consistent with pharmaceutical industry practices. Settlement of rebates and fees may generally occur from one to five months from date of sale. The Company provides a provision for contractual allowances at the time of sale based on the historical relationship between sales and such allowances. Contractual allowances are reflected in the condensed consolidated financial statements as a reduction of revenue and accounts receivable or as accrued expenses.

The Company exercises significant judgment in its estimates of the variable transaction price at the time of the sale and recognizes revenue when the performance obligation is satisfied. Factors that determine the final net transaction price include chargebacks, fees for service, cash discounts, rebates, returns, warranties, and other factors. The Company estimates all of these variables based on historical data obtained from previous sales finalized with the end-user customer on a product-by-product basis. At the time of sale, revenue is recorded net of each of these deductions. Through the normal course of business, the wholesaler will sell the product to the end-user, determining the actual chargeback, return products, and take advantage of cash discounts, charge fees for services, and claim warranties on products. The final transaction price per product is compared to the initial estimated net sale price and reviewed for accuracy. The final prices and other factors are immediately included in the Company’s historical data from which it will estimate the transaction price for future sales. The underlying contracts for these sales are generally purchase orders including a single performance obligation, generally the shipment or delivery of products and the Company recognizes this revenue at a point-in-time.

Disaggregation of revenue

The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer.

	For the Three Months Ended March 31, 2019
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform		Commercial Platform		Consolidated Total
United States	$	—	$	5,660	$	14,675	$	20,335
India		—		777		—		777
Austria		—		2,173		—		2,173
China		144		242		—		386
United Kingdom		—		1,023		—		1,023
Other foreign countries		—		613		—		613
Total revenue	$	144	$	10,488	$	14,675	$	25,307

	For the Three Months Ended March 31, 2018
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform		Commercial Platform		Consolidated Total
United States	$	—	$	1,208	$	8,694	$	9,901
India		—		962		—		962
Austria		—		1,243		—		1,243
China		231		417		—		648
Spain		25,000		—		—		25,000
Other foreign countries		—		82		—		82
Total revenue	$	25,231	$	3,911	$	8,694	$	37,836

The Company also disaggregates its revenue by product group which can be found in Note 13 – Business Segment, Geographic, and Concentration Risk Information .

Contract balances

The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers.

	March 31, 2019			December 31, 2018
	(In Thousands)
Accounts receivable, gross	$	31,032		$	26,061
Chargebacks and other deductions		(10,448	)		(13,101	)
Allowance for doubtful accounts		(8	)		(9	)
Accounts receivable, net	$	20,576		$	12,951
Deferred revenue		131			190
Total contract liabilities	$	131		$	190

The following tables illustrate accounts receivable balances by reportable segments.

	March 31, 2019
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform			Commercial Platform			Consolidated Total
Accounts receivable, gross	$	—	$	7,876		$	23,156		$	31,032
Allowance for doubtful accounts, chargebacks, and other deductions		—		(13	)		(10,443	)		(10,456	)
Accounts receivable, net	$	—	$	7,863		$	12,713		$	20,576

	December 31, 2018
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform			Commercial Platform			Consolidated Total
Accounts receivable, gross	$	—	$	7,814		$	18,247		$	26,061
Allowance for doubtful accounts, chargebacks, and other deductions		—		(9	)		(13,101	)		(13,110	)
Accounts receivable, net	$	—	$	7,805		$	5,146		$	12,951

As of March 31, 2019, $0.1 million of the deferred revenue balance relates to customer deposits made by customers of the Global Supply Chain Platform and is included within accrued expenses on the condensed consolidated balance sheet.

As of December 31, 2018, the $0.2 million contract liability related to customer deposits made by customers of the Global Supply Chain Platform. The Company satisfied its performance obligations allocated to these contract liabilities during the three months ended March 31, 2019.

There were no other material changes to contract balances during the three months ended March 31, 2019.

Practical expedients used

During the adoption of ASC 606, the Company applied the practical expedient in paragraph 606-10-10-4, the Portfolio Approach . This allowed the Company to apply the new revenue standard to a portfolio of contracts with similar characteristics because it reasonably expected that the effects on the financial statements of applying the guidance to the portfolio would not differ materially from applying the guidance to the individual contracts within that portfolio. The Company used this to determine the cumulative catch-up required under the modified retrospective transaction method. The Company used the portfolio approach for product sales under the Global Supply Chain Platform and product sales under the Commercial Platform. The Company did not use this approach for its out-licensing contracts, because each of those contracts have unique economic characteristics.

The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations related to the license of intellectual property (“IP”). This practical expedient is applied because the out-licensing agreements include sales-based royalties in exchange for the license of IP accounted for in accordance with Topic 606 and there is significant uncertainty surrounding the future variable consideration that could be received.

15. Commitments and Contingencies

Future minimum payments under the non-cancelable operating lease consists of the following as of December 31, 2018 (in thousands):

Year ending December 31:	Minimum payments
2019	$	2,943
2020		2,466
2021		2,040
2022		1,902
2023		1,675
Thereafter		3,099
	$	14,125

Legal Proceedings

From time to time, the Company may be subject to claims and litigation arising in the ordinary course of business. These claims could include assertions that the Company’s products infringe existing patents or claims that the use of its products has caused personal injuries. The Company intends to vigorously defend any such litigation that may arise under all defenses that would be available. Regardless of the outcome, litigation can have an adverse impact on us because of prosecution, defense and settlement costs, unfavorable awards, diversion of management resources and other factors.

Vas o pressin (Generic version of Vasostrict® )

On August 13, 2018, Athenex Pharma Solutions and Athenex Pharmaceutical Division, LLC, our wholly-owned subsidiaries, filed a complaint for declaratory judgment against Par Pharmaceuticals, Inc., Par Sterile Products, LLC and Endo Par Innovation Company, LLC (together, Par) in the United States District Court for the Western District of New York (the Court), seeking a declaratory judgment from the Court that our compounded vasopressin drug products in ready-to-use form do not infringe on patents that Par has with respect to its Vasostrict® product and that Par’s patents are invalid. On October 22, 2018, Par filed a motion to dismiss the complaint on the basis that the Court does not have subject matter jurisdiction. Athenex has opposed Par’s motion and that motion is fully briefed and currently pending. Par has not filed a claim for infringement of its patents in this suit but if Par’s motion to dismiss Athenex’s patent suit is denied and the declaratory action proceeds, Par could proceed to lodge a counterclaim for patent infringement. If such an infringement claim were brought and the Court ruled for Par, Athenex could be enjoined from further production of compounded vasopressin within in the United States and sale of compounded vasopressin in or from the United States and for payment of damages to Par for U.S. manufacture or sale of compounded vasopressin that has already taken place, which could have a material adverse effect on our business.

In addition, on August 13, 2018, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC filed a motion to intervene and seek the dismissal of Par’s complaint against the FDA and certain governmental officials in the United States District Court for the District of Columbia. Par has sought declaratory and injunctive relief against the FDA and certain governmental officials that: (i) vasopressin be delisted from Category 1 of the FDA’s list of bulk drug substances under evaluation pursuant to Section 503B of the Federal Food, Drug and Cosmetic Act (FDCA), (ii) the expansion of the FDA’s enforcement discretion to Category 1 substances, be enjoined; and (iii) that the FDA be enjoined from authorizing the compounding of vasopressin under Section 503B of the FDCA. Our motion to intervene was granted. Par filed a preliminary injunction motion and we and the FDA filed motions for judgment on the pleadings. This action is currently stayed. On March 4, 2019, the FDA published in the Federal Register its final decision not to include vasopressin on the list of bulk drug substances for which there is a clinical need. Also, on March 4, 2019, Athenex, Inc., APS, and APD filed a complaint against the FDA seeking to vacate its decision. In this case, the FDA has represented to the Court that “until the Court issues a decision on the merits of this action, the FDA will not initiate enforcement action against Athenex based solely on Athenex’s use of the bulk drug substance vasopressin to compound drugs and distribute those drugs” and the Court has incorporated the FDA’s representation into its published order. Because of the Court’s order, Athenex will continue to produce and distribute compounded vasopressin during the period that the case is pending and will reevaluate its position after the Court issues its decision on the merits of Athenex’s lawsuit. The Court is expected to issue its opinion during the second or third quarter of 2019. On August 14, 2018, the Company began selling compounded vasopressin injection in ready-to-use premix IV bags. If the Company is unsuccessful in obtaining the relief it seeks in its lawsuit against the FDA, or there is an adverse final determination that Par’s patent is valid and infringed, the Company would have to abandon this revenue-generating line of business; such events could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

16. Subsequent Events

On May 3, 2019, the Company entered into a share purchase agreement (the “Share Purchase Agreement”) with Perceptive Life Sciences Master Fund, Ltd., venBio Select Fund LLC, OrbiMed Partners Master Fund Limited, and The Biotech Growth Trust PLC (collectively, the “Investors”), pursuant to which the Company agreed to sell an aggregate of 10 million shares of its common stock to the Investors at a purchase price of $10.00 per share for aggregate gross proceeds of $100 million (the “Private Placement”). The Private Placement closed on May 7, 2019.

Pursuant to the Share Purchase Agreement, the Company agreed to enter into a registration rights agreement (the “Registration Rights Agreement”) with the Investors at the closing of the Private Placement. Under the Registration Rights Agreement, the Company agreed to register for resale the shares of common stock the Investors purchased in the offering under the Securities Act of 1933, as amended (the “Securities Act”). Pursuant to the Registration Rights Agreement, the Company will prepare and file a registration statement with the Securities and Exchange Commission within 90 days of the closing date of the Private Placement and agreed to use its best efforts to have the registration statement declared effective as soon as practicable. For each month the Company is unable to meet its obligations to have the registration statement declared effective, it will be obligated to pay each Investor an amount in cash equal to one percent of the aggregate purchase price paid by that Investor pursuant to the Share Purchase Agreement, provided that in no event will the total payment to that Investor exceed 25% of its aggregate purchase price. In addition, subject to certain limitations, following the signing of the Registration Rights Agreement, the Investors will have piggyback registration rights if no registration statement registering the shares sold in the Private Placement is effective and the Company is otherwise filing a registration statement under the Securities Act for the sale of its securities for its own account or for the account of any of its stockholders.

Item 2. Management’s Dis cussion and Analysis of Financial Condition and Results of Operations.

The following discussion contains management’s discussion and analysis of our financial condition and results of operations and should be read together with the unaudited condensed consolidated financial statements and the notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and related notes thereto for the year ended December 31, 2018 included in our Annual Report on Form 10-K for the year ended December 31, 2018. Unless the context indicates otherwise, as used in this Quarterly Report, the terms “Athenex,” the “Company,” “we,” “us,” and “our” refer to Athenex, Inc., a Delaware corporation, and its subsidiaries taken as a whole, unless otherwise noted. This discussion and other parts of this quarterly report contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2018.

NOTE ABOUT FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and section 27A of the Securities Act of 1933, as amended (the “Securities Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of this Quarterly Report. These forward-looking statements may include, but are not limited to, statements regarding our future results of operations and financial position, business strategy, potential market size, potential growth opportunities, the timing and results of clinical trials, and potential regulatory approval and commercialization of product candidates. In some cases, forward-looking statements may be identified by terminology such as “believe,” “may,” “will,” “should,” “predict,” “goal,” “strategy,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect,” “seek” and similar expressions and variations thereof. These words are intended to identify forward-looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the “Risk Factors” section included in our Annual Report on Form 10-K for the year ended December 31, 2018. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business. In light of these risks, uncertainties and assumptions, actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of our Annual Report on Form 10-K for the year ended December 31, 2018 to conform these statements to actual results or to changes in our expectations, except as required by law.

Overview and Recent Developments

We are a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline in the Oncology Innovation Platform is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine Deprivation Therapy. We have assembled a leadership team and have established global operations in the U.S. and China across the pharmaceutical value chain to execute our mission to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. Below we describe our current plans to advance the technology in our Oncology Innovation Platform.

Lead Orascovery drug candidate: Oraxol (oral paclitaxel and HM30181A).

In January 2018, we received positive feedback from the US Food and Drug Administration (FDA) on the design of the ongoing Phase 3 trial (KX-ORAX-001), which indicated that if the study meets the primary endpoint with an acceptable benefit to risk profile, it could be adequate as a single comparative trial to support registration of Oraxol in the U.S. for the indication of metastatic breast cancer. The Oraxol Phase 3 clinical trial is a randomized controlled clinical trial comparing Oraxol monotherapy against IV paclitaxel monotherapy in patients with metastatic breast cancer. Also, in January 2018, the China National Medical Product Administration (NMPA, formerly known as the China Food and Drug Administration) allowed the Investigational New Drug (IND) application for Oraxol, which allowed us to commence a clinical trial program for Oraxol in China.

In April 2018, the FDA granted Orphan Drug status to Oraxol for the treatment of angiosarcomas.

In August 2018, we received a positive recommendation by the Data Safety and Monitoring Board (DSMB) of the second interim analysis of the Oraxol Phase 3 Clinical Trial, a randomized controlled clinical trial comparing Oraxol monotherapy against IV paclitaxel monotherapy in patients with metastatic breast cancer.

In October 2018, we presented encouraging efficacy and safety data of Oraxol in the treatment of metastatic breast cancer patients obtained from a Phase 2 clinical trial conducted in Taiwan at the European Society for Medical Oncology (ESMO) Congress. Results from twenty-four patients with metastatic breast cancer were reported showing that eleven patients (45.8%) achieved partial remission, ten patients (41.7%) had stable disease, and three patients (12.5%) had progressive disease. Drug-related serious adverse events consisting of grade 4 neutropenia were observed in three patients and all recovered completely, and there was no dose limiting neuropathy observed.

In November 2018, we initiated a Phase 1/2 clinical study to assess the safety, tolerability and activity of Oraxol in combination with an anti-PD1 antibody (pembrolizumab) in patients with advanced solid malignancies, in collaboration with Mayo Clinic. Also in November 2018, we licensed the rights to develop and commercialize Oradoxel (oral docetaxel and HM30181A) in Taiwan, Singapore, and Vietnam to PharmaEssentia Corporation.

In December 2018, our global Phase 1b clinical trial of Oraxol plus ramucirumab (monoclonal antibody to VEGF-R2) in gastric cancer patients who failed previous chemotherapies completed the second cohort of patients and results indicated positive signals of efficacy. For the second cohort of six patients on an escalated Oraxol dose of 250 mg/m2, partial response, according to RECIST criteria, occurred in 3 patients (50%), compared to the first cohort of six patients who were treated with a 200 mg/m2 dose where partial responses were observed in 2/6 patients (33.3%) and stable disease observed in 1/6 patient (16.7%). The Oraxol dose is currently being further escalated to 300 mg/m2 in the third cohort of patients and the study is ongoing.

In January 2019, the target enrollment of 360 evaluable patients in the Oraxol Phase 3 clinical trial in metastatic breast cancer was achieved. In March 2019, we presented a poster highlighting the preclinical data of Oraxol in angiosarcoma, an FDA approved orphan indication for Oraxol, at the American Association of Cancer Research Annual Meeting. In May 2019, we announced preliminary data showing promising early clinical responses in the first part of a two-part study of Oraxol monotherapy in patients with unresectable cutaneous angiosarcoma. We also continued to advance the development of other Orascovery candidates. For instance, in October 2018, the FDA allowed the IND application for Eribulin ORA, our oral version of eribulin plus HM30181A (or encequidar).

If we receive approval from the FDA, our strategy is to develop and commercialize oral paclitaxel and encequidar in the US through our Commercial Platform. We also plan to evaluate go-to-market options outside the US, including using our internal resources, partnering with others, or out-licensing the product. If our Phase Three study in metastatic breast cancer (MBC) is successful, we intend to establish oral paclitaxel and encequidar as the chemotherapy of choice for patients receiving chemotherapy for MBC and intend to file a New Drug Application with the FDA to secure regulatory approval of oral paclitaxel and encequidar for MBC. If successful, we will then explore establishing oral paclitaxel and encequidar in other oncology indications where taxanes have been and we expect will continue to be foundational treatments. During 2019, we plan to focus on:

•

quantitative and qualitative market research to understand our customers, patients, and the market;

•

preliminary forecasts;

•

examining our competitive landscape;

•

developing and completing brand strategy;

•

developing key opinion leader relationships;

•

attending priority medical conferences to increase awareness of the Company and oral paclitaxel and encequidar;

•

creating a market access strategy;

•

developing and executing a scientific publication plan;

•

developing our distribution and patient support plans;

•

completing our organizational design to determine the overall size of our go-to-market commercial team based on our market opportunity; and

•

beginning hiring for key commercial and medical affairs leadership roles.

We can provide no assurance that we will be successful in obtaining the FDA ’s approval to commercialize oral paclitaxel and encequidar.

Lead candidate in the Src Kinase Inhibition platform: KX2-391 ointment, for Actinic Keratosis (AK)

Patient enrollment in two Phase 3 studies was completed in February 2018. The studies enrolled a total of 702 patients across 62 sites in the US. KX2-391 ointment 1% or vehicle (randomized 1:1) was self-administered to 25 cm2 of the face or scalp encompassing 4-8 typical AK lesions, once daily for 5 consecutive days.

In July 2018, we announced that both of our Phase 3 pivotal efficacy studies achieved their primary endpoint of 100% clearance of AK lesions at Day 57 within the face or scalp treatment areas, with each study achieving statistical significance (p<0.0001).

In March 2019, we presented topline results from the two Phase 3 studies in a late breaker session at the 2019 American Academy of Dermatology Annual Meeting. Results showed that 44% and 54% of patients in studies KX01-AK-003 and KX-01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57 (see Table 1). The patient compliance rate in these two studies was greater than 99%. There was a statistically significant clearance rate in favor of the KX2-391 ointment versus the vehicle in each of the patient subgroups. Safety results showed that KX2-391 ointment was well tolerated. Adverse events were few. Treatment related adverse events were mild to moderate application site symptoms, such as pruritus or pain. There were no serious adverse events or early discontinuations due to study drug related adverse events. Local skin reactions (LSRs) (erythema, flaking/scaling, crusting, swelling, vesiculation/postulation and erosion/ulceration) were mostly mild to moderate. We believe that this product, if approved by the regulatory authorities, could have a major impact in the medical treatment of AK.

Table 1: Efficacy Results of KX2-391 Ointment in the Field Treatment of Actinic Keratosis

Study	KX01-AK-003			KX01-AK-004
% of Subjects in the Intent-To-Treat Population (Number of Subjects)	KX2-391 N=175	Vehicle N=176	p-value	KX2-391 N=178	Vehicle N=173	p-value
100% AK Clearance on Day 57	44% (N=77)	5% (N=8)	<0.0001 ^a	54% (N=97)	13% (N=22)	<0.0001 ^a
Face Scalp	50% 30%	6% 2%	<0.0001 <0.0001	61% 41%	14% 11%	<0.0001 0.0003
≥75% AK Clearance on Day 57	68%	16%	<0.0001 ^a	76%	20%	<0.0001 ^a

Note:

a = p-value calculated based on Cochran-Mantel-Haenszel (CMH)

New in-licensed programs: TCR-T Immunotherapy and Arginine Deprivation Therapy

In 2018, we commenced development of two new in-licensed programs. TCR-T immunotherapy technology harnesses and enhances the patient’s own immune cells to target and eliminate cancer. It is a cell-based therapy that takes advantage of the unique attributes of TCR mediated target recognition and provides a potent and selective TCR-T directed response against cancer cells.

We have three operating segments: our Oncology Innovation Platform, Global Supply Chain Platform and Commercial Platform. Since inception, we have devoted a substantial amount of our resources to research and development of our lead product candidates under our Orascovery, Src Kinase Inhibition research platforms, and TCR-T Immunotherapy and Arginine Deprivation Therapy. We have incurred significant net losses since inception. Our net losses were $36.2 million and $7.3 million for the three months ended March 31, 2019 and 2018, respectively. As of March 31, 2019 and December 31, 2018 we had an accumulated deficit of $478.9 million and $443.7 million, respectively. We expect to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:

•

Continue to advance our lead programs, Orascovery and Src Kinase Inhibition research platforms, through clinical development;

•

Continue our current preclinical and clinical research program and development activities ;

•

Advance the preclinical and clinical research program and development activities of our recently in-licensed technology platforms, TCR-T Immunotherapy and Arginine Deprivation Therapy;

•

Seek to identify additional research programs and product candidates;

•

Continue to invest in acquiring or in-licensing other drugs and technologies;

•

Continue to invest in our manufacturing facilities;

•

Continue to invest in further developing our Commercial Platform ahead of our intended proprietary drug launch;

•

Hire additional research, development and business personnel;

•

Maintain, expand and protect our intellectual property portfolio; and

•

Incur additional costs associated with operating as a public company.

On May 7, 2019, we completed a private placement equity offering of 10 million shares of common stock. All shares were offered by us at a price of $10.00 per share to three institutional investors, namely Perceptive Advisors, Avoro Capital Advisors (formerly known as venBio Select Advisor), and OrbiMed. The aggregate net proceeds received by us from the offering were $99.8 million, net of offering expenses of approximately $0.2 million.

We have funded our operations to date primarily from the issuance and sale of our common stock through public offerings, private placements, and convertible bonds, debt and, to a lesser extent, through revenue generated from our Global Supply Chain Platform. As of March 31, 2019, we had cash, cash equivalents and short-term investments of $71.3 million.

Key Components of Results of Operations

Revenue

We derive our consolidated revenue primarily from (i) the sales of 503B and API products by our Global Supply Chain Platform; (ii) the sales of generic injectable products by our Commercial Platform; (iii) licensing and collaboration projects conducted by our Oncology Innovation Platform, which generates revenue in the form of upfront payments, milestone payments and payments received for providing research and development services for our collaboration projects and for other third parties; and (iv) grant awards from government agencies and universities for our continuing research and development efforts.

We do not anticipate revenue being generated from sales of our product candidates under development in our Oncology Innovation Platform until we have obtained regulatory approval. We cannot assure you that we will succeed in achieving regulatory approval for our drug candidates as planned, or at all.

Cost of Sales

Along with sourcing from third-party manufacturers, we manufacture clinical products in our cGMP facility in New York and APIs at our cGMP facility in China through our Global Supply Chain Platform. Cost of sales primarily includes the cost of finished products, raw materials, labor costs, manufacturing overhead expenses and reserves for expected scrap, as well as transportation costs. Cost of sales also includes depreciation expense for production equipment, changes to our excess and obsolete inventory reserves, and certain direct costs such as shipping costs, net of costs charged to customers.

Research and Development Expenses

Research and development expenses consist of the costs associated with in-licensing of product candidates, milestone payments, conducting preclinical studies and clinical trials, activities related to regulatory filings and other research and development activities. Our current research and development activities mainly relate to the clinical development of the following programs:

Orascovery platform —Comprised of our in-licensed and novel P-gp inhibitor, HM30181A, that is combined with various chemotherapeutic agents and enables the agents to be absorbed into the blood when given orally:

•

Oraxol, combining HM30181A with an oral dosage form of paclitaxel;

•

Oratecan, combining HM30181A with an oral dosage form of irinotecan;

•

Oradoxel, combining HM30181A with an oral dosage form of docetaxel;

•

Oratopo, combining HM30181A with an oral dosage form of topotecan; and

•

Eribulin ORA, combining HM30181A with an oral dosage form of eribulin.

We have received approval of the International Nonproprietary Name (INN) “encequidar” for our novel P-gp pump inhibitor molecule, HM30181A.

Src Kinase Inhibition platform —Targets the tyrosine kinase protein in regulating cell growth that leads to blockade of metastasis:

•

KX2-391 (also known as KX-01) ointment, Src kinase inhibitor topically administered to treat skin cancers and pre-cancers;

•

KX2-391 oral, Src kinase inhibitor orally administered to treat certain solid and liquid tumors; and

•

KX2-361 (also known as KX-02), Src kinase inhibitor orally administered to treat brain cancer, such as glioblastoma multiforme (GBM).

TCR-T Immunotherapy and Arginine Deprivation Therapy platform — licensed in July 2018, and are still in early stage R&D development phase:

•

The TCR-T immunotherapy technology harnesses and enhances the patient’s own immune cells to target and eliminate cancer. It is a cell-based therapy that takes advantage of unique attributes of TCR mediated target recognition and provides a potent and selective TCR-T directed response against cancer cells.

•

The Arginine Deprivation Therapy product, based on pegylated genetically engineered human arginase, targets cancer growth and survival by interrupting the supply of an essential amino acid, arginine, to a proportion of cancers with disrupted urea cycle.

We expense research and development costs as incurred. We record costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment or clinical site activations. We do not allocate employee-related costs, depreciation, rental and other indirect costs to specific research and development programs because these costs are deployed across multiple product programs under research and development.

We cannot determine with certainty the duration, costs and timing of the current or future preclinical or clinical studies of our drug candidates. The duration, costs, and timing of clinical studies and development of our drug candidates will depend on a variety of factors, including:

•

The scope, rate of progress, and costs of our ongoing, as well as any additional, clinical studies and other research and development activities;

•

Future clinical study results;

•

Uncertainties in clinical study enrollment rates;

•

Significant and changing government regulation; and

•

The timing and receipt of any regulatory approvals.

A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate.

Research and development activities are central to our business model. We expect our research and development expenses to continue to increase for the foreseeable future as we continue to support the clinical trials of Oraxol, Oratecan, Oradoxel, Oratopo, Eribulin ORA, KX-01 ointment, KX-01 oral and KX-02, as well as initiate and prepare for additional clinical and preclinical studies, including TCR-T and Arginine deprivation program activities. We also expect spending to increase in the research and development for API, 503B and specialty products. There are numerous factors associated with the successful commercialization of any of our drug candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will likely impact our clinical development programs and plans.

Selling, Gene ral and Administrative Expenses

Selling, general and administrative, (“SG&A”), expenses primarily consist of compensation, including salary, employee benefits and stock-based compensation expenses for sales and marketing personnel, and for administrative personnel that support our general operations such as executive management, legal counsel, financial accounting, information technology, and human resources personnel. SG&A expenses also include professional fees for legal, patent, consulting, auditing and tax services, as well as other direct and allocated expenses for rent and maintenance of facilities, development of the facility in Dunkirk, NY, insurance and other supplies used in the selling, marketing, general and administrative activities. SG&A expenses also include costs associated with our commercialization efforts for our proprietary drugs, such as market research, brand strategy and development work on market access, scientific publication, product distribution and patient support. Our expenses related to operating as a public company may increase when we are no longer able to rely on the “emerging growth company” exemption to certain disclosure and attestation requirements pursuant to the Jumpstart our Business Startups Act of 2012 (JOBS Act).

Results of Operations

Three Months Ended March 31, 2019 Compared to Three Months Ended March 31, 2018

The following table sets forth a summary of our condensed consolidated results of operations for the three months ended March 31, 2019 and 2018, together with the changes in those items in dollars and as a percentage. This information should be read together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. Our operating results in any period are not necessarily indicative of the results that may be expected for any future period.

	Three Months Ended March 31,
	2019			2018			Change
	(in thousands)			(in thousands)			(in thousands)			%
Revenue
Product sales, net	$	25,163		$	12,605		$	12,558			100	%
License fees and consulting revenue		105			25,091			(24,986	)		-100	%
Grant revenue		39			140			(101	)		-72	%
Total revenue		25,307			37,836			(12,529	)		-33	%
Cost of sales		(19,902	)		(11,326	)		(8,576	)		76	%
Research and development expenses		(24,475	)		(21,303	)		(3,172	)		15	%
Selling, general, and administrative expenses		(15,188	)		(13,080	)		(2,108	)		16	%
Interest (expense) income		(1,472	)		227			(1,699	)	NM
Income tax (expense) benefit		(500	)		307			(807	)	NM
Net loss		(36,230	)		(7,339	)		(28,891	)
Less: net loss attributable to non-controlling interests		(997	)		(41	)		(956	)	NM
Net loss attributable to Athenex, Inc.	$	(35,233	)	$	(7,298	)	$	(27,935	)

Revenue

Our product sales increased significantly to $25.2 million for the three months ended March 31, 2019, from $12.6 million for the three months ended March 31, 2019. However, total revenue for the three months ended March 31, 2019 decreased by $12.5 million, or 33%, as compared to $37.8 million for the three months ended March 31, 2018. The decrease was primarily due to a decrease in licensing revenue of $25.0 million related to a milestone payment in the first quarter of 2018, together with a $0.6 million decrease in both medical device product sales and contract manufacturing revenue. This decrease in total revenue was offset by the significant increase in product sales, including a $6.0 million increase in specialty product sales, a $5.0 million increase in 503B product sales, driven significantly by Vasopressin, and a $2.1 million increase in API product sales.

Cost of Sales

Cost of sales for the three months ended March 31, 2019 totaled $19.9 million, an increase of $8.6 million, or 76%, as compared to $11.3 million for the three months ended March 31, 2018. This was primarily due to the increase of $6.2 million in cost of sales from the sale of specialty products and $2.4 million in cost of sales from 503B and API products.

Research and Development Expenses

Research and development (“R&D”) expenses for the three months ended March 31, 2019 totaled $24.5 million, an increase of $3.2 million, or 15%, as compared to $21.3 million for the three months ended March 31, 2018. This was primarily due to an increase in licensing fees and preclinical development activities and included the following:

•

$6.0 million increase as a result of milestone payments for drug in-licensing fees, including to MAIA for Levothyroxine Sodium, to Ever Pharma for Eribulin and to XLifeSc for the successful IND submission in China of TAEST therapy; and

•

$1.7 million increase of preclinical development costs related to Pegtomarginase and Eribulin.

These increased costs were offset by a decrease of $2.5 million R&D costs due to the winding down of the two AK Phase 3 studies, and a decrease of $2.0 million other R&D costs related to API and 503B product development.

Selling, General, and Administrative Expenses

SG&A expenses for the three months ended March 31, 2019 totaled $15.2 million, an increase of $2.1 million, or 16%, as compared to $13.1 million for the three months ended March 31, 2018. This was primarily due to an increase of $2.6 million related to the pre-launch costs of our proprietary drugs, offset by a decrease of $0.5 million in general administrative expenses.

Interest (Expense) Income

Interest expense for the three months ended March 31, 2019 totaled $1.5 million, a change of $1.7 million as compared to $0.2 million interest income for the three months ended March 31, 2018. The interest expense in the current period was incurred from our long-term debt entered into during the third quarter of 2018.

Liquidity and Capital Resources

Capital Resources

Since our inception, we have incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from funding our R&D programs, SG&A costs associated with our operations, and the development of our specialty drug operations in our Commercial Platform and 503B operations and the investment we are making in our Commercial Platform in anticipation of commercializing our proprietary drugs. We incurred net losses of $36.2 million and $7.3 million for the three months ended March 31, 2019 and 2018, respectively. As of March 31, 2019, we had an accumulated deficit of $478.9 million. Our primary use of cash is to fund R&D costs and to fund our Commercial Platform. Our operating activities used $33.0 million and $12.7 million of cash during the three months ended March 31, 2019 and 2018, respectively. The increased cash outflow in our operating activities was primarily due to the increased R&D costs related to the funding requirements for our Commercial Platform and advancing our clinical programs, while in the same period last year, we had a significant inflow of cash resulting from an upfront license fee payment we received. We intend to continue to advance our various clinical programs which we expect will lead to increased cash outflow of R&D costs and increase our investments in commercialization activities for our proprietary drugs. In addition, we can provide no assurance that the funding requirements to diversify the product portfolio for specialty drug products in the Commercial Platform and 503B operations will decline in the future. Our principal sources of liquidity as of March 31, 2019 are cash, cash equivalents and short-term investments totaling of $71.3 million.

In July 2018, we closed a privately placed debt and equity financing deal with Perceptive for gross proceeds of $100.0 million and received aggregate net proceeds of $97.1 million, net of fees and offering expenses. We entered into a 5-year senior secured loan for $50.0 million of this financing and issued 2,679,528 shares of its common stock at a purchase price of $18.66 per share for the remaining $50.0 million. The loan matures on the fifth anniversary from the closing date and bears interest at a floating per annum rate equal to London Interbank Offering Rates (“LIBOR”) (with a floor of 2.0%) plus 9.0%. We are required to make monthly interest-only payments with a bullet payment of the principal at maturity. The loan agreement contains specified financial maintenance covenants. In connection with the loan agreement, we granted Perceptive a warrant for the purchase of 425,000 shares of common stock at a purchase price of $18.66 per share.

Based on the current operating plan, we expect that our cash and cash equivalents as of March 31, together with proceeds we have recently raised from the private placement and cash to be generated from our operating activities, will enable us to fund our operations through at least the next twelve months. We expect that our expenses will increase substantially as we continue to fund clinical and preclinical development of our research programs, pre-launch activities of our proprietary drugs and funding of our

Commercial Platform and working capital and other general corporate purposes. We have based our estimates on assumptions that might pro ve to be wrong, and we might use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to accurately esti mate the amounts of increased capital outlays and operating expenditures necessary to complete the development and commercialization of our drug candidates.

Our future capital requirements will depend on many factors, including:

•

Our ability to generate revenue and profits from our Commercial Platform or otherwise;

•

The costs, timing and outcome of regulatory reviews and approvals;

•

Progress of our drug candidates to progress through clinical development successfully;

•

The initiation, progress, timing, costs and results of nonclinical studies and clinical trials for our other programs and potential drug candidates;

•

The costs of preparing our Commercial Platform for the commercialization of our proprietary drugs;

•

The number and characteristics of the drug candidates we pursue;

•

The costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property related claims;

•

The extent to which we acquire or in-license other products and technologies; and

•

Our ability to maintain and establish collaboration arrangements on favorable terms, if at all.

We believe that the existing cash and cash equivalents and short-term investments will not be sufficient to enable us to complete all necessary development or commercially launch our proprietary drug candidates. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and government grants. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect rights of holders of common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and might require the issuance of warrants, which could potentially dilute the ownership interest of holders of common stock. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we might have to relinquish valuable rights to our technologies, future revenue streams or research programs or to grant licenses on terms that might not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we might be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market products or drug candidates that we would otherwise prefer to develop and market ourselves.

Cash Flows

The following table provides information regarding our cash flows for the three months ended March 31, 2019 and 2018:

	Three Months Ended March 31,
	2019			2018
	(in thousands)
Net cash used in operating activities	$	(32,971	)	$	(12,726	)
Net cash provided by (used in) investing activities		52,198			(56,800	)
Net cash provided by financing activities		976			68,981
Net effect of foreign exchange rate changes		1,006			478
Net increase (decrease) in cash and cash equivalents	$	21,209		$	(67	)

Net Cash Used in Operating Activities

The use of cash in our operating activities resulted primarily from our net loss adjusted for non-cash charges and changes in components of working capital. The primary use of our cash in the periods presented was to fund our research and development, regulatory and other clinical trial costs, drug licensing costs, inventory purchases, pre-launch commercialization activities, and other expenditures related to sales, marketing and administration.

Net cash used i n operating activities was $ 3 3.0 million for the three months ended March 31, 2019 . This resulted p rimarily from our n et loss of $ 36.2 million, adjus ted for non-cas h charges of $ 3.4 million, and by cash used by our operati ng assets and liabilities of $ 0. 2 million. Our operating assets in creased $ 7.6 million for accounts receivable mainly relate d to the increase sales of our specialty product s , API and 503B product s in the current year , and $11.9 million for prepaid and accrued expenses related to Dunkirk construction . I nventory de creased by $ 3.6 million primarily related to the sale of specialty drugs . Our operating liabiliti es increased by $16.4 million mainly due to an increase in accrued license fees and accrued inventory purchases . Our net non-cash charges during the three months ended March 31, 201 9 primarily consisted of $ 1.8 million of stock-based compensation expense , $ 0.9 million depreciation and amortization expense and $0.5 million of deferred income tax expense .

Net cash used in operating activities was $12.7 million for the three months ended March 31, 2018. This resulted principally from our net loss of $7.3 million, adjusted for non-cash charges of $3.3 million, and by cash used in our operating assets and liabilities of $8.7 million. Our operating assets decreased $0.6 million for accounts receivable related to API product sales, and $0.5 million for prepaid expenses primarily related to our ERP system, while inventory for API products and 503B increased by $2.0 million. Our operating liabilities decreased by $7.8 million mainly due to a decrease in accrued license fees and accrued inventory purchases. Our net non-cash charges during the three months ended March 31, 2018 primarily consisted of $2.7 million of stock-based compensation expense and $0.9 million depreciation and amortization expense.

Net Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities was $52.2 million for the three months ended March 31, 2019, compared to $56.8 million net cash used in the three months ended March 31, 2018. This was primarily due to cash obtained by the maturities of short-term investments, including commercial paper, corporate notes, and U.S. government bonds.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was $1.0 million for the three months ended March 31, 2019, which was primarily consisted of net proceeds of $0.7 million from the issuance of debt to fund our Chinese operations and $0.3 million from the exercise of employee stock options.

Contractual Obligations

A summary of our contractual obligations as of March 31, 2019 is as follows:

	Payments Due by Period
	Within 1 Year		1 to 3 years		3 to 5 years		More than 5 years		Total Amounts Committed
	(in thousands)
Operating leases	$	2,551	$	5,504	$	4,451	$	3,952	$	16,458
Long-term debt		1,535		—		50,000		—		51,535
Finance lease obligations		161		428		20		—		609
Licensing fees		654		—		—		—		654
	$	4,901	$	5,932	$	54,471	$	3,952	$	69,256

The above table includes the Company’s operating leases and the amounts committed under those leases by each location: (1) The rental of our global headquarters in the Conventus Center for Collaborative Medicine in Buffalo, NY; (2) the rental of our research and development facility in the IC Development Centre in Hong Kong; (3) the rental of the Commercial Platform headquarters in Chicago, IL; (4) the rental of our clinical research and development facility in Cranford, NJ; (5) the rental of our clinical data management center in Taipei, Taiwan; (6) the rental of our Global Supply Chain distribution office in Houston, TX; (7) the rental of our Global Supply Chain API manufacturing facility in Chongqing, China; and (8) the rental of various other facilities and equipment located mainly in Buffalo, NY.

Off Balance Sheet Arrangements

We do not maintain any off-balance sheet partnerships, arrangements, or other relationships with unconsolidated entities or others, often referred to as structured finance or special purpose entities, which are established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Critical Accounting Policies and Significant Judgments and Estimates

Our condensed consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical experience and on various other assumptions that we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

We believe that the assumptions and estimates associated with research and development expenses, chargebacks, stock-based compensation and inventory reserves have the most significant impact on our condensed consolidated financial statements. Therefore, we consider these to be our critical accounting policies and estimates.

With the exception of the change in accounting for leases under ASC 842 (see Note 9 – Debt and Lease Obligations), there have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Operations included in our Annual Report on Form 10-K for the year ended December 31, 2018.

Recent Accounting Pronouncements

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board, the Securities and Exchange Commission (SEC), or other authoritative accounting bodies to determine the potential impact they may have on our condensed consolidated financial statements. See Note 2 of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this quarterly report on Form 10-Q for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

JOBS Act

Under Section 107(b) of the Jumpstart Our Business Startups Act of 2012, (the “JOBS Act,”) an “emerging growth company” can delay the adoption of new or revised accounting standards until such time as those standards would apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, as a result, we will adopt new or revised accounting standards at the same time as other public companies that are not emerging growth companies. There are other exemptions and reduced reporting requirements provided by the JOBS Act that we are currently evaluating. For example, as an emerging growth company, we are exempt from Sections 14A (a) and (b) of the Exchange Act which would otherwise require us to (1) submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay,” “say-on-frequency” and “say-on-golden parachutes;” and (2) disclose certain executive compensation related matters. We also rely on an exemption from the rule requiring us to provide an auditor’s attestation report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and the rule requiring us to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will continue to remain an “emerging growth company” until the earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering, or December 31, 2022, (2) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1 billion, (3) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years, or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Foreign Currency Exchange Risk

A significant portion of our business is located outside the United States and, as a result, we generate revenue and incur expenses denominated in currencies other than the U.S. dollar, a majority of which is denominated in Chinese Renminbi, (“RMB”). In the three months ended March 31, 2019 and 2018, approximately 1% and 2%, respectively, of our sales, excluding intercompany sales, were denominated in foreign currencies. As a result, our revenue can be significantly impacted by fluctuations in foreign currency exchange rates. We expect that foreign currencies will represent a lower percentage of our sales in the future due to the anticipated growth of our U.S. business. Our international selling, marketing, and administrative costs related to these sales are largely denominated in the same foreign currencies, which somewhat mitigates our foreign currency exchange risk rate exposure.

Currency Convertibility Risk

A portion of our revenues and expenses, and a portion of our assets and liabilities are denominated in RMB. On January 1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the People’s Bank of China, (“PBOC”). However, the unification of exchange rates does not imply that RMB is readily convertible into U.S. dollars or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approvals of foreign currency payments by the PBOC or other institutions require submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts.

Additionally, the value of the RMB is subject to changes in Chinese central government policies and international economic and political developments affecting supply and demand in the PRC foreign exchange trading system market.

Interest Rate Sensitivity

We had cash, cash equivalents and short-term investments of $71.3 million as of March 31, 2019. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in U.S. market interest rates is not expected to have a material impact on our condensed consolidated financial condition or results of operations. We do not believe that our cash or cash equivalents have significant risk of default or illiquidity.

As of March 31, 2019, we had $50 million of debt with Perceptive that bears interest at a floating per annum rate equal to 1-Month LIBOR (with a floor of 2%) plus 9%. If 1-Month LIBOR increased by 1%, we would be required to pay Perceptive an additional $0.5 million in interest annually. If 1-Month LIBOR decreased by 1%, we would be required to pay Perceptive $0.5 million less in interest annually. A material change in the short-term interest rate environment could have a material adverse effect on our condensed consolidated financial condition or results of operations.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Board Chairman (Principal Executive Officer) and our Chief Financial Officer (Principal Financial and Accounting Officer), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2019. The term “disclosure controls and procedures,” as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2019, our Chief Executive Officer and Board Chairman (Principal Executive Officer) and our Chief Financial Officer (Principal Financial and Accounting Officer) concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended March 31, 2019 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

On August 13, 2018, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC, our wholly-owned subsidiaries, filed a complaint for declaratory judgment against Par Pharmaceuticals, Inc., Par Sterile Products, LLC and Endo Par Innovation Company, LLC (together, Par) in the United States District Court for the Western District of New York (the Court), seeking a declaratory judgment from the Court that our compounded vasopressin drug products in ready-to-use form do not infringe on patents that Par has with respect to its Vasostrict® product and that Par’s patents are invalid. On October 22, 2018, Par filed a motion to dismiss the complaint on the basis that the Court does not have subject matter jurisdiction. Athenex has opposed Par’s motion and that motion is fully briefed and currently pending. Par has not filed a claim for infringement of its patents in this suit but if Par’s motion to dismiss Athenex’s patent suit is denied and the declaratory action proceeds, Par could proceed to lodge a counterclaim for patent infringement. If such an infringement claim were brought and the Court ruled for Par, Athenex could be enjoined from further production of compounded vasopressin within in the United States and sale of compounded vasopressin in or from the United States and for payment of damages to Par for U.S. manufacture or sale of compounded vasopressin that has already taken place, which could have a material adverse effect on our business.

In addition, on August 13, 2018, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC filed a motion to intervene and seek the dismissal of Par’s complaint against the FDA and certain governmental officials in the United States District Court for the District of Columbia. Par has sought declaratory and injunctive relief against the FDA and certain governmental officials that: (i) vasopressin be delisted from Category 1 of the FDA’s list of bulk drug substances under evaluation pursuant to Section 503B of the Federal Food, Drug and Cosmetic Act (FDCA), (ii) the expansion of the FDA’s enforcement discretion to Category 1 substances, be enjoined; and (iii) that the FDA be enjoined from authorizing the compounding of vasopressin under Section 503B of the FDCA. Our motion to intervene was granted. Par filed a preliminary injunction motion and we and the FDA filed motions for judgment on the pleadings. This action is currently stayed. On March 4, 2019, the FDA published in the Federal Register its final decision not to include vasopressin on the list of bulk drug substances for which there is a clinical need. Also, on March 4, 2019, Athenex, Inc., APS, and APD filed a complaint against the FDA seeking to vacate its decision. In this case, the FDA has represented to the Court that “until the Court issues a decision on the merits of this action, the FDA will not initiate enforcement action against Athenex based solely on Athenex’s use of the bulk drug substance vasopressin to compound drugs and distribute those drugs” and the court has incorporated the FDA’s representation into its published order. Because of the court’s order, Athenex will continue to produce and distribute compounded vasopressin during the period that the case is pending and will reevaluate its position after the Court issues its decision on the merits of Athenex’s lawsuit. The Court is expected to issue its opinion during the second or third quarter of 2019. On August 14, 2018, the Company began selling compounded vasopressin injection in ready-to-use premix IV bags. If we are unsuccessful in obtaining the relief we seek in our lawsuit against the FDA, or there is an adverse final determination that the patent is valid and infringed, we would have to abandon this revenue-generating line of business; such events could have an adverse effect on the Company’s business, results of operations, financial condition and cash flows.

Item 1A. Risk Factors.

See “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018, for a detailed discussion of the risk factors affecting the Company. There have been no material changes to our previously disclosed risk factors.

Item 6. E xhibits.

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.

		Incorporated by Reference (Unless Otherwise Indicated)
Exhibit Number	Exhibit Title	Form	File	Exhibit	Filing Date

10.31.1	First Amendment to Agreement by and between M+W U.S., Inc. and Athenex, Inc., effective as of March 27, 2018	—	—	—	Filed herewith

10.31.2	Second Amendment to Agreement by and between M+W U.S., Inc. and Athenex, Inc., effective as of October 1, 2018.	—	—	—	Filed herewith

10.31.3	Third Amendment to Agreement by and between Exyte U.S., Inc. (f/k/a M+ W U.S., Inc., effective as of January 23, 2019.	—	—	—	Filed herewith

31.1	Certification of the Chief Executive Officer and Board Chairman (Principal Executive Officer) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .	—	—	—	Filed herewith

31.2	Certification of the Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.	—	—	—	Filed herewith

32.1	Certification of the Chief Executive Officer and Board Chairman (Principal Executive Officer) and the Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	—	—	—	Filed herewith

101.INS	XBRL Instance Document.	—	—	—	Filed herewith

101.SCH	XBRL Taxonomy Extension Schema Document.	—	—	—	Filed herewith

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.	—	—	—	Filed herewith

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.	—	—	—	Filed herewith

101.LAB	XBRL Taxonomy Extension Label Linkbase Document.	—	—	—	Filed herewith

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.	—	—	—	Filed herewith

SIGNAT URES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Athenex, Inc.

Date: May 9, 2019	By:	/s/ Johnson Y.N. Lau
		Chief Executive Officer and Board Chairman (Principal Executive Officer)
Date: May 9, 2019	By:	/s/ Randoll Sze
		Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 10.31.1

FIRST AMENDMENT

TO THE

AGREEMENT

THIS FIRST AMENDMENT TO THE AGREEMENT (the “ First Amendment ”) effective as of March 27, 2018 , (the “ First Amendment Effective Date ”), is by and between Athenex, Inc. , a(n) New York Company/Corporation/Sole Proprietor/LLC, having an address at Conventus Building, 1001 Main Street, Suite 600, Buffalo NY 14023 (hereinafter referred to as “Owner”) and M+W U.S., Inc. , a Delaware Corporation, having an address at 201 Fuller Road, Suite 401, Albany, New York 12203 , (hereinafter referred to as “ M+W ” ) . Capitalized terms used and not otherwise defined herein shall have the meaning set forth in the AGREEMENT (as defined below).

RECITALS :

Whereas Owner and M+W entered into that certain Agreement , between M+W U.S., Inc. and Owner , (collectively the “parties”), dated 29 December, 2017 (the “Original Agreement”).

Whereas, Owner and M+W desire to further supplement and amend the Original Agreement, including all previous Amendments, if any, on the terms and conditions set forth herein.

Whereas, the Original Agreement executed by the parties is in the form of AIA A141 (the “Form”). The Form is structured to allow for Preliminary Design to be accomplished and then, by using such Preliminary Design documents approved by the Owner, establish a Guaranteed Maximum Price (GMP) for the overall Contract Sum. The Form is structured to memorialize such GMP in AIA A141 Exhibit A, (called the ‘Amendment’)

Whereas, the Original Agreement requires the parties agree to a GMP prior to continuing on with the execution of the remainder of the Work, specifically the:

Detailed design; and

Construction (including procurement of Long Lead Materials and Equipment).

Whereas, the parties agree that “Phase I of the Work” of the Original Agreement ( §1.1.6.1 ) and “ Phase II of the Work” (BOD) ( §1.1.6.2.2), have both been properly performed.

Whereas, the parties agree that they will not be prepared to agree to a GMP by February 28, 2018 as contemplated by the Original Agreement

NOW, THEREFORE , for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Owner and M+W agree that the Original Agreement shall be further amended as of the First Amendment Effective Date as follows which shall supersede the Original Agreement as stated herein:

The parties have agreed to extend the targeted date of executing Exhibit A of the Form to a date which is mutually agreed and reasonably appropriate for the progress of the Project.

The parties agree that, for the avoidance of doubt, and the Substantial Completion Date is as originally agreed, and remains December 31, 2019;

The parties agrees that the existing §14.1.11 shall be DELETED in its entirety and REPLACED with the following:

“§ 14.1.11 In order to recover liquidated damages, the Owner is under no obligation to prove the actual damages sustained by the Owner due to the Design-Builder’s delay in performance. The parties agree that liquidated damages shall be computed as follows for each and every day that completion of the Work shall be delayed beyond the date of the Date of Substantial Completion (as may have been adjusted during the course of the Project by Change Order). For the first thirty (30) days after the Date of Substantial Completion, Design Builder shall owe the Owner no liquidated damages for every day past the Date of Substantial Completion for the Project (as it may have been adjusted by Change Order). Design Builder shall owe the Owner liquidated damages in the amount of $2,500 per day for every day the Design-Builder fails to achieve Substantial Completion per the schedule for Project (as it may have been adjusted by Change Order)for the thirty-first (31 ^st ) through ninetieth (90 ^th ) day of said failure. The Design-Builder shall owe the Owner liquidated damages in the amount of $5,000 per day for failure to achieve Substantial Completion within ninety-one (91) to one hundred fifty (150) days of the contractually required date of Substantial Completion (as it may have been adjusted by Change Order). Any failure of the Design-Builder to achieve Substantial Completion (as it may have been adjusted by Change Order) pursuant to the Project schedule after one hundred fifty (150) days shall result in liquidated damages of $7,500 per day.”

The parties agree that the conditional dates listed in §1.1.7.4 b), c), d) and e) shall be modified to read as follows:

“§1.1.7.4 b) placement of Electrical Switchgear Equipment order by 30 July, 2018;

§1.1.7.4 c) delivery of Electrical Switchgear Equipment at the site by 22 March, 2019;

§1.1.7.4 d) Letter of Intent for structural steel mill pricing - Issued by 19 March, 2018;

§1.1.7.4 e) Commencement of the Phase III site work by 16 April, 2018.”

Failure to achieve any or all of the dates listed at no fault of Design Builder, the parties therein shall also further extend the agreed-to Substantial Completion Date on the stated day-for-day basis. Additional new dates shall trigger further extension of Substantial Completion Dates.

The parties agrees that the existing §1.1.6.3 and §1.1.6.4 shall be DELETED in their entirety:

and REPLACED with the following:

“ 1.1.6.3

Phase III A of the Work consists of; (amount of fund committed to by Owner and agreed to between the parties as of the Effective Date of this Amendment #1 ) and become part of the committed costs of the Original Agreement via this Amendment #1. Thus the total current committed cost to date by the Owner is as indicated in #7 below, which includes:

Owner Committed Funding that shall be compensated on a Cost of Work + Indirects (“CWI”) Basis up to a Not-To-Exceed (NTE) amount currently set as shown and described for the portion of the Work defined as Phase III A in AMND#1- Exhibit – 1 .

Minimum Owed Design-Builder’s Fee @ 2.5% of the Cost of Work ;

Services shall be progress-invoiced for payment on a monthly basis;

“ 1.1.6 . 4

Phase III B of the Work consists of the remainder of the Work described in the Design-Builder’s BOD Report for the remaining amount of the total amount of ($238,607,321), the GMP, (described in the Design-Builder’s letter dated 26 March, 2018 from Mr. Werner Greyling to Mr. Rich Nassar; including the savings and sharing described therein) but which additional scope is not identified in detail in AMND#1- Exhibit – 1 as part of Phase III A; The parties agree this final portion (i.e. Phase III B) of the scope, the schedule and the GMP for the Project shall be memorialized and agreed-to in Exhibit A (the Amendment) as originally planned.”

“1.1.6.5

Qualification and Validation is not included in Design-Builder’s estimated GMP.”

7) COMPENSATION – Adjustments to the Contract Sum are as shown below:


Original Agreement Contract Sum	$ 4,518,676.00
Authorized Change Orders as of Effective Date of this Amendment	$ 0
Sub-Total	$ 4,518,676.00
Total Adjustment(s) by Previous Amendment(s)	$ 0
Sub-Total	$ 4,518,676.00
Adjustment(s) by This Amendment	$ 73,045,379.35
Total Contract Sum as of Effective Date of this Amendment # 1*	$ 77,564,055.35

* NOTE: The Total Contract Sum shown here may be further adjusted by additional mutually agreed to Change Orders in accordance with the provisions of the Original Agreement between the parties, after the Effective Date of this Amendment. The parties each agree execution of this Amendment does not prohibit such further adjustments to the Contract Sum after the Effective Date of this Amendment.

IN WITNESS WHEREOF , Owner and M+W have entered into this First Amendment to the Original Agreement effective as of the First Amendment Effective Date indicated above.

Agreed and accepted by :


M+W U.S., Inc.		M+W U.S., Inc.		Athenex, Inc.
/s/ Werner Greyling	March 29, 2018	/s/ Rick Whitney	March 29, 2018	/s/ Richard Nassar	March 28, 2018
Signature	Date	Signature	Date	Signature	Date
Werner Greyling		Rick Whitney		Richard Nassar
Print Name		Print Name		Print Name
VP Operations		CEO		VP of Operations
Title (an authorized representative of M+W U.S., Inc.)		Title (an authorized representative of M+W U.S., Inc.)		Title (an authorized representative of Owner)

1.Detail Design-March thru Oct 12 2018

AMND#1- Exhibit - 1

5/31/2018 R

Detail Design forward, providing design support of early procurement of process equipment and long lead mechanical /electrical equipment. Review shop drawings for early construction packages answer bidders questions. And completing DD to allow Bidding Activities for Construction

M+W Process & Overall Management			2,088,956.90
Genesis MEP & Architectural			2,218,318.00
Ryan Biggs – Structural			100,000.00
CPL – Complete Design			66,100.00
Process Automation – Automation/ I&C			372,928.00
M+W Printing, postage, Contingency			200,000.00
M+W Travel Allowance			102,120.00
Commissioning Support (DEFERED to AFTER OCT)			-
			5,148,422.90

2.Construction Support Services from Design - March thru Oct 12 2018

Detail Design Team, providing design support of early procurement of process equipment and long lead mechanical /electrical equipment. Review shop drawings for early construction packages answer bidders questions. And submittal package reviews from DD to allow Bidding Activities for Construction

	Bridging Amount	Full Allowance
M+W Process & Overall Management	102,213.15	681,421
Genesis MEP & Architectural	159,660.00	638,640
Ryan Biggs – Structural	75,000.00	100,000
CPL – Complete Design	131,100.00	131,100
Process Automation – Automation/ I&C	-	60,000
M+W Printing, postage, Contingency	25,000.00	92,900
M+W Travel Allowance	15,000.00	34,040
	507,973.15	1,738,101

3,Construction Management Services March thru Oct 12, 2018

Services provided for early procurement packages for Site,Steel,Foundations,Building Core/Shell, Process and Long Lead Mechanical/ Electrical Equipment,Construction Trailor Setup and Temporary Power Hookup. Construction Management Services, invoicing, team set up and site oversite.

The Pike Management Team manpower Labor Hours funding	Bridging Amount		Full Allowance
M+W Management Team manpower Labor Hours funding		1,378,417.82		3,061,360
General Conditions Allowance funding		1,563,882.18		5,873,509
General Items - $600K		600,000.00		2,900,000
		3,542,300.00		11,834,869

4.Construction Commitments

Following Packages will need to be able to make financial Commitments: Values	Date / Commit
a) Temporary Construction Trailers Order, set up, utilities hook up - $400K		400,000.00	April 9, 2018
b) Temporary Power set up, hook ups w/ Single Source Elect Contractor - $160K		160,000.00	April 9, 2018
c) Site Development Activities Package		8,825,654.00	April 1, 2018
Div 31-$6,253,300; Div 32-$403,860; Div 33-$2,168,494
d) Steel Procurement / Fabrication Package		10,480,139.00	March 16 2018	Div 05
e) Foundations Package		2,933,220.00	March 30 2018	Div 03
f) Slab on Grade & Slab on Deck		3,812,937.00	March 30 2018	Div 03
g) Siding		3,109,941.00	June 1, 2018	Div 07
h) Fire Proofing		402,240.00	July 1, 2018	Div 07
i) EPDM Roofing		3,329,898.00	July 23 2018	Div 07
j) Site Electric		1,700,000.00	July 1, 2018	Div 33
k) Under Ground Plumbing (inside Bldg)		2,400,000	April 16 2018	Div 22
	$	37,554,029.00

5.Long Lead Equipment


a) LL Mech Equipment; Chillers, Cooling Towers, Boilers, Compressors	Est -	9,700,000	Apr - June 2018	Div 23
b) Long Lead Electrical Switch Gear, XMFR’s, equipment	Es	9,200,000	July 30, 2018	Div 26
c) Long Lead Process Equipment		5,000,000	Apr - June 2018	Div 41
		$ 23,900,000.00

6, Insurance

a) M+W Insurance Thru to MAR 2018	$	506.000
b) M+W Insurance 2 Quarter Prior Oct	$	304.000

7, Fee at 2.5% on COW To Be Billed Monthly on COW

Fee Commitment Against Item 4 & 5

1,536,351

8, T ravel Allowance

Increase beyond BOD Values		$	46,303.57
Total Requested Commitment Funds			$ 73,045,379.35

Exhibit 10.31.2

SECOND AMENDMENT

TO THE

AGREEMENT

THIS SECOND AMENDMENT TO THE AGREEMENT (the “ Second Amendment ”) effective as of October 1, 2018 , (the “ Second Amendment Effective Date ”), is by and between Athenex, Inc. , a(n) New York Company/Corporation/Sole Proprietor/LLC, having an address at Conventus Building, 1001 Main Street, Suite 600, Buffalo NY 14023 (hereinafter referred to as “Owner”) and M+W U.S., Inc. , a Delaware Corporation, having an address at 201 Fuller Road, Suite 401, Albany, New York 12203 , (hereinafter referred to as “ M+W ” ) . Capitalized terms used and not otherwise defined herein shall have the meaning set forth in the AGREEMENT (as defined below).

RECITALS :

Whereas Owner and M+W entered into that certain Agreement , between M+W U.S., Inc. and Owner , (collectively the “parties”), dated 29 December, 2017 (the “Original Agreement”) and the First Amendment dated effective March 27, 2018.

Whereas, Owner and M+W desire to further supplement and amend the Original Agreement and the First Amendment , including all previous Amendments, if any, on the terms and conditions set forth herein.

Whereas, the Original Agreement and the First Amendment require the parties agree to a GMP prior to continuing on with the execution of the remainder of the Work, specifically the:

Detailed design; and

Construction (including procurement of Long Lead Materials and Equipment).

NOW, THEREFORE , for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Owner and M+W agree that the Original Agreement shall be further amended as of the Second Amendment Effective Date as follows which shall supersede the Original Agreement and the First Amendment as stated herein:

The parties have agreed to extend the targeted date for executing Exhibit A of the Form (i.e. establishment of the GMP), from October 12, 2018 until November 16, 2018, based on the following timeline:

9/15: 85% Package issued to bidders

10/12: IFC from GEI

10/16: Provide IFC drawings and specifications to bidders

10/26: Bids Due from subs

10/29 – 11/2: Bids opened / leveling start / Assemble GMP

11/5 – 11/9: M+W Germany Approval Expected to Start

11/12: Target Date for GMP value submitted to Athenex. Submitted expected to be no later than 11/16.

11/30: Final AIA A141 Exhibit A (the “Amendment”) executed.

The parties agree that, for the avoidance of doubt, and the Substantial Completion Date is as originally agreed, and remains December 31, 2019;

The parties agree that in order to maintain the current project schedule prior to the date establishing the GMP (as shown above in Section 1.g), additional funding is necessary. Owner agrees to commit an additional amount (shown in #4 below) via this 2 ^nd Amendment to increase the Contract Sum. This increase is based on the parties’ reasonable estimate necessary to maintain funding between the Second Amendment Effective Date and the execution of Exhibit A (now scheduled as shown in Section 1.h above). Such funding shall be for construction management, bidding, awarding the work, material/equipment order commitments, other costs, reimbursables, design and fees, as required under the Original Agreement, the 1 ^st Amendment and this 2 ^nd Amendment.

COMPENSATION – Adjustments to the Contract Sum are as shown below:


Original Agreement Contract Sum	$ 4,518,676.00
Previous Amendment(s)	$73,045,379.35
Sub-Total	$ 77,564,055.35
Authorized Change Orders as of Effective Date of this 2 ^nd Amendment (deductive)	($ 132,097.00)
Sub-Total	$ 77,431,958.35
Adjustment(s) by this 2 ^nd Amendment	$64,768,445.00
Total Contract Sum as of Effective Date of this 2 ^nd Amendment*	$142,200,403.35

* NOTE: The Total Contract Sum shown here may be further adjusted by additional mutually agreed to Change Orders in accordance with the provisions of the Original Agreement and First Amendment between the parties, after the Effective Date of this 2 ^nd Amendment. The parties each agree execution of this 2 ^nd Amendment does not prohibit such further adjustments to the Contract Sum after the Effective Date of this 2 ^nd Amendment.

IN WITNESS WHEREOF , Owner and M+W have entered into this Second Amendment to the Original Agreement and the First Amendment effective as of the Second Amendment Effective Date indicated above.

Agreed and accepted by :


M+W U.S., Inc.		M+W U.S., Inc.		Athenex, Inc.
/s/ Rick Whitney	October 4, 2018	/s/ Todd Muckelroy	October 4, 2018	/s/ Richard Nassar	October 5, 2018
Signature	Date	Signature	Date	Signature	Date
Rick Whitney		Todd Muckelroy		Richard Nassar
Print or Type Name		Print or Type Name		Print or Type Name
CEO		CFO		VP of Operations
Title (an authorized representative of M+W U.S., Inc.)		Title (an authorized representative of M+W U.S., Inc.)		Title (an authorized representative of Owner)

Amendment #2 Funding Summary

							Hard Bids		Estimated Costs
COW
Division	Applicable GMP Est.		Current Funding		Current Commitments		Pending RTA's		PCO's		Add'l Commitments Forecasted (by 12/1)		Total Forecasted Commitments as of 12/1		Delta			Amendment 2 Funding			Revised Contract Value			Notes	Comments
1	$	5,015,730	$	560,000	$	468,973					$	350,000	$	818,973	$	(258,973	)	$	600,000		$	1,160,000
3	$	7,727,690	$	7,946,157	$	6,415,313	$	0.00	$	1,423,920	$	750,000	$	8,589,233	$	(643,076	)	$	643,076		$	8,589,233			PCO's based on current log 8/16. Additional Forecast based on curbs, exterior apron and housekeeping pads.
5	$	12,038,894	$	11,980,139	$	10,179,632	$	-	$	1,553,850	$	1,200,000	$	12,933,482	$	(953,343	)	$	1,012,098		$	12,992,237			PCO's based on current log 8/16. $305K for revisions to steel framing, Parapet framing, structural studs at area A. ($58,755 remaining budget + $953,343 Contingency)
7	$	7,879,221	$	6,842,079	$	3,053,083	$	2,957,000	$	50,000	$	750,000	$	6,810,083	$	31,996		$	500,000		$	7,342,079			Roofing & Spray Fireproofing. PCO is for expected blocking.
8	$	3,747,181	$	-	$	-	$	800,000			$	1,200,000	$	2,000,000	$	(2,000,000	)	$	2,000,000		$	2,000,000			Curtain Wall based on RTA value. Additional funds for roll-up doors, storefront doors, other misc. openings.
9	$	7,879,221	$	-							$	3,600,000	$	3,600,000	$	(3,600,000	)	$	3,600,000		$	3,600,000			Needed for studs, drywall start, coordinate with MEP.
11	$	2,525,360	$	-	$	-	$	-			$	1,200,000	$	1,200,000	$	(1,200,000	)	$	1,200,000		$	1,200,000			Loading docks and DEA vault estimate
13	$	4,375,270	$	-							$	3,800,000	$	3,800,000	$	(3,800,000	)	$	3,800,000		$	3,800,000			Clean Room - need to place order and start design coordination/shop drawings.
14	$	470,316	$	-	$	-	$	-			$	940,000	$	940,000	$	(940,000	)	$	940,000		$	940,000			Elevators and Coolers. (Need to confirm Cooler budget location)
21	$	2,157,401	$	-	$	-	$	-			$	2,157,401	$	2,157,401	$	(2,157,401	)	$	2,157,401		$	2,157,401			Sprinkler Contractor - Need for Insurance/final design
22	$	10,826,130	$	2,400,000	$	2,593,039	$	-	$	130,000	$	6,000,000	$	8,723,039	$	(6,323,039	)	$	6,500,000		$	8,900,000			Underground plumbing awarded, but over current funding. $6M based on 50% of Mech/Plumbing budget, need to award for coordination with Arch.
23	$	41,064,161	$	9,700,000	$	-	$	-			$	24,500,000	$	24,500,000	$	(14,800,000	)	$	14,800,000		$	24,500,000			Based on LLE & ability to award wet mech. (Includes $3.0M for purchase of previously VE'd mech. Equipment for full build-out. Anticipated budget to award wet mechanical $19M.
25	$	5,869,253	$	-	$	-	$	-			$	4,800,000	$	4,800,000	$	(4,800,000	)	$	4,800,000		$	4,800,000			I&C needed to coordinate MEP/communications.
26	$	16,044,041	$	9,200,000	$	6,325,000	$	-	$	300,000	$	4,500,000	$	11,125,000	$	(1,925,000	)	$	1,925,000		$	11,125,000			Additional gear need to procure includes interior gear, generators.
31	$	7,060,929	$	6,253,300	$	5,597,122	$	-	$	186,025	$	750,000	$	6,533,147	$	(279,847	)	$	807,629		$	7,060,929
32	$	2,446,666	$	746,670	$	577,920	$	-	$	50,000	$	1,800,000	$	2,427,920	$	(1,681,250	)	$	1,699,996		$	2,446,666			Balance of exterior improvements - client request to award to existing contractor before 12/1.
33	$	9,497,824	$	4,825,684	$	2,166,008	$	-	$	20,000	$	3,200,000	$	5,386,008	$	(560,324	)	$	600,000		$	5,425,684			Scope required to get electrical duct bank, site lighting and other site services completed before end of year.
41	$	18,251,360	$	1,000,000	$	-	$	-	$	-	$	11,000,000	$	11,000,000	$	(10,000,000	)	$	10,000,000		$	11,000,000			Replaces
Contingency	$	22,552,021	$	-	$	-	$	-							$	-		$	4,500,000		$	4,500,000			Contingency for future reallocation
Contingency																		$	(643,076	)	$	(643,076	)		Division 3 Allocation
Contingency																		$	(953,343	)	$	(953,343	)		Division 5 Allocation
Contingency																		$	(469,684	)	$	(469,684	)		Division 14 Allocation
Total COW	$	187,428,669	$	61,454,029	$	37,376,090	$	3,757,000	$	3,713,795	$	72,497,401	$	117,344,286	$	(55,890,257	)	$	60,019,097		$	121,473,126

Indirects
Insurance	$	1,772,880	$	810,000	$	810,000					$	152,000						$	152,000		$	962,000			One quarter of insurance billing
BOD	$	4,564,980	$	4,507,676	$	4,507,676					$	-						$	-		$	4,507,676
DD/CA	$	6,936,524	$	5,656,396	$	5,656,396					$	1,280,128						$	1,280,128		$	6,936,524			Need toc commit balance of detailed design and CA efforts, already underway.
EPCM	$	8,934,869	$	2,942,300	$	2,942,300					$	1,200,000						$	1,200,000		$	4,142,300			Additional CM Efforts
GC's	$	2,900,000	$	600,000	$	600,000					$	600,000						$	600,000		$	1,200,000			GC's needed to cover monthly costs. (Large commitments early for trailer set-up. Plotter, copier, etc.) Deducted the $74,793 from GC' s
FEE	$	4,432,201	$	1,536,351	$	1,536,351					$	1,439,584						$	1,517,220		$	3,053,571
Total	$	29,541,454	$	16,052,723	$	16,052,723	$	-	$	-	$	4,671,712	$	-	$	-		$	4,749,348		$	20,802,071

																		$	64,768,445		$	142,275,197		Revised Contract Value	Requested Funding - Amendment 2
																		$	77,506,752		Included above				Current Funding
																		$	(74,794	)	$	(74,794	)		Change Orders
																		$	142,200,403		$	142,200,403			Revised Contract Value with Amendment 2

5/8/2019

Revision 8

Exhibit 10.31.3

AIA ^® Document A141™ – 2014 Exhibit A Design-Build Amendment

This Amendment is incorporated into the accompanying AIA Document A141™–2014, Standard Form of Agreement Between Owner and Design-Builder dated the 29 ^th of December 2017 (the “Agreement”). The effective date of this Exhibit A Amendment (“Third Amendment”) is the 23 ^rd day of January in the year 2019.

(In words, indicate day, month and year.)

for the following PROJECT:

(Name and location or address)

Athenex Dunkirk Plant Project, for Athenex, Inc. Manufacturing Facility located in

Dunkirk, NY

THE OWNER:

(Name, legal status and address)

Athenex, Inc. ("Athenex")

Conventus Building

1001 Main Street, Suite 600

Buffalo, New York 14203

THE DESIGN-BUILDER:

(Name, legal status and address)

Exyte U.S., Inc. ("Exyte” f/k/a M+W U.S. Inc.)

1001 Klein Road, Suite 400

Plano, Texas 75074

Design-Builder’s Architect (“Architect” or “Subconsultant”) is:

Genesis Architects

523 Plymouth Road

Plymouth Meeting, PA 19462

RECITALS

WHEREAS, Owner and Design-Builder entered into that certain Agreement on or about December 29, 2017;

WHEREAS, Owner and Design-Builder entered into the First Amendment to the Agreement, dated effective March 27, 2018 (“First Amendment”);

WHEREAS, Owner and Design-Builder entered into the Second Amendment to the Agreement (“Second Amendment”), dated effective October 1, 2018;

WHEREAS, Owner and Design-Builder desire to amend the Agreement by entering into this Exhibit A (as referenced in the Agreement) Third Amendment to the Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Owner and Design-Builder hereby amend the Agreement as follows.

TABLE OF ARTICLES

A.1 CONTRACT SUM

A.2 CONTRACT TIME

A.3 INFORMATION UPON WHICH THIRD AMENDMENT IS BASED

A.4 DESIGN-BUILDER’S PERSONNEL, CONTRACTORS AND SUPPLIERS

A.5 COST OF THE WORK

ARTICLE A.1 CONTRACT SUM

§ A.1.1 The Owner shall pay the Design-Builder the Contract Sum in current funds for the Design-Builder’s performance of the Contract after the execution of this Third Amendment.

(Check the appropriate box.)

[ ] Stipulated Sum, in accordance with Section A.1.2 below

[ ] Cost of the Work plus the Design-Builder’s Fee, in accordance with Section A.1.3 below

[ XX ] Cost of the Work plus the Design-Builder’s Fee with a Guaranteed Maximum Price, in accordance with Section A.1.4 below

(Based on the selection above, complete Section A.1.2, A.1.3 or A.1.4 below.)

§ A.1.2 Not used.

§ A.1.3 Not used.

§ A.1.4 Cost of the Work Plus Design-Builder’s Fee With a Guaranteed Maximum Price

§ A.1.4.1 The Cost of the Work is as defined in Article A.5, Cost of the Work.

§ A.1.4.2 The Design-Builder’s Fee: 2.5% of Cost of Work

(State a lump sum, percentage of Cost of the Work or other provision for determining the Design-Builder’s Fee and the method for adjustment to the Fee for changes in the Work.)

The Design-Builder’s Fee shall be 2.5% of the Cost of Work.

§ A.1.4.3 Guaranteed Maximum Price

§ A.1.4.3.1 The sum of the Cost of the Work, the Design-Builder’s Fee, and Pike’s Fee (defined below) is guaranteed by the Design-Builder not to exceed Two hundred twelve million, five hundred ninety four thousand, eight hundred six dollars ($ 212,594,806 ), subject to additions and deductions for changes in the Work as provided in the Design-Build Documents. Costs that would cause the Guaranteed Maximum Price (“GMP”) to be exceeded shall be paid by the Design-Builder without reimbursement by the Owner.

(Insert specific provisions if the Design-Builder is to participate in any savings.)

Design-Builder is entitled to shared savings based on the final Contract cost including Fee (“Final Cost”), being delivered under $ 212,594,806 . If the Final Cost of the Project is less than $ 212,594,806 , then Design-Builder shall be entitled to the first $150,000 (one-hundred and fifty thousand dollars) of the total savings. Thereafter, Design-Builder shall be compensated in a shared savings value, which shall equal Forty Percent (40%) of the difference between the Final Cost and $ 212,444,806 (GMP - $150,000 = $212,444,806) .

§ A.1.4.3.2 Itemized Statement of the Guaranteed Maximum Price

Provided below is an itemized statement of the Guaranteed Maximum Price organized by trade categories, allowances, contingencies, alternates, the Design-Builder’s Fee, and other items that comprise the Guaranteed Maximum Price.

(Provide information below or reference an attachment.)

See Exyte Cost Breakdown of Guaranteed Maximum Price, including Design-Builder's fee, attached hereto as EXHIBIT 1.

The Guaranteed Maximum Price is based on the total dollar value of the Project and shall not be considered a line-item GMP. For the avoidance of doubt, Design-Builder is striving to ensure that that Project’s overall Final Cost is delivered at or under the GMP amount; however, Design-Builder is not guaranteeing to meet any particular line-item amount. As such, Design-Builder shall have the authority to reallocate funds within the GMP value as necessary, without increasing the GMP budget.

§ A.1 .4.3 .3 The Guaranteed Maximum Price is based on the following alternates, if any, which are described in the Design-Build Documents and are hereby accepted by the Owner:

(State the numbers or other identification of accepted alternates. If the Owner is permitted to accept other alternates subsequent to the execution of this Third Amendment, attach a schedule of such other alternates showing the change in the Cost of the Work and Guaranteed Maximum Price for each and the deadline by which the alternate must be accepted.)

GMP includes equipment purchases for Boilers, Chillers and Cooling Towers as outlined in signed Recommendation to Award, (RTA), executed prior to execution of this Agreement.

Additional requests by Athenex to reduce scope and defer various areas/equipment are incorporated into this price; however, contract documents (drawings and specifications) have not been updated to reflect the reduced scope. Drawings 1-A-214_RJ_Notes_25OCT18 and 1-A-224_RI_Notes_22OCT18 as outlined on the Drawings list (Exhibit 3) clearly identify the scope reduction areas. GMP pricing sheets as shown in Exhibit 1 (dated March 1, 2019) hereto outline the process equipment and other items removed from the GMP and associated scopes of work (including but not limited to other disciplines such as mechanical, electrical, architectural, and controls). For the avoidance of doubt, the following packages have been removed from the GMP and associated scopes of work:


Bid Package Number	Bid Package Description
PQ008	Formulation Tanks and Platforms
PQ009	TCU
PQ011	Transfer and Utility Panels
PQ013	Syringe Assembly and labeling
PQ017	Downflow Booths
PQ018	Mixproof Valve Manifold

GMP price includes costs for winter conditions, temporary in-fills, temporary power and temporary heat as previously agreed and currently being executed to maintain the project schedule. Owner agrees that these costs are included within the GMP and shall be reimbursed.

§ A.1 .4.3 .4 Unit Prices, if any:

(Identify item, state the unit price, and state any applicable quantity limitations.)


Item	Units and Limitations	Price per Unit ($0.00)
NOT APPLICABLE

§ A. 1.4.3. 5 Assumptions, if any, on which the Guaranteed Maximum Price is based:

GMP is based on Phase 1 area only, including equipment lists and User Requirements Specification Number 5, dated February 20, 2018.

User Requirements Specification Number 6, dated October 19, 2018 and issued November 2, 2018, lists deferred areas and scope reductions captured via the subcontractor bidding efforts. For the avoidance of doubt, the terms and the scope in User Requirements Specification Number 6 is not included in this Third Amendment, the Agreement, and/or all related exhibits and amendments thereto, and the items outlined in the User Requirements Specifications that are not included in the drawings are not considered required scope for this Project. The Parties further understand and agree that the Contract Drawings and Specifications listed in Exhibits 2 & 3 represent the agreed-upon scope of work, and therefore, supersede and override the terms of User Requirements Specifications.

The Parties hereto understand and agree that if deferred scope is added back into the Project, then a Change Order, increasing the GMP cost and Contract Time , shall be issued to address all additional scope changes, in accordance with § 6.2 and 8.2 of the Agreement.

§ A.1.5 Payments

§ A.1.5.1 Progress Payments

§ A.1.5.1.1 Based upon Applications for Payment submitted to the Owner by the Design-Builder, the Owner shall make progress payments on account of the Contract Sum to the Design-Builder as provided below and elsewhere in the Design-Build Documents.

§ A.1 .5.1.2 The period covered by each Application for Payment shall be one calendar month ending on the last day of the month, or as follows:

§ A.1.5. 1.3 Provided that an Application for Payment is received not later than the 30TH day of the month, the Owner shall make payment of the certified and undisputed amount to the Design-Builder not later than the 30TH day of the subsequent month. Timely payment is a material term to this Agreement. Exyte also recognizes that Project funding is being provided to Athenex by the State of New York. Amounts remaining unpaid sixty (60) days after certified and undisputed invoiced amounts are received by Athenex from Exyte shall bear interest at the rate of 1.5% per month on the unpaid balance. Exyte acknowledges that approval of the New York State Empire State Development Corporation is required under this Contract prior to payment. Said approval shall not be unreasonably withheld. Exyte further acknowledges its responsibility to provide appropriate documentation required by the New York State Empire Development Corporation, including, but not limited to, all required payment application forms and MWBE information/certifications.

(Federal, state or local laws may require payment within a certain period of time.)

§ A.1.5.1.4 With each Application for Payment where the Contract Sum is based upon the Cost of the Work, or the Cost of the Work with a Guaranteed Maximum Price, the Design-Builder shall submit payrolls, petty cash accounts, receipted invoices or invoices with check vouchers attached, and any other evidence required by the Owner to demonstrate that cash disbursements already made by the Design-Builder on account of the Cost of the Work equal or exceed (1) progress payments already received by the Design-Builder, less (2) that portion of those payments attributable to the Design-Builder’s Fee; plus (3) payrolls for the period covered by the present Application for Payment.

§ A.1.5.1.5 With each Application for Payment where the Contract Sum is based upon a Stipulated Sum or Cost of the Work with a Guaranteed Maximum Price, the Design-Builder shall submit the most recent schedule of values in accordance with the Design-Build Documents. The schedule of values shall allocate the entire Contract Sum among the various portions of the Work. Compensation for design services, if any, shall be shown separately. Where the Contract Sum is based on the Cost of the Work with a Guaranteed Maximum Price, the Design-Builder’s Fee shall be shown separately. The schedule of values shall be prepared in such form and supported by such data to substantiate its accuracy as the Owner may require. This schedule of values, unless objected to by the Owner, shall be used as a basis for reviewing the Design-Builder’s Applications for Payment.

§ A.1.5.1.6 In taking action on the Design-Builder’s Applications for Payment, the Owner shall be entitled to rely on the accuracy and completeness of the information furnished by the Design-Builder and shall not be deemed to have made a detailed examination, audit or arithmetic verification of the documentation submitted in accordance with Sections A.1.5.1.4 or A.1.5.1.5, or other supporting data; to have made exhaustive or continuous on-site inspections; or to have made examinations to ascertain how or for what purposes the Design-Builder has used amounts previously paid. Such examinations, audits and verifications, if required by the Owner, will be performed by the Owner’s auditors acting in the sole interest of the Owner.

§ A.1.5.1 .7 Except with the Owner’s prior approval, the Design-Builder shall not make advance payments to suppliers for materials or equipment which have not been delivered and stored at the site.

§ A.1.5.2 Not used.

§ A.1.5.3 Not used.

§ A.1.5.4 Progress Payments—Cost of the Work Plus a Fee with a Guaranteed Maximum Price

§ A.1.5.4.1 Applications for Payment where the Contract Sum is based upon the Cost of the Work Plus a Fee with a Guaranteed Maximum Price shall show the percentage of completion of each portion of the Work as of the end of the period covered by the Application for Payment. The percentage of completion shall be the lesser of (1) the percentage of that portion of the Work which has actually been completed; or (2) the percentage obtained by dividing (a) the expense that has actually been incurred by the Design-Builder on account of that portion of the Work for which the Design-Builder has made or intends to make actual payment prior to the next Application for Payment by (b) the share of the Guaranteed Maximum Price allocated to that portion of the Work in the schedule of values.

§ A.1.5.4.2 Subject to other provisions of the Design-Build Documents, the amount of each progress payment shall be computed as follows:

.1 Take that portion of the Guaranteed Maximum Price properly allocable to completed Work as determined by multiplying the percentage of completion of each portion of the Work by the share of the Guaranteed Maximum Price allocated to that portion of the Work in the schedule of values. Pending final determination of cost to the Owner of changes in the Work, amounts not in dispute shall be included as provided in Section 6.3.9 of the Agreement.

.2 Add that portion of the Guaranteed Maximum Price properly allocable to materials and equipment delivered and suitably stored at the site for subsequent incorporation in the Work, or if approved in advance by the Owner, suitably stored off the site at a location agreed upon in writing;

.3 Add the Design-Builder’s Fee, less retainage of ten percent ( 10 %). The Design-Builder’s Fee shall be computed upon the Cost of the Work at the rate stated in Section A.1.4.2 or, if the Design-Builder’s Fee is stated as a fixed sum in that Section, shall be an amount that bears the same ratio to that fixed-sum fee as the Cost of the Work bears to a reasonable estimate of the probable Cost of the Work upon its completion;

.4 Unless noted otherwise in the individual subcontract(s) or purchase order(s), the subtract retainage of ten percent ( 10 %) from that portion of the Work that the Design-Builder self-performs;

.5 Subtract the aggregate of previous payments made by the Owner;

.6 Subtract the shortfall, if any, indicated by the Design-Builder in the documentation required by Section A.1.5.1.4 to substantiate prior Applications for Payment, or resulting from errors subsequently discovered by the Owner’s auditors in such documentation; and

.7 Subtract amounts, if any, for which the Owner has withheld or nullified a payment as provided in Section 9.5 of the Agreement.

§ A.1. 5 .4.3 The Owner and Design-Builder shall agree upon (1) a mutually acceptable procedure for review and approval of payments to the Architect, Consultants, and Contractors and (2) the percentage of retainage held on agreements with the Architect, Consultants, and Contractors; and the Design-Builder shall execute agreements in accordance with those terms.

§ A.1. 5 .4.4 The Owner agrees that Design-Builder’s subcontractor, The Pike Company (“Pike”) is entitled to a fee (“Pike’s Fee”) based on Pike’s management of the Civil/Structural and Architectural scopes of Work (“Pike’s Scope”). Pike’s fee is a Not to Exceed amount of $1,350,000 M USD (one million three-hundred and fifty thousand dollars), and is itemized in the GMP breakdown sheet in Exhibit 1, dated March 1, 2019. The Parties agree that Pike’s Fee as stated herein is separate and in addition to the consultant management fee in an amount not to exceed $3,061,360 as referenced in § 4.1 of Design Builder’s subcontract with Pike dated December 12, 2018. The Parties hereto further understand and agree that Pike’s Fee is separate and independent from Design-Builder’s Fee. Design-Builder shall compensate Pike for Pike’s Fee, provided however, that Owner shall pay Design-Builder for the full amount of Pike’s Fee, and such amount paid by the Owner shall equal the amount that Design-Builder pays for Pike’s Scope of services.

§ A. 1.5.5 Final Payment

§ A.1.5 .5.1 Final payment, constituting the entire unpaid balance of the Contract Sum, shall be made by the Owner to the Design-Builder not later than 30 days after the Design-Builder has fully performed the Contract and the requirements of Section 9.10 of the Agreement have been satisfied, except for the Design-Builder’s responsibility to correct non-conforming Work discovered after final payment or to satisfy other requirements, if any, which extend beyond final payment.

§ A.1.5 . 5.2 If the Contract Sum is based on the Cost of the Work, the Owner’s auditors will review and report in writing on the Design-Builder’s final accounting within 30 days after the Design-Builder delivers the final accounting to the Owner. Based upon the Cost of the Work the Owner’s auditors report to be substantiated by the Design-Builder’s final accounting, and provided the other conditions of Section 9.10 of the Agreement have been met, the Owner will, within seven days after receipt of the written report of the Owner’s auditors, either issue a final Certificate for Payment, or notify the Design-Builder in writing of the reasons for withholding a certificate as provided in Section 9.5.1 of the Agreement.

ARTICLE A.2 CONTRACT TIME

§ A.2.1 Contract Time, as defined in the Agreement at Section 1.4.13, is the period of time, including authorized adjustments, for Substantial Completion of the Work.

§ A.2.2 The Design-Builder shall achieve Substantial Completion of the Work not later than: January 31, 2020.

(Insert number of calendar days. Alternatively, a calendar date may be used when coordinated with the date of commencement. If appropriate, insert requirements for earlier Substantial Completion of certain portions of the Work.)


Portion of Work	Substantial Completion Date
Substantial Completion	January 31, 2020

, subject to adjustments of the Contract Time as provided in the Design-Build Documents. The Parties acknowledge and agree that all references to the Substantial Completion Date in the Contract, the First Amendment, the Second Amendment, and/or all Contract exhibits, attachments, or related documents shall be removed, replaced, and updated with the Substantial Completion Date stated herein.

(Insert provisions, if any, for liquidated damages relating to failure to achieve Substantial Completion on time or for bonus payments for early completion of the Work.)

Parties have agreed to Liquidated Damages as defined in Section 14.1.7 in the A141-2017 Agreement Between Owner and Design Builder with the Effective Date of December 29, 2017 and as superseded by the First Amendment, with a First Amendment with an Effective Date of March 27, 2018.

The Liquidated Damages, as agreed by the First Amendment, start February 1, 2020.

ARTICLE A.3 INFORMATION UPON WHICH THIRD AMENDMENT IS BASED

§ A.3.1 The Contract Sum and Contract Time set forth in this Third Amendment are based on the following:

See Attachment 1 for summary of the Contract Sum; See Attachment 2 for summary of the Contract Time.

§ A.3.1.1 The Supplementary and other Conditions of the Contract:

Document

Title

Date

Pages

First Amendment – 27 MAR 18

Second Amendment - Executed 5 OCT 18

§ A.3.1.2 The Specifications:

(Either list the specifications here or refer to an exhibit attached to this Third Amendment.)

See Exhibit 2


Section	Title	Date	Pages

§ A.3.1.3 The Drawings:

(Either list the drawings here or refer to an exhibit attached to this Third Amendment.)

See Exhibit 3


Number	Title	Date

§ A.3.1.4 The Sustainability Plan, if any: - NOT USED.

(If the Owner identified a Sustainable Objective in the Owner’s Criteria, identify the document or documents that comprise the Sustainability Plan by title, date and number of pages, and include other identifying information. The Sustainability Plan identifies and describes the Sustainable Objective; the targeted Sustainable Measures; implementation strategies selected to achieve the Sustainable Measures; the Owner’s and Design-Builder’s roles and responsibilities associated with achieving the Sustainable Measures; the specific details about design reviews, testing or metrics to verify achievement of each Sustainable Measure; and the Sustainability Documentation required for the Project, as those terms are defined in Exhibit C to the Agreement.)


Title	Date	Pages
None

Other identifying information

None

§ A.3.1.5 Allowances and Contingencies:

(Identify any agreed upon allowances and contingencies, including a statement of their basis.)

.1 Allowances

Allowances, also identified as “Yet to Buy” costs, for various Scopes of Work are shown by work package or division. See Exhibit 1 (dated March 1, 2019).

.2 Contingencies

Contingency is identified in Exhibit 1 (dated March 1, 2019)and is intended to be used by Design-Build Contractor as required to support project execution.

§ A.3.1.6 Design-Builder’s assumptions and clarifications:

Client will be responsible for Commissioning of all building systems for both validated and non-validated systems. Commission, Qualification and Validation (CQV) requirements for all validated systems have not been provided to the design-build contractor and efforts to support those requirements are not included in this GMP . Client agrees that assembly, execution and acceptance of all documentation and turn-over packages required to support commissioning efforts are within their scope. Design-Build contractor will provide labor, via subcontractors, to support execution of the clients commissioning efforts for non-validated systems.

§ A.3.1.7 Deviations from the Owner’s Criteria as adjusted by a Modification:

There are no known deviations from the Owner’s Criteria at this time, however several late changes have been excluded (see Exhibit 3, referred to as “Deferred Scope Drawings”) or identified to be covered under contingency (see Exhibit 1, dated March 1, 2019). Drawings and Specifications have been generated and reviewed with the Owner and all Owner questions or concerns have been addressed and are accepted by all parties. Drawing list and pricing back-up identify deferred scope and applicable price reductions. Credit for areas and equipment removed from the scope are incorporated into this GMP.

§ A.3.1.8 To the extent the Design-Builder shall be required to submit any additional Submittals to the Owner for review, indicate any such submissions below:

Not Applicable

ARTICLE A.4 DESIGN-BUILDER’S PERSONNEL, CONTRACTORS AND SUPPLIERS

§ A.4.1 The Design-Builder’s key personnel are identified below:

(Identify name, title and contact information.)

.1 Superintendent

Jerry Robert

.2 Project Manager

Bill Zurek

.3 Others

Lee Ogle – Project Director

§ A.4.2 The Design-Builder shall retain the following Consultants, Contractors and suppliers, identified below:

(List name, discipline, address and other information.)

Design-Builder’s Architect (“Architect”) is:

Genesis Architects

523 Plymouth Road

Plymouth Meeting, PA 19462

Ryan Biggs/Clark Davis Engineering and Surveying P.C.

257 Ushers Road

Clifton Park, NY 12065

Clark Patterson Lee

205 St. Paul Street, Suite 500

Rochester, NY 14604

The Pike Company, Inc.

One Circle Street

Rochester, NY 14607

ARTICLE A.5 COST OF THE WORK

§ A.5.1 Cost To Be Reimbursed as Part of the Contract

§ A.5.1.1 Labor Costs

§ A.5.1.1.1 Wages of construction workers directly employed by the Design-Builder to perform the construction of the Work at the site or, with the Owner's prior approval, at off-site offices or workshops.

§ A.5.1.1.2 With the Owner’s prior approval, wages or salaries of the Design-Builder's supervisory and administrative personnel when stationed at the site.

(If it is intended that the wages or salaries of certain personnel stationed at the Design-Builder's principal or other offices shall be included in the Cost of the Work, identify below the personnel to be included, whether for all or only part of their time, and the rates at which their time will be charged to the Work.)


Person Included	Status (full-time/part-time)	Rate ($0.00)	Rate (unit of time)
See Table – Exhibit 4, dated March 1, 2019

§ A.5.1.1.3 Wages and salaries of the Design-Builder's supervisory or administrative personnel engaged at factories, workshops or on the road, in expediting the production or transportation of materials or equipment required for the Work, but only for that portion of their time required for the Work. Annual rate increases for staffing will be provided in the 2 ^nd Quarter of each year and incorporated into the billable rates previously provided. Any rate increases shall not increase the project GMP Cost.

§ A.5.1.1. 4 Costs paid or incurred by the Design-Builder for taxes, insurance, contributions, assessments and benefits required by law or collective bargaining agreements and, for personnel not covered by such agreements, customary benefits such as sick leave, medical and health benefits, holidays, vacations and pensions, provided such costs are based on wages and salaries included in the Cost of the Work under Section A.5.1.1.

§ A.5.1.1.5 Not used.

§ A.5.1.2 Contract Costs. Payments made by the Design-Builder to the Architect, Consultants, Contractors and suppliers in accordance with the requirements of their subcontracts.

§ A.5.1.3 Costs of Materials and Equipment Incorporated in the Completed Construction

§ A.5.1.3.1 Costs, including transportation and storage, of materials and equipment incorporated or to be incorporated in the completed construction.

§ A.5.1.3.2 Costs of materials described in the preceding Section A.5.1.3.1 in excess of those actually installed to allow for reasonable waste and spoilage. Unused excess materials, if any, shall become the Owner's property at the completion of the Work or, at the Owner's option, shall be sold by the Design-Builder. Any amounts realized from such sales shall be credited to the Owner as a deduction from the Cost of the Work.

§ A.5.1.4 Costs of Other Materials and Equipment, Temporary Facilities and Related Items

§ A.5.1.4.1 Costs of transportation, storage, installation, maintenance, dismantling and removal of materials, supplies, temporary facilities, machinery, equipment and hand tools not customarily owned by construction workers that are provided by the Design-Builder at the site and fully consumed in the performance of the Work. Costs of materials, supplies, temporary facilities, machinery, equipment and tools that are not fully consumed shall be based on the cost or value of the item at the time it is first used on the Project site less the value of the item when it is no longer used at the Project site. Costs for items not fully consumed by the Design-Builder shall mean fair market value.

§ A.5.1.4.2 Rental charges for temporary facilities, machinery, equipment and hand tools not customarily owned by construction workers that are provided by the Design-Builder at the site and costs of transportation, installation, minor repairs, dismantling and removal. The total rental cost of any Design-Builder-owned item may not exceed the purchase price of any comparable item. Rates of Design-Builder-owned equipment and quantities of equipment shall be subject to the Owner's prior approval.

§ A.5.1.4.3 Costs of removal of debris from the site of the Work and its proper and legal disposal.

§ A.5.1.4.4 Costs of document reproductions, electronic communications, postage and parcel delivery charges, dedicated data and communications services, teleconferences, Project websites, extranets and reasonable petty cash expenses of the site office.

§ A.5.1.4.5 Costs of materials and equipment suitably stored off the site at a mutually acceptable location, with the Owner's prior approval.

§ A.5.1.5 Miscellaneous Costs

§ A.5.1.5.1 Premiums for that portion of insurance and bonds required by the Design-Build Documents that can be directly attributed to the Contract. With the Owner's prior approval self-insurance for either full or partial amounts of the coverages required by the Design-Build Documents.

§ A.5.1.5.2 Sales, use or similar taxes imposed by a governmental authority that are related to the Work and for which the Design-Builder is liable.

§ A.5.1.5.3 Fees and assessments for the building permit and for other permits, licenses and inspections for which the Design-Builder is required by the Design-Build Documents to pay.

§ A.5.1.5.4 Fees of laboratories for tests required by the Design-Build Documents, except those related to defective or nonconforming Work for which reimbursement is excluded by Section 15.5.3 of the Agreement or by other provisions of the Design-Build Documents, and which do not fall within the scope of Section A.5.1.6.3.

§ A.5.1.5.5 Royalties and license fees paid for the use of a particular design, process or product required by the Design-Build Documents; the cost of defending suits or claims for infringement of patent rights arising from such requirement of the Design-Build Documents; and payments made in accordance with legal judgments against the Design-Builder resulting from such suits or claims and payments of settlements made with the Owner's consent. However, such costs of legal defenses, judgments and settlements shall not be included in the calculation of the Design-Builder's Fee or subject to the Guaranteed Maximum Price. If such royalties, fees and costs are excluded by the second to last sentence of Section 3.1.13.2 of the Agreement or other provisions of the Design-Build Documents, then they shall not be included in the Cost of the Work.

§ A.5.1.5.6 With the Owner's prior approval, costs for electronic equipment and software directly related to the Work

§ A.5.1.5.7 .Deposits lost for causes other than the Design-Builder's negligence or failure to fulfill a specific responsibility in the Design-Build Documents.

§ A.5.1.5.8 With the Owner's prior approval, which shall not be unreasonably withheld, legal, mediation and arbitration costs, including attorneys' fees, other than those arising from disputes between the Owner and Design-Builder, reasonably incurred by the Design-Builder after the execution of the Agreement and in the performance of the Work.

§ A.5.1.5. 9 With the Owner’s prior approval, expenses incurred in accordance with the Design-Builder's standard written personnel policy for relocation, and temporary living allowances of, the Design-Builder's personnel required for the Work.

§ A.5.1.5.10 That portion of the reasonable expenses of the Design-Builder's supervisory or administrative personnel incurred while traveling in discharge of duties connected with the Work.

§ A.5.1.6 Other Costs and Emergencies

§ A.5.1.6.1 Other costs incurred in the performance of the Work if, and to the extent, approved in advance in writing by the Owner.

§ A.5.1.6.2 Costs incurred in taking action to prevent threatened damage, injury or loss in case of an emergency affecting the safety of persons and property.

§ A.5.1.6.3 Costs of repairing or correcting damaged or nonconforming Work executed by the Design-Builder, Contractors or suppliers, provided that such damaged or nonconforming Work was not caused by negligence or failure to fulfill a specific responsibility of the Design-Builder and only to the extent that the cost of repair or correction is not recovered by the Design-Builder from insurance, sureties, Contractors, suppliers, or others.

§ A.5.1.7 Related Party Transactions

§ A.5.1.7.1 For purposes of Section A.5.1.7, the term “related party” shall mean a parent, subsidiary, affiliate or other entity having common ownership or management with the Design-Builder; any entity in which any stockholder in, or management employee of, the Design-Builder owns any interest in excess of ten percent in the aggregate; or any person or entity which has the right to control the business or affairs of the Design-Builder. The term “related party” includes any member of the immediate family of any person identified above.

§ A.5.1.7.2 If any of the costs to be reimbursed arise from a transaction between the Design-Builder and a related party, the Design-Builder shall notify the Owner of the specific nature of the contemplated transaction, including the identity of the related party and the anticipated cost to be incurred, before any such transaction is consummated or cost incurred. If the Owner, after such notification, authorizes the proposed transaction, then the cost incurred shall be included as a cost to be reimbursed, and the Design-Builder shall procure the Work, equipment, goods or service from the related party, as a Contractor, according to the terms of Section A.5.4. If the Owner fails to authorize the transaction, the Design-Builder shall procure the Work, equipment, goods or service from some person or entity other than a related party according to the terms of Section A.5.4.

§ A.5.2 Costs Not to Be Reimbursed as Part of this Contract

The Cost of the Work shall not include the items listed below:

.1 Salaries and other compensation of the Design-Builder's personnel stationed at the Design-Builder's principal office or offices other than the site office, except as specifically provided in Section A.5.1.1;

.2 Expenses of the Design-Builder's principal office and offices other than the site office;

.3 Overhead and general expenses, except as may be expressly included in Section A.5.1;

.4 The Design-Builder's capital expenses, including interest on the Design-Builder's capital employed for the Work;

.5 Except as provided in Section A.5.1.6.3 of this Agreement, costs due to the negligence or failure of the Design-Builder, Contractors and suppliers or anyone directly or indirectly employed by any of them or for whose acts any of them may be liable to fulfill a specific responsibility of the Contract;

.6 Any cost not specifically and expressly described in Section A.5.1; and

.7 Costs, other than costs included in Change Orders approved by the Owner, that would cause the Guaranteed Maximum Price to be exceeded.

§ A.5.3 Discounts, Rebates, and Refunds

§ A.5.3.1 Cash discounts obtained on payments made by the Design-Builder shall accrue to the Owner if (1) before making the payment, the Design-Builder included them in an Application for Payment and received payment from the Owner, or (2) the Owner has deposited funds with the Design-Builder with which to make payments; otherwise, cash discounts shall accrue to the Design-Builder. Trade discounts, rebates, refunds and amounts received from sales of surplus materials and equipment shall accrue to the Owner, and the Design-Builder shall make provisions so that they can be obtained.

§ A.5.3.2 Amounts that accrue to the Owner in accordance with Section A.5.3.1 shall be credited to the Owner as a deduction from the Cost of the Work.

§ A.5.4 Other Agreements

§ A.5.4.1 When the Design-Builder has provided a Guaranteed Maximum Price, and a specific bidder (1) is recommended to the Owner by the Design-Builder; (2) is qualified to perform that portion of the Work; and (3) has submitted a bid that conforms to the requirements of the Design-Build Documents without reservations or exceptions, but the Owner requires that another bid be accepted, then the Design-Builder may require that a Change Order be issued to adjust the Guaranteed Maximum Price by the difference between the bid of the person or entity recommended to the Owner by the Design-Builder and the amount of the subcontract or other agreement actually signed with the person or entity designated by the Owner.

§ A.5.4.2 Agreements between the Design-Builder and Contractors shall conform to the applicable payment provisions of the Design-Build Documents, and shall not be awarded on the basis of cost plus a fee without the prior consent of the Owner. If an agreement between the Design Builder and a Contractor is awarded on a cost plus a fee basis, the Design-Builder shall provide in the agreement for the Owner to receive the same audit rights with regard to the Cost of the Work performed by the Contractor as the Owner receives with regard to the Design-Builder in Section A.5.5, below.

§ A.5.4.3 The agreements between the Design-Builder and Architect and other Consultants identified in the Agreement shall be in writing. These agreements shall be promptly provided to the Owner upon the Owner’s written request.

§ A.5.5 Accounting Records

The Design-Builder shall keep full and detailed records and accounts related to the cost of the Work and exercise such controls as may be necessary for proper financial management under the Contract and to substantiate all costs incurred. The accounting and control systems shall be satisfactory to the Owner. The Owner and the Owner’s auditors shall, during

regular business hours and upon reasonable notice, be afforded access to, and shall be permitted to audit and copy, the Design-Builder’s records and accounts, including complete documentation supporting accounting entries, books, correspondence, instructions, drawings, receipts, subcontracts, Contractor’s proposals, purchase orders, vouchers, memoranda and other data relating to the Contract. The Design-Builder shall preserve these records for a period of three years after final payment, or for such longer period as may be required by law.

§ A.5.6 Relationship of the Parties

The Design-Builder accepts the relationship of trust and confidence established by this Agreement and covenants with the Owner to exercise the Design-Builder’s skill and judgment in furthering the interests of the Owner; to furnish efficient construction administration, management services and supervision; to furnish at all times an adequate supply of workers and materials; and to perform the Work in an expeditious and economical manner consistent with the Owner’s interests.

§ A.5.7 Additional Terms

§ A.5.7.1 The Parties acknowledge, understand, and agree that Design-Builder underwent a name-change on or about August 31, 2018, wherein Design-Builder changed its name from “M+W U.S., Inc.” (“M+W”) to “Exyte U.S., Inc.” (“Exyte”). As such, all references to “M+W” in the Agreement, the First Amendment, the Second Amendment, and all other related Contract documents, exhibits, and/or attachments shall be removed and replaced with “Exyte.”

§ A.5.7.2 Notwithstanding anything in the Agreement, the First Amendment, the Second Amendment, and all other related Contract documents, exhibits, and/or attachments to the contrary, Owner acknowledges and agrees that any and all warranties related to the pre-purchase of long lead equipment (hereinafter, “Long Lead Equipment Warranties”, which shall mean equipment purchased by Design-Builder and assigned to a subcontractor for installation. Examples include, but are not limited to: Chillers, Boilers, Cooling Towers, Electrical Switchgear, and process equipment as identified in the procurement matrix) may be subject to expiration prior to the warranty periods set forth in the Agreement. As such, the Parties acknowledge and agree that Design-Builder shall have no obligation, duty, or liability to correct defective Work following the expiration of the respective Long Lead Equipment Warranties, and Owner hereby releases Design-Builder from all damages, costs, or liabilities following the expiration of such Long Lead Equipment Warranties.

§ A.5.7.3 In addition to the limitation of liability outlined in § 3.1.14.3 of the Agreement, Owner acknowledges and agrees that Design-Builder’s liability shall be capped for all damages that arise out of or relate to Eaton Corporation’s (“Eaton”) and/or Mechanical Equipment Corporation, Inc.’s (“MECO”) acts or omissions, work, or respective subcontract. Notwithstanding anything in the Agreement, the First Amendment, the Second Amendment, and all other related Contract documents, exhibits, and/or attachments to the contrary:

A.5.7.3.1 In the event that Eaton causes or contributes to any liabilities, costs, and/or direct or indirect damages to Owner (consequential or otherwise), Design-Builder, and/or the Project (including, but not limited to, the performance or non-performance of Eaton’s equipment or work) (collectively, “Eaton-related Damages”), Owner agrees that Design-Builder’s liability in connection with the Eaton-related Damages shall not exceed the amount that Design-Builder actually recovers from Eaton for the Eaton-related Damages. For the avoidance of doubt, Owner agrees that Design-Builder will not be responsible for any Eaton-related Damages or costs that exceed the amount that Design-Builder actually recovers from Eaton.

A.5.7.3.2 In the event that MECO causes or contributes to any liabilities, costs, and/or direct or indirect damages to Owner (consequential or otherwise), Design-Builder, and/or the Project (including, but not limited to, the performance or non-performance of MECO’s equipment or work) (collectively, “MECO-related Damages”), Owner agrees that Design-Builder’s liability in connection with the MECO-related Damages shall not exceed the amount that Design-Builder actually recovers from MECO for the MECO-related Damages. For the avoidance of doubt, Owner agrees that Design-Builder will not be responsible for any MECO-related Damages or costs that exceed the amount that Design-Builder actually recovers from MECO.

§ A.5.7.4 The Owner acknowledges and agrees that should Design-Builder submit its Applications for Payment in accordance with the terms of the Agreement and the forms included in Exhibit E to the Agreement, then Owner shall, diligently and without delay, proceed with issuing a Certification for Payment in accordance with the seven day timeframe referenced in § 9.4 (“Certificates for Payment”) of the Agreement. The Parties hereto understand and agree that all invoiced amounts ending in cents may be rounded to the nearest whole dollar amount, and as such, the Owner further acknowledges and agrees that the issuances of a Certification for Payment shall not be delayed, withheld, or rejected due to matters involving rounding discrepancies and/or mismatches.

This Third Amendment to the Agreement entered into as of the day and year first written above.


ATHENEX, INC.		Exyte U.S., INC.
/s/ Richard Nassar March 7, 2019		/s/ Todd Muckelroy March 7, 2019
OWNER (Signature)		DESIGN-BUILDER (Signature)
RICH NASSAR, Vice-President Operations		TODD MUCKELROY, CFO
(Printed name and title)		(Printed name and title)
		/s/ Rick Whitney March 8, 2019
		DESIGN-BUILDER(Signature)
		RICK WHITNEY, President
		(Printed name and title)

Athenex GMP Summary

Exyte U.S. Inc.

				March 2018 BOD Estimate		Current Commitments	PCO Forecast		Procurement Forecast		Total
1	Division 01	General Requirements	$	5,015,730	$	465,290			$	4,384,717	$	4,850,007
2	Division 02	Existing Conditions	$	28,766	$	28,766			$	-	$	28,766
3	Division 03	Concrete	$	7,727,690	$	7,738,324	$	3,205,932	$	-	$	10,944,257
4	Division 04	Masonry	$	2,713,860	$	-	$	-	$	2,336,042	$	2,336,042
5	Division 05	Metals	$	12,038,894	$	11,648,614	$	4,254,505	$	-	$	15,903,119
6	Division 06	Wood, Plastic & Composites	$	635,459	$	-	$	-	$	-	$	-
7	Division 07	Thermal & Moisture Protection	$	7,879,221	$	5,340,124	$	1,684,451	$	-	$	7,024,575
8	Division 08	Openings	$	3,747,181	$	704,000	$	283,298	$	285,000	$	1,272,298
9	Division 09	Finishes	$	8,440,596	$	-	$	-	$	11,234,602	$	11,234,602
10	Division 10	Specialties	$	451,326	$	-	$	-	$	602,053	$	602,053
11	Division 11	Equipment	$	2,528,360	$	12,760	$	-	$	1,375,099	$	1,387,859
12	Division 12	Furnishings	$	619,073	$	-	$	-	$	753,000	$	753,000
13	Division 13	Special Construction	$	4,600,078	$	-	$	-	$	4,894,067	$	4,894,067
14	Division 14	Coveying Equipment	$	470,316	$	-	$	-	$	406,400	$	406,400
21	Division 21	Fire Suppression	$	2,157,401	$	-	$	-	$	2,064,600	$	2,064,600
22	Division 22	Plumbing	$	10,826,130	$	2,981,686	$	306,851	$	2,838,839	$	6,127,376
23	Division 23	Heating, Ventilation & AC	$	41,064,161	$	2,183,853	$	-	$	22,996,572	$	25,180,425
25	Division 25	Integrated Automation	$	5,869,253	$	-	$	-	$	9,129,149	$	9,129,149
26	Division 26	Electrical	$	16,044,041	$	12,858,263	$	518,000	$	12,532,000	$	25,908,263
27	Division 27	Communications	$	1,839,190	$	-	$	-	$	1,551,000	$	1,551,000
28	Division 28	Electronic Safety and Security	$	1,431,839	$	-	$	-	$	336,758	$	336,758
31	Division 31	Earthwork	$	7,060,929	$	5,813,140	$	454,025	$	-	$	6,267,166
32	Division 32	Exterior Improvements	$	2,446,666	$	1,787,020	$	60,000	$	-	$	1,847,020
33	Division 33	Utilities	$	9,497,824	$	4,761,082	$	15,000	$	659,950	$	5,436,032
34	Division 34	Transportation	$	-	$	-	$	-	$	-	$	-
35	Division 35	Waterway & Marine Const.	$	-	$	-	$	-	$	-	$	-
40	Division 40	Process Integration	$	3,902,677	$	-	$	-	$	-	$	-
41	Division 41	Materials Processing & Handling Equipment	$	18,251,360	$	-	$	-	$	14,552,248	$	14,552,248
											$	-
		COW:	$	177,288,021	$	56,322,922	$	10,782,063	$	92,932,096	$	160,037,081
		Yet-to-buy									$	4,804,470
		Indirects	$	29,541,453							$	34,565,930
		Contingency	$	31,777,847							$	13,187,324

		Totals	$	238,607,321							$	212,594,806

Exhibit 1 - Page 1 of 14

March 1, 2019

CONFIDENTIAL

Athenex GMP Pending Procurement Summary

Exyte U.S. Inc.

Division	Bid Package Number	Bid Package Description	FINAL BID Selected for GMP		Estimated Amount "Yet to Buy" in Award Value	Recommended Award Value		Grand Total Contingency		GMP Value		Bidder Selected for Pricing
1	GRxx	General Requirements	$	3,844,717		$	3,844,717	$	-	$	3,844,717	N/A - multiple
1	S101	Security Services (GR's)				$	-	$	-	$	-	Summerville
1	E102	Building Temporary Power	$	540,000		$	540,000	$	-	$	540,000	Ferguson
1	BP52	Waste Management (Void - GR's)	$	-		$	-	$	-	$	-	GR's
1	BP54	Portable Toilets (Void - GR's)	$	-		$	-	$	-	$	-	GR's
1	BP56	Deck / Stairs Trailers (Void - GR's)	$	-		$	-	$	-	$	-	GR's
1	BP57	Maintain lawns, temp roads, snow plowing (Div 1)				$	-	$	-	$	-
3	BP44	Concrete Curbs and exterior slabs (In Div. 3)						$	-			State Group
3	BP48	Exterior foundations - out buildings (VOID)						$	-			Void
3	BP61	Polished Concrete Sealer (None shown See BP50)				$	-	$	-	$	-	Void
3		Concrete floor cutting / core drilling & in-fill (YTB)				$	-	$	-	$	-	Void
4	BP10	Exterior Stone Veneer	$	334,000		$	334,000	$	-	$	334,000	FSR
4	BP55	Interior CMU	$	2,002,042		$	2,002,042	$	-	$	2,002,042	FSR
5	BP18	Misc. Metals, Lobby Stairs, Railings (In Div. 5)				$	-	$	-	$	-	Stone Bridge
5	BP24	Stainless Steel Wall Sheathing and equipment platforms (Void - In Div 5?)				$	-	$	-	$	-
5	BP51	Exterior Structural Studs (In Committed Log)	$	-		$	-	$	-	$	-	Mader
5		Misc. Metals to support MEP penetrations/roof curbs				$	-	$	-	$	-
6	TBD	BUDGET PLACEHOLDER - DIV. 6	$	635,459		$	635,459	$	-	$	-
7	BP11	Spray on Fireproofing	$	-		$	-	$	-	$	-	Mader
7	BP12	Insulated Wall Panels/Louvers						$	-			Building Inovations Group (BIG)
7	BP16	Curtain Wall & storefront						$	-			Krueg
7	BP17	Roofing - Need to ensure cutting of deck for MEP trades.				$	-	$	-	$	-	A.W. Farrell
8	BP15	Interior Overhead Coiling Doors (Void - in BP19)	$	-		$	-	$	-	$	-
8	BP28	Glass and Glazing; interior storefronts	$	285,000		$	285,000	$	-	$	285,000	R.E. Krug
8		BUDGET PLACEHOLDER	$	2,222,209		$	2,222,209	$	-	$	-	Removed for De-scope
9	BP14	Doors/Frames/Hardware - Core and Shell (Void in BP 27)				$	-	$	-	$	-
9	BP25	Millwork & Cabinets	$	989,602		$	989,602	$	-	$	989,602	Infinity Northeast (Only Bidder)
9	BP26	Sealants (In BP27)				$	-	$	-	$	-
9	BP27	Interior gyp board walls, ceilings, ACT ceilling, door/frames/hardware; top of wall firestopping; wall and corner guards; fire extinguishers; floor mats	$	7,300,000		$	7,300,000	$	-	$	7,300,000	Huber Construction (Low Bidder)
9	BP29	Ceramic Tile	$	559,700		$	559,700	$	-	$	559,700	Tiede-Zoeller
9	BP32	Resilent Flooring & Carpeting	$	653,150		$	653,150	$	-	$	653,150	Heritage Contract Flooring
9	BP31	Carpeting (In BP32)				$	-	$	-	$	-
9	BP33	Painting	$	604,500		$	604,500	$	-	$	604,500	ICC (RW)
9	BP37	Toilet/Bath Accessories (In BP27)				$	-	$	-	$	-
9	BP38	Operable Partitions (In BP27)				$	-	$	-	$	-
9	BP50	Epoxy Resin Flooring	$	1,127,650		$	1,127,650	$	-	$	1,127,650	MJA
10	BP34	Toilet Partitions	$	91,625		$	91,625	$	-	$	91,625	Infinity Northeast (Only Bidder)
10	BP35	Interior Signage (Code & Interior/exterior)	$	240,000		$	240,000	$	-	$	240,000	ASI
10	BP36	Lockers	$	270,428		$	270,428	$	-	$	270,428	Kraftwerks

Exhibit 1 - Page 2 of 14

March 1, 2019

CONFIDENTIAL

Athenex GMP Pending Procurement Summary

Exyte U.S. Inc.

Division	Bid Package Number	Bid Package Description	FINAL BID Selected for GMP			Estimated Amount "Yet to Buy" in Award Value			Recommended Award Value			Grand Total Contingency		GMP Value			Bidder Selected for Pricing
11	BP19	Loading Dock Equipment (Includes BP15 budget)	$	875,099					$	875,099		$	-	$	875,099		Rite Hite
11	BP20	Vaults	$	-					$	-		$	-	$	-		Custom Vault
11	BP21	Coolers	$	500,000					$	500,000		$	-	$	500,000		Darwin Chambers
12	BP40	Laboratory Casework	$	753,000					$	753,000		$	-	$	753,000		Kraftwerks
13	C101	Clean Room Systems	$	4,871,317					$	4,871,317		$	-	$	4,871,317		PCI
13	BP47	Pre-Cast Building	$	22,750					$	22,750		$	-	$	22,750		Hy-Grade Precast
14	BP22	Elevators	$	406,400					$	406,400		$	-	$	406,400		Schindler
21	FP101	Fire Protection	$	2,064,600					$	2,064,600		$	-	$	2,064,600		SRI
22	M102	Plumbing	$	2,838,839					$	2,838,839		$	-	$	2,838,839
22	BP23	Underground Plumbing										$	-				WT Spaeder
23	M101	Wet Mechanical	$	10,769,004					$	10,769,004		$	-	$	10,769,004
23	M101	Multi-package award credit	$	(1,298,000	)				$	(1,298,000	)	$	-	$	(1,298,000	)	JW Danforth
23	M103	Dry Mechanical	$	13,525,568					$	13,525,568		$	-	$	13,525,568		JW Danforth
25	E101-040	I&C	$	9,129,149					$	9,129,149		$	-	$	9,129,149		U & S
26	E101	Electrical Distirbution (MV)	$	12,532,000					$	12,532,000		$	-	$	12,532,000		Ferguson
26		Switchyard	$	-					$	-		$	-	$	-		Ferguson
26		Long Lead Switch Gear	$	-								$	-				Eaton
26	LLE007	Stand-By Generators	$	-								$	-	$	-		Kinsley (Kohler)
27	E101-027	IT	$	1,551,000					$	1,551,000		$	-	$	1,551,000		Ferguson
28	E101-028	Security Safety (Cameras/Badge Readers)	$	336,758					$	336,758		$	-	$	336,758		Buffalo Fire and Secuity
28	E101-023	Fire Alarm (Void 0 In E101)	$	-					$	-		$	-	$	-
32	BP43	Asphalt Paving (In PCO Log)										$	-				St. George
32	BP45	Fencing (Client Request)	$	-					$	-		$	-	$	-		St. George
32	BP42	Soil Prep & Landscaping (Void - In BP05)							$	-		$	-	$	-
33	BP59	Water Storage Tank and Pad	$	659,950					$	659,950		$	-	$	659,950		The State Group (only bidder)
40	N/A	Process Automation							$	-		$	-	$	-
41	P101	Process Piping Systems	$	5,215,289					$	5,215,289		$	-	$	5,215,289		JW Danforth
41	PQ001	Parts Washer	$	342,065					$	342,065		$	-	$	342,065		Biopharma Systems, LLC
41	PQ002	Terminal Steriler & Autoclaves	$	283,419					$	283,419		$	-	$	283,419		Biopharma Systems, LLC
41	PQ003	Pure Steam	$	218,305					$	218,305		$	-	$	218,305		AquaChem
41	PQ005	WFI Pretreatment & Generation	$	1,176,670					$	1,176,670		$	-	$	1,176,670		Meco
41	PQ006	WFI Storage and Distribution	$	735,882					$	735,882		$	-	$	735,882		Meco
41	PQ007	OFCA Generation	$	328,950					$	328,950		$	-	$	328,950		Ingersol Rand
41	PQ008	Formulation Tanks and Platforms							$	-		$	-				Deferred
41	PQ009	TCU	$	-					$	-		$	-				Deferred
41	PQ011	Transfer and Utility Panels							$	-		$	-				Deferred
41	PQ013	Syringe Assembly and labeling							$	-		$	-				Deferred
41	PQ014	CIP Skids	$	335,927					$	335,927		$	-	$	335,927		TBD - Redesign on-going
41	PQ015	WWT Tanks (Including lift stations/neutralization)	$	1,056,446					$	1,056,446		$	-	$	1,056,446		Burt Process Equipment
41	PQ016	pH Neutrailzation and Lift Station (Void in PQ15)							$	-		$	-	$	-		In PQ15
41	PQ017	Downflow Booths							$	-		$	-	$	-		Deferred
41	PQ018	Mixproof Valve Manifold							$	-		$	-	$	-		Deferred
41	PQ010	WFI Cooler	$	946,700					$	946,700		$	-	$	946,700		Harrington / Exergy
41	PQ019	Pallet Washer							$	-		$	-	$	-		Deferred
41	PQ020	Heat Exchanger (Void - in PQ15)							$	-		$	-	$	-		In PQ15
41	PQ021	Centrifugal Pumps (Void - in PQ15)							$	-		$	-	$	-		In PQ15
41	PQ022	AODD Pumps (Void - in PQ15)							$	-		$	-	$	-		In PQ15
41	TBD	Remaining Misc. Equipment	$	3,912,595					$	3,912,595		$	-	$	3,912,595		Estimate per Equipment List Rev. 6
									$	-
				Yet To Buy			$	-				$	-	$	92,932,096		Both Yet to Buy and Contingency Relocated to Cover Sheet 21JAN19

Exhibit 1 - Page 3 of 14

March 1, 2019

CONFIDENTIAL

Athenex GMP - Process Equipment List

*The equipment listed below identifies the process equipment to be procured via the GMP. With the exception of equipment packages listed on the "Pending Procurement" sheets, under division 41, equiment which is not listed or funded below, is not included in the GMP

Div.	Description	BOD Estimate		Status (Deferred, Athenex, Exyte, Other Package)	GMP Value
41	Utility Panel for Portable Tank	$	19,397	Deferred	$	-
41	API Benchtop Powder Hood #1	$	23,387	Deferred	$	-
41	API Benchtop Scale #1	$	7,997	Deferred	$	-
41	Utility Panel for Portable Tank	$	19,397	Deferred	$	-
41	API Benchtop Powder Hood #2	$	23,387	Deferred	$	-
41	API Benchtop Scale #2	$	7,997	Deferred	$	-
41	IV/Syringe Used-to-clean EQ Pass through	$	20,327	Deferred	$	-
41	Walkie Lift	$	4,192	Athenex	$	-
41	Isolated Filling Line (2- 100mL) 30 unit/min	$	219,122	Deferred	$	-
41	Automated Tub Cover and liner removal	$	38,259	Deferred	$	-
41	Syringe Filler #2 30 unit/min	$	38,259	Deferred	$	-
41	Plunger Insertion	$	38,259	Deferred	$	-
41	Isolator TBD	$	38,259	Deferred	$	-
41	VHP Unit for Isolator TBD	$	38,259	Deferred	$	-
41	Wash Station	$	4,795	Deferred	$	-
41	Utility Carts	$	2,096	Deferred	$	-
41	Automated Denester	$	310,685	Deferred	$	-
41	Machine Inspection (cosmetic, particulate)	$	1,550,774	Deferred	$	-
41	Automated Renester	$	310,149	Deferred	$	-
41	Manual Syringe Inspection system in lieu of Automated	$	(1,750,000)	Deferred	$	-
41	Placeholder for EQ Line items	$	5,843,675	Deferred	$	-
41	Summarized Packaging utility use	$	2,096	Deferred	$	-
41	Utility Carts	$	15,206	Deferred	$	-
41	Manual Quality Checking Station	$	6,957	Deferred	$	-
41	Hand Packing Station	$	6,957	Deferred	$	-
41	Case Taper Machine MISC-007	$	4,527	Deferred	$	-
41	Label Dispenser MISC-008	$	4,527	Deferred	$	-
41	Isolated Filling System 10 unit/min	$	78,798	Deferred	$	-
41	Bag Filler (2 head custom filler)	$	12,575	Deferred	$	-
41	Isolator TBD	$	21,125	Deferred	$	-
41	VHP Unit for Isolator TBD		0	Deferred	$	-
41	Manual Quality Checking Station	$	3,806	Deferred	$	-
41	Hand Packing Station	$	3,806	Deferred	$	-
41	Case Taper Machine MISC-009	$	3,806	Deferred	$	-
41	Label Dispenser MISC-010	$	5,332	Deferred	$	-
41	ISO 5 Laminar Flow Bench #1 8 ft.	$	7,427	Athenex	$	-
41	ISO 5 Laminar Flow Bench #2 8 ft.	$	7,427	Athenex	$	-
41	ISO 5 Laminar Flow Bench #3 8 ft.	$	9,523	Athenex	$	-
41	ISO 5 Laminar Flow Bench #4 8 ft.	$	9,523	Athenex	$	-
41	ISO 5 Laminar Flow Bench #5 8 ft.	$	13,715	Athenex	$	-
41	ISO 5 Laminar Flow Bench #6 8 ft.	$	4,192	Athenex	$	-
41	Terminal Sterilizer #1 (Air/Steam) 380 cf	$	933,551	Deferred	$	-
41	Homogenizer 50 L MX-001	$	25,685	Athenex	$	-
41	Top-loading balance (Isolator) WS-006	$	12,575	Athenex	$	-
41	Process Water POU	$	4,192	PQ10 (WFI Coolers)	$	-
41	Sachet Filler 120 unit/min	$	45,468	Athenex	$	-
41	Discharge Conveyor	$	2,096	Athenex	$	-
41	Ointment Ultrasonic cleaner 10 gal	$	9,791	Athenex	$	-
41	Process Water POU	$	26,606	PQ10 (WFI Coolers)	$	-
41	Wash Sink	$	32,893	Exyte	$	32,893.00
41	Ointment Used-to-clean EQ Pass through MISC-036	$	8,138	Deferred	$	-
41	Checkweigher CW-001	$	17,017	Athenex	$	-
41	Hand Packing Station	$	3,806	Athenex	$	-
41	Case Taper Machine MISC-013	$	3,806	Athenex	$	-
41	Label Dispenser MISC-014	$	3,806	Athenex	$	-
41	Excipient Bench Scale #1	$	26,606	Deferred	$	-
41	Excipient Portable Floor Scale #1 3300 lbs.	$	22,063	Deferred	$	-
41	Down flow Booth Solvent or Powder 10 ft.	$	200,876	Deferred	$	-
41	3 lab sinks, glassware washer	$	17,302	Exyte provide Lab Sinks, Athenex provide Glass Washers	$	17,302.00
41	Misc. Lab Sinks, Benchtop EQ	$	4,192	Exyte provide Lab Sinks, Athenex provide Benchtop Eq.	$	4,192.00
41	Misc. Lab Sinks, Benchtop EQ	$	15,206	Exyte provide Lab Sinks, Athenex provide Benchtop Eq.	$	15,206.00
41	Decontamination Sterilizer 35 cf AUTO-004	$	376,574	PQ2 (Autoclave)	$	-
41	Pallet Washer, Automatic	$	103,187	Athenex	$	-
41	Isco Sampler	$	4,376	Athenex	$	-
41	Incubators (3)	$	141,750	Exyte	$	141,750
41	ISO 5 Laminar Flow Bench #1 - Diana, flow, balances	$	36,500	Exyte - Athenex Estimate	$	36,500.00
41	ISO 5 Laminar Flow Bench #2 - Diana, flow, balances	$	36,500	Exyte - Athenex Estimate	$	36,500.00
41	ISO 5 Laminar Flow Bench #3 - Diana, flow, balances	$	36,500	Exyte - Athenex Estimate	$	36,500.00
41	ISO 5 Laminar Flow Bench #4 - Diana, flow, balances	$	36,500	Exyte - Athenex Estimate	$	36,500.00
41	ISO 5 Laminar Flow Bench #5 - Diana, flow, balances	$	36,500	Exyte - Athenex Estimate	$	36,500.00
41	ISO 5 Laminar Flow Bench #6 - Diana, flow, balances	$	36,500	Exyte - Athenex Estimate	$	36,500.00
41	Carts / Totes / Balance Cable 15 / 100 / 8	$	17,650	Exyte - Athenex Estimate	$	17,650.00

Exhibit 1 - Page 4 of 14

March 1, 2019

Athenex GMP - Process Equipment List

Div.	Description	BOD Estimate		Status (Deferred, Athenex, Exyte, Other Package)	GMP Value
41	Labler Printers - SW / INK	$	50,500	Exyte - Athenex Estimate	$	50,500.00
41	Formulation Isolator	$	200,000	Exyte - Athenex Estimate	$	200,000.00
41	Formulation TCU	$	8,000	Exyte - Athenex Estimate	$	8,000.00
41	Homogenizer - INCREASE SIZE TO 100L (from 10L)	$	200,000	Exyte - Athenex Estimate	$	200,000.00
41	Top-loading balance (Isolator)	$	18,000	Exyte - Athenex Estimate	$	18,000.00
41	Top-loading balance (Formulation)	$	18,000	Exyte - Athenex Estimate	$	18,000.00
41	Sachet Filler -	$	750,000	Exyte - Athenex Estimate	$	750,000.00
41	Discharge Conveyor	$	10,000	Exyte - Athenex Estimate	$	10,000.00
41	Ointment Ultrasonic cleaner - INCREASED TO 2 CLEANE	$	12,000	Exyte - Athenex Estimate	$	12,000.00
41	Checkweigher - ADDED COST OF CHECKWEIGHER	$	87,000	Exyte - Athenex Estimate	$	87,000.00
41	OINTMENT PACKAGING AND SERIALIZATION	$	250,000	Exyte - Athenex Estimate	$	250,000.00
41	Filter Integrity Testing Equipment - $46,000 each - 1 only	$	46,000	Exyte - Athenex Estimate	$	46,000.00
41	Placeholder for Conveyor Line items	$	15,000	Exyte - Athenex Estimate	$	15,000.00
41	Pallet Washer, Automatic	$	103,000	Exyte - Athenex Estimate	$	103,000.00
41	Central Stretchwrapper	$	8,000	Exyte - Athenex Estimate	$	8,000.00
41	ISCO Sampler	$	4,376	Exyte - Athenex Estimate	$	4,376.00
41	Portable Autoclave	$	37,275	Exyte - Athenex Estimate	$	37,275.00
41	Laminar Flow Hood #1	$	5,355	Exyte - Athenex Estimate	$	5,355.00
41	Laminar Flow Hood #2	$	5,355	Exyte - Athenex Estimate	$	5,355.00
41	Biosafety Cabinet #1	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	Biosafety Cabinet #2	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	Biosafety Cabinet #3	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	Biosafety Cabinet #4	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	Biosafety Cabinet #5	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	Biosafety Cabinet #6	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	Biosafety Cabinet #7	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	Biosafety Cabinet #8	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	Refrigerator: Reach-in #1	$	10,500	Exyte - Athenex Estimate	$	10,500.00
41	Refrigerator: Reach-in #2	$	10,500	Exyte - Athenex Estimate	$	10,500.00
41	Refrigerator: Reach-in #5	$	10,500	Exyte - Athenex Estimate	$	10,500.00
41	Freezer: Reach-in #1	$	13,650	Exyte - Athenex Estimate	$	13,650.00
41	Freezer: Reach-in #2	$	13,651	Exyte - Athenex Estimate	$	13,651.00
41	Forced Air Oven, 3.7 cu ft	$	4,200	Exyte - Athenex Estimate	$	4,200.00
41	Lab ultrasonic Bath, 2.8 L	$	2,100	Exyte - Athenex Estimate	$	2,100.00
41	Milliflex single head pump	$	12,600	Exyte - Athenex Estimate	$	12,600.00
41	Milliflex 3 head pump head	$	18,900	Exyte - Athenex Estimate	$	18,900.00
41	pH/conductivity meters	$	13,230	Exyte - Athenex Estimate	$	13,230.00
41	Plate Reader	$	61,950	Exyte - Athenex Estimate	$	61,950.00
41	XPE56 series micro analytical balance	$	81,900	Exyte - Athenex Estimate	$	81,900.00
41	XPE205 analytical balance	$	37,800	Exyte - Athenex Estimate	$	37,800.00
41	Viscometer, RVDV2T	$	4,095	Exyte - Athenex Estimate	$	4,095.00
41	Viscometer, LVDV2T CP	$	4,410	Exyte - Athenex Estimate	$	4,410.00
41	Viscometer sample cup	$	945	Exyte - Athenex Estimate	$	945.00
41	0.8 deg CP spindle	$	420	Exyte - Athenex Estimate	$	420.00
41	3 deg /2.4 cm CP spindle	$	420	Exyte - Athenex Estimate	$	420.00
41	TOC Meter, M9 Laboratory	$	38,850	Exyte - Athenex Estimate	$	38,850.00
41	TOC Meter, M series autosampler	$	11,550	Exyte - Athenex Estimate	$	11,550.00
41	TOC Meter Part 11 compliance package DataPro 2 SW	$	3,465	Exyte - Athenex Estimate	$	3,465.00
41	TOC IQOQ Package and on-site validation/calibration	$	8,820	Exyte - Athenex Estimate	$	8,820.00
41	micro lab laminar flow bench 36"	$	25,200	Exyte - Athenex Estimate	$	25,200.00
41	autotitrator	$	34,650	Exyte - Athenex Estimate	$	34,650.00
41	autotitrator 21 CFR Part 11 SW package and validaiton	$	5,250	Exyte - Athenex Estimate	$	5,250.00
41	glassware washer	$	48,300	Exyte - Athenex Estimate	$	48,300.00
41	glassware washer racks	$	48,300	Exyte - Athenex Estimate	$	48,300.00
41	small glassware washer	$	11,550	Exyte - Athenex Estimate	$	11,550.00
41	bosch visual inspection hood for lab	$	8,400	Exyte - Athenex Estimate	$	8,400.00
41	UPLC - Total of 7	$	735,000	Exyte - Athenex Estimate	$	735,000.00
41	software	$	56,994	Exyte - Athenex Estimate	$	56,994.00
41	Software SQT	$	8,736	Exyte - Athenex Estimate	$	8,736.00
41	annual software maintenance	$	17,850	Exyte - Athenex Estimate	$	17,850.00
41	LACE Server	$	42,000	Exyte - Athenex Estimate	$	42,000.00
41	annual calibration service - 7 UPLC's	$	162,855	Exyte - Athenex Estimate	$	162,855.00
	Original Estimated Value	$	12,772,811	Final GMP Value	$	3,912,595.00

Exhibit 1 - Page 5 of 14

March 1, 2019


	Yet To Buy Analysis	.

Definitions:

Yet-to-buy: Identified tasks, which cannot be quantified or qualified in sufficient detail during the procurement process, but are necessary to provide a complete and functional system. The cost for bonds, as deemed necessary by the design-build contractor, are also included in these funds.

Contingency: Costs for a future event or circumstance which is possible, but can not be predicted with certainty.

GMP YTB Summary

Division	Package	YTB Value		Comments
1	Temp Power	$	18,000	Did not increase Div. 1 total of $4.8M
4	Exterior Stone Veneer	$	20,000	Coordination with exterior devices. Doors, badge readers, etc. Misc. blocking/coordination with cold form
4	Interior CMU	$	100,000	Misc. angles/supports and fire stopping required to support late bulletin changes to CMU package. Includes penetrations for duct, cable tray, not clearly shown. Include remobilization for walls left open to support process equipment move-in.
8	Glass and Glazing: interiors	$	30,000	Coordination with stair landings and exterior mullions at lobby. Know this will required additional coordination
9	Millwork & Cabinets	$	35,000	Rigging, move-in and coordination with other trades for utilities/power/IT, including protection of finished product
9	Interiors Package	$	365,000	Significant number of penetrations and late changes will add fire stopping, door hardware coordination and finish changes. Hold-areas for move-in of equipment. Coordination with IT/Secuirty and other hardware issues expected.
9	Ceramic Tile	$	30,000	Additional sub-base excluded by bidders. Includes coordination with other trades and OT as needed.
9	Resilent Flooring and Carpet	$	25,000	Coordination with interiors, temporary protection of finished floor and repairs due to damages.
9	Painting	$	-
9	Epoxy Resign Flooring	$	50,000	Coordination with interiors, temporary protection of finished floor and repairs due to damages.
10	Toilet Partitions	$	8,000	Misc. metals to support hung partitions.
10	Lockers	$	15,000	Protection of final products. Coordination with other trades/services.
10	Interior Signage	$	-
11	Loading Dock Equipment	$	85,000	6% Price increase expected 2/1 due to lack of award. Expect to relocate steel and air-curtains due to coordination of insulated doors
11	Coolers	$	25,000	Rigging, move-in coordination. POC coordintion locations need to be finalized
12	Laboratory Casework	$	50,000	Coordination with other trades for utilities, rigging and protection of finished product.
13	Clean Room Systems	$	250,000	Known door changes, additional rough-in for clocks, EMS/PCS devices, extended GC to hold open areas for process equipment move-in.
13	Precast Buildings	$	5,000	Additional fans, lights, desk-top items & finish requests
14	Elevators	$	10,000	Pit coordination issue known. Depth/sump locations expected to be changed
21	Fire Protection	$	50,000	Additional heads due to wall changes, height changes. Ductwork blockages will required added heads.
22	Plumbing	$	150,000	Overtime and rework of floor drains/restrooms or other coordination requirements.
23	Wet mechanical	$	500,000	Winter conditions, coordination of deferred scope with end of line by-passes. Support of IT rooms with potential changes to cooling design. (CRAC's vs rack cooling) Flushing issues with AHJ or environment groups. (Frac tanks). Includes OT or shift differential as needed to support schedule.
23	Dry mechanical	$	850,000	Balancing issues, damper testing for AHJ, exhaust fan issues due to deferred scope, winter continues, support with dehumidication to support finishes, OT, winter conditions, potential off- shift differential. Added back AHU-120, however removed $100K for fencing and $150K for exterior "A" signage on building.
25	I&C	$	450,000	Relocation of RIO's, I/O's. Coordination with VFD's and owner SOO changes not currently available.
26	Electrical Distribution	$	600,000	Panel Schedule changes due to deferred scope, gaps in equipment feeders. Sequence of Op's/communications plan for generators and ATS. Wiring to Gen Sets/Communications to primary substations. Includes $120K winter conditions. Includes potential union wage rate increase. Includes power for dehumidification units. Includes additional Buss-Ties of approx. $100k.
27	IT	$	50,000	Changes to clock system, device locations which continue to be on-going. Minor wiring diagram changes, supports within rooms.
28	Security	$	50,000	Additional devices, cameras and badge reader support. Cable lengths for 24V power seems to be too long and expect additional transformers.
33	Water Storage Tank and Pad	$	20,000	Site leveling/grading and coordination with fire water pump building
41	Process Piping	$	300,000	Rigging coordination, support of CQV efforts which are not identified but are expected. Spec gases for testing/commissioning support. Costs to relocate devices based on process equipment requirements/POC's.

Exhibit 1 - Page 6 of 14

March 1, 2019

CONFIDENTIAL


	Yet To Buy Analysis	.

41	Parts Washer	$	57,000	$32K in alternates provided by vendor and anticipated to be needed. Coordination with other trades for POC's and internior configuration of equipment. Includes expediting submittals/equipment due to schedule.
41	Autoclave	$	54,000	Includes lternates provided by vendor and anticipated to be needed. Coordination with other trades for rigging and connections to POC's. Includes expediting submittals/equipment due to schedule.
41	Pure Steam	$	60,000	Includes additional POC's, filters/start-up concerns. Includes pre-heater, graphics manager, other alternates expecting client approval.
41	WFI Pretreatment & Generation	$	150,000	Includes SOO changes expected, additional testing/validation by vendor expected to be required. Includes vendor alternates expected to be required by owner.
41	WFI Storage & Distribution	$	50,000	Includes alternates provided by vendor and expected to be requested by owner.
41	OFCA	$	35,000	Includes reduction for smaller dryer (option) and other options.
41	CIP Skids	$	-
41	WWT Tanks	$	60,000	Rigging/move-in coordination due to late arrival of equipment. Includes DEC testing support, chemicals and minor AHJ requests
41	WFI Coolers	$	35,000	Rigging and start-up support - multiple mobilizations.
41	Remaining process equipment	$	-
	SUBTOTAL	$	4,642,000
	Fee/Insurance	$	162,470	Added due to request to move this value below COW Value
	TOTAL	$	4,804,470	Total value carried "below the line" for YTB.

Exhibit 1 - Page 7 of 14

March 1, 2019

CONFIDENTIAL

Athenex GMP Indirects Summary

Indirect Cost Categories		Total (Deferred Scope)
Design	$	12,557,128
EPCM Services	$	12,329,008
EPCM GC's	$	2,697,883
EPCM Fee (M+W)	$	4,000,927
EPCM Fee (Pike)	$	1,350,000
EPCM Insurance	$	1,600,371
Pike GL Insurance	$	30,613

Total:	$	34,565,930

Design Summary

Description		Total (Deferred Scope)
Concept Design / Site Conditions	$	397,225
Basis of Design including Bridging /PCM Services	$	1,920,489
BOD Accelerated Efforts / Pre-Con Services/ PCM Services	$	2,247,266
Detail Design Allowance	$	5,846,935
Construction Administration	$	2,145,213

Total	$	12,557,128

Exhibit 1 - Page 8 of 14

March 1, 2019

CONFIDENTIAL


	Athenex GMP Indirects Summary	.

	Athenex Facility - Dunkirk, NY
	General Conditions - GMP Value
	January, 2019

GEN	ERAL CONDITIONS		Cost	Comments
1	Safety Equipment/PPE	$	18,600
2	Safety incentives	$	23,250
3	Safety training / documentation	$	74,000
4	First aid supplies	$	15,000
5	Safety signage, type, AHJ Requirements during Construction	$	38,500
6	Blue Prints - Drawings/Reprographics	$	57,500
7	Bid Advertisement	$	45,000
8	Office supplies - printer ink, paper, pens, reproduction, etc.	$	51,000
9	Pantry Supplies (Napkins, paper towels, plastic silver ware, etc.)	$	18,500
10	Toilet Supplies (toilet paper, hands was liquid, broom, mop, cleaning liquids)	$	16,600
11	Cell Phones / Walkie Talkies	$	82,720
12	Office Vehicles (Rental, Fuel, Maintenance Costs)	$	22,000
13	Team Meetings/Catering/Site Recognition Events	$	19,000
14	Computers, software, printers, Copier, Plotters, service maint. contracts, etc.	$	205,530
15	Furnishings, white boards, chairs	$	78,000
16	Postal/ messenger services	$	26,000
17	Staff relocation	$	80,000
18	Monthly staff per diem	$	608,200
19	Offsite Staff Travel	$	105,500
20	Construction waste dumpsters	$	0	General Requirement
21	Construction turnstiles	$	0	Not Required
22	Project signage	$	31,000
23	Water truck	$	0	General Requirement
24	Site inspections / Factory inspections M+W Staff only	$	0	Not Required
25	Site trailer (Construction, site meetings) 6-wide 72'x60', Safety 2-wide 24'x60', 2-wide Break 24' x 60'	$	369,200
	Muldowney Warehouse- 7,000sf	$	0	Athenex Paid Direct
	Muldowney Parking Acreage 3.1	$	0	Athenex Paid Direct
26	Utilities for Muldowney Rented Spaces	$	0	Athenex Paid Direct
27	Site Conex	$	51,300
28	Utilities for site trailers (tie-ins for water, power, septic)	$	321,000
29	Temp Construction Utilities (e.g. Construction Power, Temp Heat)	$	0	Athenex Paid Direct
30	Permits	$	0	Athenex Paid Direct
31	Snow removal	$	0	General Requirement
32	Road sweeping	$	0	General Requirement
33	Site gators ($46,490 Cost to date + $1,500 maintance/repairs if needed)	$	47,990
34	Site Security	$	0	General Requirement
35	Site Fencing	$	0	Site Contractor (COW)
35	BIM Coordination Efforts	$	491,800
		$	2,897,190
	Adjustments
1	Muldowney Warehouse- 7,000sf	-$	42,000
2	Muldowney Parking Acreage 3.1	-$	30,000
3	Utilities for Muldowney Rented Spaces	-$	108,000
4	National Grid Adjustment - Paid by Athenex	-$	4,236
5	National Grid Adjustment - Paid by Athenex	-$	15,071

	GMP Value - General Conditions	$	2,697,883

Exhibit 1 - Page 9 of 14

March 1, 2019

CONFIDENTIAL


	Athenex GMP General Conditions	.

	Athenex Facility - Dunkirk, NY
	General Conditions - GMP Value
	January, 2019

GEN	ERAL CONDITIONS		Cost	Comments
1	Safety Equipment/PPE	$	18,600
2	Safety incentives	$	23,250
3	Safety training / documentation	$	74,000
4	First aid supplies	$	15,000
5	Safety signage, type, AHJ Requirements during Construction	$	38,500
6	Blue Prints - Drawings/Reprographics	$	57,500
7	Bid Advertisement	$	45,000
8	Office supplies - printer ink, paper, pens, reproduction, etc.	$	51,000
9	Pantry Supplies (Napkins, paper towels, plastic silver ware, etc.)	$	18,500
10	Toilet Supplies (toilet paper, hands was liquid, broom, mop, cleaning liquids)	$	16,600
11	Cell Phones / Walkie Talkies	$	82,720
12	Office Vehicles (Rental, Fuel, Maintenance Costs)	$	22,000
13	Team Meetings/Catering/Site Recognition Events	$	19,000
14	Computers, software, printers, Copier, Plotters, service maint. contracts, etc.	$	205,530
15	Furnishings, white boards, chairs	$	78,000
16	Postal/ messenger services	$	26,000
17	Staff relocation	$	80,000
18	Monthly staff per diem	$	608,200
19	Offsite Staff Travel	$	105,500
20	Construction waste dumpsters	$	0	General Requirement
21	Construction turnstiles	$	0	Not Required
22	Project signage	$	31,000
23	Water truck	$	0	General Requirement
24	Site inspections / Factory inspections M+W Staff only	$	0	Not Required
25	Site trailer (Construction, site meetings) 6-wide 72'x60', Safety 2-wide 24'x60', 2-wide Break 24' x 60'	$	369,200
	Muldowney Warehouse- 7,000sf	$	0	Athenex Paid Direct
	Muldowney Parking Acreage 3.1	$	0	Athenex Paid Direct
26	Utilities for Muldowney Rented Spaces	$	0	Athenex Paid Direct
27	Site Conex	$	51,300
28	Utilities for site trailers (tie-ins for water, power, septic)	$	321,000
29	Temp Construction Utilities (e.g. Construction Power, Temp Heat)	$	0	Athenex Paid Direct
30	Permits	$	0	Athenex Paid Direct
31	Snow removal	$	0	General Requirement
32	Road sweeping	$	0	General Requirement
33	Site gators ($46,490 Cost to date + $1,500 maintance/repairs if needed)	$	47,990
34	Site Security	$	0	General Requirement
35	Site Fencing	$	0	Site Contractor (COW)
35	BIM Coordination Efforts	$	491,800
		$	2,897,190
	Adjustments
1	Muldowney Warehouse- 7,000sf	-$	42,000
2	Muldowney Parking Acreage 3.1	-$	30,000
3	Utilities for Muldowney Rented Spaces	-$	108,000
4	National Grid Adjustment - Paid by Athenex	-$	4,236
5	National Grid Adjustment - Paid by Athenex	-$	15,071

	GMP Value - General Conditions	$	2,697,883

Exhibit 1 - Page 10 of 14

March 1, 2019

CONFIDENTIAL


	Athenex GMP General Requirement Summary	Division 1.

Division 1

Item	Scope Overview		Total ($)	Comments
1	Temporary Heat	$	320,000	Installation/Removal (Not utilities)
2	Temporary Guard Shacks with Security Gate	$	9,900
3	Security personnel	$	264,000
4	Document Support for Commissioning	$	302,750
5	Temporary Construction Power	$	600,000
6	Site General Condition	$	-	Civil Contractor (COW)
7	Textura Program	$	-	Not Used
8	Roof Access (Stair Towers) 12 Months	$	75,036
9	Lull w/ Operator	$	93,900
10	Maintain Perimeter Cable System/Toe Boards for Openings	$	130,061
11	First Aid Equip	$	-	General Conditions
12	Safety - Fire Protection	$	100,000
13	Temp Floor Protection (Material and Labor)	$	222,893
14	Temp Protection at Exteriors & Openings (Material and Labor)	$	399,210
15	Temp. Access Pathway for Athenex personell after TCO	$	-	Not Required per Athenex
16	Temp Elevator Protection	$	16,717
17	Temp Toilet(Rent - 20 ea @ 20 mos.)	$	78,014
18	Parking / Site / Roads (Clearing, Snow/Salting, and Maintenance)	$	356,637
19	Lawn Maintenance	$	11,145
20	Job Photographs	$	-	Not Required per Athenex
21	Blue Prints	$	-	General Conditions
22	Bid Advertising	$	-	General Conditions
23	Supplies - Postage & Handling	$	-	General Conditions
24	Job Sign	$	17,832
25	Job Signs/Temp	$	557
26	Surveying - 2-man crew, initial bldg layout, BM's	$	27,862
27	Current Cleanup including Slab Maintenance (4 Laborers)	$	551,290
28	Rent Dumpster (C&D, Metals, Cardboard) (10/week @ 20 mos)	$	872,202
29	Final Cleanup - Core and Shell	$	400,000
	GENERAL REQUIREMENTS TOTAL	$	4,850,007

Exhibit 1 - Page 11 of 14

March 1, 2019

CONFIDENTIAL

	September 2017 to February 2018 April 2018 to September 2018 February 2018 to September 2019 October 2019 to June 2020			1900
		Title/Position	Resource		Duration/ Quantity		Hr Rate $$		Total
		Executive Team
					-	$	205	$	-
		Construction Operations Team
		Project Director	Exyte		3,880	$	206.85	$	802,578
		Lee Ogle	Exyte
		Project Manager	Exyte		4,340	$	206.85	$	897,729
		Bill Zurek	Exyte
		MEP CM 1 - Process	Exyte		3,600	$	148.75	$	535,500
		Gerald Brewster
		MEP CM 2 - Mechanical	Exyte		3,640	$	148.75	$	541,450
		Derek Maiellaro - Lotus
		MEP CM 3 - Electrical/ELVS	Exyte		3,720	$	148.75	$	553,350
		Mike Driscoll
		MEP CM 4 - ELVS. (LSS/I&C/FMCS)	Exyte		3,320	$	148.75	$	493,850
		Tody Montoya
		General Super	Exyte		3,440	$	171.25	$	589,100
		Jerry Roberts
		MV/ELECT SI 1	Exyte		3,480	$	136.85	$	476,238
		Tommy Sanders	Exyte
		Electrical SI 2	Exyte		-	$	136.85	$	-
		I&C Support - Removed 19OCT	Exyte
		CA SI - 3 Code Support Super	Exyte		2,520	$	136.85	$	344,862
		TBD	Exyte
		Project Eng 1	Exyte		4,120	$	106.80	$	440,016
		Jarrod Mills	Exyte
		Project Eng 3	Exyte		3,400	$	106.80	$	363,120
		John Bauman / Ben Crewdson	Exyte
EHS		Office
		Office Admin/Doc Lead	Exyte		4,496	$	78.75	$	354,060
		Kellie Saller / Miles Wilson
		Office Admin Support	Exyte		3,600	$	78.75	$	283,500
		Courtney Rice
EHS
		EHS Manager	Exyte		152	$	171.25	$	26,030
		Jeff Dennis
		EHS Field	Exyte		3,680	$	97.90	$	360,272
		Joseph McGowan

Exhibit 1 - Page 12 of 14

March 1, 2019

CONFIDENTIAL

	EHS Adm	Exyte	3,280	$	55.00	$	180,400
	Destiny Clemens
Project	Commercial Team
		Exyte	-			$	-
	Procurement
	Procurement Specialist	Exyte	1,840	$	137.00	$	252,080
	Steve Licursi			$	0.00
	Procurement Specialist	Exyte	1,640	$	137.00	$	224,680
	Nicole Lamarre			$	0.00
	Estimating
	CSA Estimator	Exyte	440	$	143.85	$	63,294
	Various
	MEP/Process Estimator	Exyte	440	$	143.85	$	63,294
	Various
	Electrical Estimator	Exyte	440	$	124.95	$	54,978
	Various
	Scheduling
	Scheduler	Exyte	2,200	$	143.85	$	316,470
	Vu Tran
	Cost / Finance
	Assit PC	Exyte	640	$	93.45	$	59,808
	Denise Fry
	Assit PC	Exyte	2,040	$	93.45	$	190,638
	Susan Marcinak
	Assit PC	Exyte	1,680	$	93.45	$	156,996
	Carol Drayton
	Commerial Manager	Exyte	600	$	171.25	$	102,750
	Bill Zurek - PM as of 6/15
	Cost Control 1	Exyte	3,960	$	107.10	$	424,116
	Carrie Ogle
	Cost Control 2		680	$	112.30	$	76,364
	Patrick Mulready
	QAQC
	Commissioning Specialist	Exyte	-	$	150.00	$	-
	Removed - Athenex Scope
	DC Asst	Exyte	-	$	52.50	$	-
	Removed - Not Expect
	DC Department Lead	Exyte	428	$	93.75	$	40,125
	Terrie Smith
	Total Labor		71696			$	9,267,648
	FULL TIME EQUIVALENTS (FTE)		11.8

Hrs per month

Exyte Cost	$	-	$	-	$ 9,267,648
PIke Cost					$ 3,061,360
			Total Labor $ 12,329,008

Exhibit 1 - Page 13 of 14

March 1, 2019

CONFIDENTIAL


	Exhibit C - Pike CM Labor Forecast

		Hours & Costs Billed thru January 31, 2019					F-19			M-19		A-19		M-19		J-19		J-19		A-19		S-19		O-19		N-19		D-19		J-20	Forecasted Total Billing Hours thru March 19
Title/Position	Resource		Hrly Billing Rate	Total Hours thru 1/31/19		Total Billed thru 2/28/19 (costs thru 1/31/19)		Month 16	Month 17		Month 18		Month 19		Month 20		Month 21		Month 22		Month 23		Month 21		Month 22		Month 23		Month 24		Hrly Billing Rate Effective 4/1/19	Hours (2018 Rates)	Hours (2019 Rates)		Total Incurred & Forecasted Billing
Executive Team
Project Executive	PIKE	$	205	175.00	$	35,875		16	16		16		16		16		16		16		16		16		16		16		16		213.06	32.00	160	$	76,525
Construction Operations Team																															-		-
Project Director (Justin F)	PIKE	$	205	2,444.00	$	501,020		173	173		173		173		173		173		173		173		173		173		173		173		213.06	346.00	1,730	$	940,544
General Superintendent (Joe A)	PIKE	$	135	1,920.00	$	259,200		173	173		173		173		173		173		173		173		173		173		173		173		155.25	346.00	1,730	$	574,493
Site Superintendent (Dave R)	PIKE	$	100	2,050.00	$	205,000		173	173		173		173		173		173		173		173		173		173		173		173		125.00	346.00	1,730	$	455,850
Building Superintendent (Dave Z)	PIKE	$	100	192.00	$	19,200		173	173		173		173		173		173		173		173		173		173		173		173		125.00	346.00	1,730	$	270,050
Project Engineer (Ikea & Tim)	PIKE	$	65	1,702.00	$	110,630		346	346		346		346		346		346		346		346		346		346		346		346		85.00	692.00	3,460	$	449,710
EHS																															-		-
Field Safety	PIKE	$	85	24.00	$	2,040																									-		-	$	2,040
Commercial Team																															-		-
Procurement																															-		-
Procurement Specialist	PIKE	$	100	1,839.00	$	183,900		20	10																						115.00	30.00	-	$	186,900
Estimating																															-		-
CSA Estimator	PIKE	$	100	1,459.00	$	145,900																									-		-	$	145,900
Cost / Finance																															-		-
Cost Accountant (Toni & Mary)	PIKE	$	65	375.00	$	24,375		40	40		40		40		40		40		40		40		40		40		40		40		85.00	80.00	400	$	63,575
Cost Engineer (Andrea)	PIKE	$	95	974.00	$	92,530		173	173		173		173		173		173		173		173		173		173		173		173		110.31	346.00	1,730	$	316,236
Doc Control 2 (Danelle)	PIKE	$	55	2,132.00	$	117,260		173	173		173		173		173		173		173		173		173		173		173		173		96.25	346.00	1,730	$	302,803
Misc. Shared Support Services																															-
Scheduler (John?)	PIKE	$	109	1,165.50	$	127,040		85	85		85		85		85		85		85		85		85		85		85		85		128.62	170.00	850	$	254,897
Total Labor				16,451.50	$	1,823,970		1545	1535		1525		1525		1525		1525		1525		1525		1525		1525		1525		1525				15,250	$	4,039,521

FULL TIME EQUIVALENTS (FTE)								9	9		8.80 9		8.80 9		8.80 9		8.80 9		8.80 9		8.80 9		8.80 9		8.80 9		8.80 9		8.80

Exhibit 1 - Page 14 of 14

March 1, 2019

CONFIDENTIAL


	Athenex GMP Specificatio	Exhibit 2 (p. 1 of 5)

Spec No.	Name	Rev	Set Name	Issuance Date
01 10 10	General Requirements	0	Div. 1 Specs	11/1/2018
01 21 00	Allowances	1	Bulletin0020-IFCPermitIssue	12/14/2018
01 30 00	Administrative Requirements	0	Div. 1 Specs	11/1/2018
01 33 00	Submittal Procedures	1	Bulletin0020-IFCPermitIssue	12/14/2018
01 40 00	Quality Requirements	1	Bulletin0020-IFCPermitIssue	12/14/2018
01 42 00	References	0	Div. 1 Specs	11/1/2018
01 45 33	Code-Required Special Inspections and Procedures	0	Div. 1 Specs	11/1/2018
01 50 00	Temporary Facilities and Controls	0	Div. 1 Specs	11/1/2018
01 58 13	Temporary Project Signage	0	Div. 1 Specs	11/1/2018
01 60 00	Product Requirements	0	Div. 1 Specs	11/1/2018
01 73 00	Execution	0	Div. 1 Specs	11/1/2018
01 74 19	Construction Waste Management and Disposal	0	Div. 1 Specs	11/1/2018
01 74 19ESD	ESD Waste Management	NA	Div. 1 Specs	11/1/2018
01 77 00	Closeout Procedures	0	Div. 1 Specs	11/1/2018
01 78 23	Operation and Maintenance Data	0	Div. 1 Specs	11/1/2018
01 78 39	Project Record Documents	0	Div. 1 Specs	11/1/2018
01 79 00	Demonstration and Training	0	Div. 1 Specs	11/1/2018
01 80 00	BIM Standards	0	Div. 1 Specs	11/1/2018
01 91 13	General Commissioning Requirements	0	Div. 1 Specs	11/1/2018
02 41 19	Selective Demolition	0	IFC Specs	4/23/2018
03 30 00	Cast-In-Place Concrete-Civil	0	IFC Specs	4/23/2018
03 30 00	Cast-In-Place Concrete-Structural	0	IFC Specs	4/23/2018
03 30 20	Concrete Slab on Grade	0	IFC Specs	4/23/2018
03 30 25	Concrete Slan on Deck	1	BOD Issue	2/8/2018
04 20 00	Unit Masonry	A	BOD Issue	2/8/2018
04 43 13 16	Adhered Stone Masonry Veneer	1	Bulletin0020-IFCPermitIssue	12/14/2018
05 12 00	Structural Steel Framing	A	BOD Issue	2/8/2018
05 30 00	Metal Decking	A	BOD Issue	2/8/2018
05 40 00	Cold-Formed Metal Framing	1	Bulletin0020-IFCPermitIssue	12/14/2018
05 50 00	Metal Fabrications	1	Bulletin0020-IFCPermitIssue	12/14/2018
05 51 13	Metal Pan Stairs	1	Bulletin0020-IFCPermitIssue	12/14/2018
05 51 19	Metal Grating Stairs	1	Bulletin0020-IFCPermitIssue	12/14/2018
05 52 13	Pipe and Tube Railings	1	Bulletin0020-IFCPermitIssue	12/14/2018
05 72 13	Clean Room Equipment Platform & Stairs	0	PQ007-9&11	9/7/2018
05 73 13	Glazed Decorative Metal Railings	1	Bulletin0020-IFCPermitIssue	12/14/2018
06 10 53	Miscellaneous Rough Carpentry	1	Bulletin0020-IFCPermitIssue	12/14/2018
06 16 00	Sheathing	1	Bulletin0020-IFCPermitIssue	12/14/2018
06 41 16	Plastic-Laminate-Faced Architectural Cabinets	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 13 26	Self-Adhering Sheet Waterproofing	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 14 16	Cold Fluid Applied Water Proofing	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 21 00	Thermal Insulation	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 21 19	Foamed-in-Place Insulation	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 27 26	Fluid-Applied Membrane Air Barriers	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 42 13 19	Insulated Metal Wall Panels	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 54 19	Polyvinyl-Chloride (PVC) Roofing	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 62 00	Sheet Metal Flashing and Trim	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 81 00	Applied Fireproofing	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 84 13	Penetration Firestopping	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 84 43	Joint Firestopping	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 91 00	Preformed Joint Seals	1	Bulletin0020-IFCPermitIssue	12/14/2018
07 92 00	Joint Sealants	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 11 13	Hollow Metal Doors and Frames	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 11 19	Stainless-Steel Doors and Frames	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 31 13	Access Doors and Frames	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 33 23	Overhead Coiling Doors	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 33 23 13	High Performance Overhead Coiling Fabric Doors	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 41 13	Aluminum-Framed Entrances and Storefronts	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 44 13	Glazed Aluminum Curtain Walls	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 71 00	Door Hardware	1	Bulletin0020-IFCPermitIssue	12/14/2018
08 80 00	Glazing	2	Bulletin0020-IFCPermitIssue	12/14/2018
08 91 19	Fixed Louvers	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 21 16 23	Gypsum Board Shaft Wall Assemblies	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 22 16	Non-Structural Metal Framing	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 29 00	Gypsum Board	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 30 13	Ceramic Tiling	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 30 23	Glass Mosaic Tiling	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 51 13	Acoustical Panel Ceilings	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 54 23	Linear Multi-Box Metal Ceilings	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 65 13	Resilient Base and Accessories	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 65 19	Resilient Tile Flooring	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 65 36	Static-Control Resilient Flooring	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 65 66	Resilient Athletic Flooring	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 67 23	Resinous Flooring	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 68 13	Tile Carpeting	1	Bulletin0020-IFCPermitIssue	12/14/2018
09 70 00	Wall Finishes	1	Bulletin0020-IFCPermitIssue	12/14/2018

1/30/2019

CONFIDENTIAL


	Athenex GMP Specificatio	Exhibit 2 (p. 2 of 5)

Spec No.	Name	Rev	Set Name	Issuance Date
09 91 23	Interior Painting	1	Bulletin0020-IFCPermitIssue	12/14/2018
10 21 13 14	Stainless-Steel Toilet Compartments	1	Bulletin0020-IFCPermitIssue	12/14/2018
10 21 13 17	Phenolic-Core Toilet Compartments	A	Issue for Bid	10/12/2018
10 22 39	Folding Panel Partitions	1	IFC Package	12/7/2018
10 26 00	Wall and Door Protection	0	Bulletin0020-IFCPermitIssue	12/14/2018
10 44 13	Fire Protection Cabinets	1	Bulletin0020-IFCPermitIssue	12/14/2018
10 44 16	Fire Extinguishers	1	Bulletin0020-IFCPermitIssue	12/14/2018
10 51 13	Metal Lockers	1	Bulletin0020-IFCPermitIssue	12/14/2018
10 56 13	Metal Storage Shelving	1	Bulletin0020-IFCPermitIssue	12/14/2018
11 05 13	Common Motor Requirements for Equipment	0	Issue for Bid	8/15/2018
11 13 13	Loading Dock Bumpers	1	Bulletin0020-IFCPermitIssue	12/14/2018
11 13 16	Loading Dock Seals and Shelters	1	Bulletin0020-IFCPermitIssue	12/14/2018
11 13 19	Master Control Panels	1	Bulletin0020-IFCPermitIssue	12/14/2018
11 13 19 01	Stationary Loading Dock Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
11 53 13	Laboratory Fume Hoods	1	Bulletin0020-IFCPermitIssue	12/14/2018
12 24 13	Roller Window Shades	1	Bulletin0020-IFCPermitIssue	12/14/2018
12 35 53 13	Metal Laboratory Casework	1	Bulletin0020-IFCPermitIssue	12/14/2018
12 48 16	Entrance Floor Grilles	1	Bulletin0020-IFCPermitIssue	12/14/2018
13 00 00	Clean Room Pre-engineered Modular Wall and Ceiling System	1	Bulletin0020-IFCPermitIssue	12/14/2018
13 21 26	Cold Storage Rooms	0	Issue for Bid	10/12/2018
13 27 00	Vaults	A	Core and Shell	6/29/2018
14 21 23 16	Machine Room-Less Electric Traction Passenger Elevators	1	Bulletin0020-IFCPermitIssue	12/14/2018
14 24 13	Hydraulic Freight Elevators	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 05 13	Common Motor Requirements for Fire-Suppression Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 05 17	Sleeves and Sleeve Seals fir Fire-Supression Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 05 18	Escutcheons for Fire-Suppression Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 05 23	General-Duty Valves for Fire Protection Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 05 29	Hangers & Supports for Fire Suppression Piping & Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 05 53	Identification for Fire-Suppression Piping and Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 11 00	Facility Fire-Suppression Water-Service Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 11 19	Fire Department Cpnnections	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 12 00	Fire-Suppression Standpipes	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 13 13	Wet-Pipe Sprinkler Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 13 16	Dry-Pipe Spinkler Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 22 00	Clean-Agent Fire-Suppression Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 31 16	Diesel-Drive, Fire Pump	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 34 13	Pressure-mainetance Pumps	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 39 00	Controllers for Fire-Pump Drivers	1	Bulletin0020-IFCPermitIssue	12/14/2018
21 44 00	Fire Protection Water Storage Tanks	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 13	Common Motor Requirements for Plumbing Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 16	Expansion Fittings and Loops for Plumbing Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 17	Sleeves And Sleeve Seals for Plumbing Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 18	Escutcheons for Plumbing Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 19	Meters and Gages for Plumbing Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 23 12	Ball Valves for Plumbing Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 23 13	Butterfly Valves for Plumbing Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 23 14	Check Valves for Plumbing Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 23 15	Gate Valves for Plumbing Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 29	Hangers and Supports for Plumbing Piping and Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 05 53	Identification for Plumbing Piping and Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 07 19	Plumbing Piping Insulation	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 11 13	Facility Water Distribution Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 11 13CPL	Facility Water Distribution Piping	0	IFC Specs	4/23/2018
22 11 16	Domestic Water Piping	0	Bulletin0020-IFCPermitIssue	12/14/2018
22 11 16 01	Domestic Water Piping	1	Pricing Issue	8/31/2018
22 11 17	Gray-Water Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 11 19	Domestic Water Piping Specialties	0	Bulletin0020-IFCPermitIssue	12/14/2018
22 11 19 01	Domestic Water Piping Specialties	1	Pricing Issue	8/31/2018
22 11 23 13	Domestic-Water Packaged Booster Pumps	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 11 23 21	Inline, Domestic-Water Pipes	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 13 13	Facility Sanitary Sewers	0	Pricing Issue	8/31/2018
22 13 16	Sanitary Waste and Vent Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 13 19	Sanitary Waste Piping Specialties	0	Pricing Issue	8/31/2018
22 13 19 01	Sanitary Waste Piping Specialties	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 14 13	Facility Storm Drainage Piping	0	Pricing Issue	8/31/2018
22 14 13 01	Facility Storm Drainage	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 14 23	Storm Drainage Piping Specialties	0	Pricing Issue	8/31/2018
22 14 23 01	Storm Drainage Piping Specialties	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 14 29	Sump Pumps	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 31 00	Domestic Water Softeners	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 32 00	Grey-Water Harvesting Equipment & Filtration System	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 33 00	Electric Domestic Water Heaters	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 35 00	Domestic-Water Heat Exchangers	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 42 13 13	Commercial Water Closets	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 42 13 16	Commercial Urinals	1	Bulletin0020-IFCPermitIssue	12/14/2018

1/30/2019

CONFIDENTIAL


	Athenex GMP Specificatio	Exhibit 2 (p. 3 of 5)

Spec No.	Name	Rev	Set Name	Issuance Date
22 42 16 13	Commercial Lavatories	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 42 16 16	Commercial Sinks	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 42 23	Commerical Showers	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 45 00	Emergency Plumbing Fixtures	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 47 16	Pressure Water Coolers	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 61 13	Compressed-Air Piping for Laboratory and Healthcare Facilities	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 63 14	Compressed Gas Piping for Laboratory and Pharmaceutical Facilities	1	Bulletin0020-IFCPermitIssue	12/14/2018
22 66 00	Chemical-Waste Systems for Laboratory and Healthcare Facilities	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 13	Common Motor Requirements for Equipment	B	Issue for Bid	10/12/2018
23 05 16	Expansion Fittings and Loops for HVAC Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 17	Sleeves and Sleeve Seals for HVAC Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 18	Escutcheons For HVAC Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 19	Meters and Gages for HVAC Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 23	General-Duty Valves for HVAC Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 29	Hangers and Supports for HVAC Piping and Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 48	Vibration and Seismic Controls for Piping and Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 53	Identification for HVAC and Piping and Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 05 93	Testing, Adjusting, and Balancing for HVAC	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 07 00	Equipment, Vessels, Piping, and Duct Insulation	0	PQ007-9&11	9/7/2018
23 07 13	Duct Insulation	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 07 16	HVAC Equipment Insulation	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 07 19	HVAC Piping Insulation	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 09 23	Building Management System (BMS)	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 09 23 01	BMS Instrumentation for HVAC Controls	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 09 23 11	Control Valves	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 09 23 12	Control Dampers	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 09 93 11	Sequence of Operations for HVAC DDC	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 11 23	Facility Natural-Gas Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 21 13	Hydronic Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 21 23	Hydronic Pumps	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 22 13	Steam and Condensate Heating Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 25 00	HVAC Water Treatment	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 31 13	Metal Ducts	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 31 19 16	Manufactured HVAC Outdoor Air Intake Plenum Casings	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 33 00	Air Duct Accessories	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 34 16	Centrifugal HVAC Fans	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 34 23 01	HVAC Power Ventilators	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 34 33	Air Curtains	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 36 00	Air Terminal Units	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 37 13	Diffusers, Registers, and Grilles	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 37 23	HVAC Gravity Ventilators	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 41 33	High-Efficiency Particulate Filtration	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 51 00	Breechings, Chimneys, and Stacks	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 52 39	Firetube Boilers	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 53 16	Deaerator and Surge Tank	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 53 18	Boiler Blowdown Equipment	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 57 00	Heat Exchangers for HVAC	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 57 10	Unfired Steam Generators	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 64 16	Centrifugal Water Chillers	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 65 00	Cooling Towers	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 73 13 01	Indoor Central-Station Air-Handling Units	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 73 13 19	Indoor Custom Air Handling Units	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 74 00	Air Rotation Units	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 74 33	Dedicated Outdoor-Air Units	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 81 23 03	Computer Room Air Conditioners, Console units	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 82 16	Air Coils	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 82 19	Fan Coil Units	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 82 29	Radiators	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 82 36	Finned-Tube Radiation Heaters	1	Bulletin0020-IFCPermitIssue	12/14/2018
23 82 39	Unit Heaters	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 00 01	Electrical Work General	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 04 45	Elevator Control Switches	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 13	Medium-Voltage Cables	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 19	Low-Voltage Electrical Power Conductors and Cables	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 26	Grounding and Bonding for Electrical Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 29	Hangers and Supports for Electrical Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 33	Raceway and Boxes for Electrical Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 36	Cable Trays for Electrical Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 43	Underground Ducts and Raceways for Electrical Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 44	Sleeves and Sleeve Seals for Electrical Raceways and Cabling	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 53	Identification for Electrical Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 73	Arc-Flash Hazard Analysis	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 05 85	Electrical Requirements for Packaged Equipment	0	PQ007-9&11	9/7/2018
26 08 00	Commissioning of Electrical Systems	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 09 13	Electrical Power Monitoring and Control	1	Bulletin0020-IFCPermitIssue	12/14/2018

1/30/2019

CONFIDENTIAL


	Athenex GMP Specificatio	Exhibit 2 (p. 4 of 5)

Spec No.	Name	Rev	Set Name	Issuance Date
26 09 23	Lighting Control Devices	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 11 01	115kV Substation with Seconday Switchgear	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 11 16 11	Secondary Unit Substations with Switchgear Secondary	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 22 13	Low-Voltage Distribution Transformers	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 24 13	Switchboards	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 24 16	Panelboards	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 25 00	Enclosed Bus Assemblies	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 27 13	Electricity Metering	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 27 26	Wiring Devices	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 28 13	Fuses	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 28 16	Enclosed Switches and Circuit Breakers	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 29 13 03	Enclosed Controllers	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 29 23	Variable-Frequency Motor Controllers	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 32 13 13	Engine Generators	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 33 53	Static Uninterruptible Power Supply	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 36 00	Transfer Switches	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 41 13	Lightning Protection for Structures	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 51 19	LED Interior Lighting	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 52 13	Emergency and Exit Lighting	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 56 19	Exterior Lighting	1	Bulletin0020-IFCPermitIssue	12/14/2018
26 58 00	Heat Tracing for HVAc Piping	1	Bulletin0020-IFCPermitIssue	12/14/2018
28 05 37 11	Bi-Directional Amplifiers	1	Bulletin0020-IFCPermitIssue	12/14/2018
28 31 11	Digital, Addressable Fire-Alarm System	1	Bulletin0020-IFCPermitIssue	12/14/2018
31 10 00	Site Clearing	0	IFC Specs	4/23/2018
31 20 00	Earth Moving	0	IFC Specs	4/23/2018
31 23 01	Excavation Backfill and Compaction Building Areas	0	IFC Specs	4/23/2018
31 23 16	Excavation	0	IFC Specs	4/23/2018
31 23 19	Dewatering	0	IFC Specs	4/23/2018
31 23 23	Soil Compaction	0	IFC Specs	4/23/2018
31 25 00	Erosion and Sedimentation Control	0	IFC Specs	4/23/2018
31 50 00	Evacuation Support and Protection	0	IFC Specs	4/23/2018
32 12 16	Asphalt Paving	0	IFC Specs	4/23/2018
32 13 13	Concrete Paving	0	IFC Specs	4/23/2018
32 17 23	Pavement Markings	0	IFC Specs	4/23/2018
32 31 13	Chain Link Fences and Gates	0	IFC Specs	4/23/2018
32 32 23	Segmental Retaining Walls	0	IFC Specs	4/23/2018
32 92 00	Turf and Grasses	0	IFC Specs	4/23/2018
33 05 00	Common Work Results for Utilities	0	IFC Specs	4/23/2018
33 41 00	Storm Utility Drainage Piping	0	IFC Specs	4/23/2018
33 46 00	Subdrainage	0	IFC Specs	4/23/2018
33 93 00	Storm-Sanitary Manholes	0	IFC Specs	4/23/2018
40 05 13 74	PVC and CPVC Piping	0	Issue for Bid	10/12/2018
40 05 13 77	PP Piping	A	BOD Issue	2/8/2018
40 53 10	Piping Fabrication, Installation, and Testing	0	Issue for Bid	1/11/2018
40 53 10.01_dat	Process Piping Data Sheet	1	Issue for Bid	10/12/2018
40 53 10.02_dat	Process Valve Data Sheet	1	Issue for Bid	10/12/2018
40 53 10.11	Copper Tubing	0	Pricing Issue	8/31/2018
40 53 10.20	Stainless Steel Piping	0	PQ007-9&11	9/7/2018
40 53 10.21	Stainless Steel Tubing	1	PQ007-9&11	9/7/2018
40 53 10.30	Carbon Steel Pipe	0	Pricing Issue	8/31/2018
40 53 10.77	Polypropylene Pipe	B	Pricing Issue	8/31/2018
40 61 13	Process Control Syste, (PCS) Specification	B	A101 Bid Package Addendum	10/24/2018
40 90 00_01	Process Instrument List	B	A101 Bid Package Addendum	10/24/2018
40 90 00_02	Process Control System Input/Output List	B	A101 Bid Package Documents	10/4/2018
40 90 00_03	Environment Monitoring System Input.Output List	B	A101 Bid Package Addendum	10/24/2018
40 90 10	Instrumentation & Control Components Furnished with Equipment	A	PQ007-9&11	9/7/2018
40 90 11.01	Pressure Indicator Transmitter (Sanitary) Data Sheet	A	A101 Bid Package Documents	10/4/2018
40 90 11.02	Pressure Indicator Transmitter (Standard) Data Sheet	A	A101 Bid Package Documents	10/4/2018
40 90 11.03	Differential Pressure indicator Transmitter Data Sheet	A	A101 Bid Package Documents	10/4/2018
40 90 15.07_OFCA	Sequence of Operation, Oil-free Compressed Air	0	PQ007-9&11	9/7/2018
40 90 15.08_PW1	Sequence of Operation, Process Waste 1	A	PQ0013-0018	9/20/2018
40 90 15.09_PW2	Sequence of Operation, Process Waste 2	A	PQ0013-0018	9/20/2018
40 90 20.01	Temperature Transmitter with RTD (Standard Specification)	A	A101 Bid Package Documents	10/4/2018
40 90 20.02	Temperature Transmitter with RTD (Sanitary Specification)	A	A101 Bid Package Documents	10/4/2018
40 90 20.04	Environment Monitoring System (EMS) Specification	B	A101 Bid Package Addendum	10/24/2018
40 90 30.01	Level Indicator Transmitter (D/P Type) Data Sheet	A	A101 Bid Package Documents	10/4/2018
40 90 31.01	Guided Wave Radar Level Indicator Transmitter Data Sheet	A	A101 Bid Package Documents	10/4/2018
40 90 50_01	Weight Transmitter with Load Cells Specification	A	Issue for Bid	10/12/2018
40 90 50_02	Weight scale with Transmitter Specifications (Floor Scale)	A	Issue for Bid	10/12/2018
40 90 50_03	Weight Scale Transmitter Specifications (Bench Scale)	A	Issue for Bid	10/12/2018
42 10 10	Heat Exchangers	0	Pricing Issue	8/31/2018
42 10 10.01 _dat	Heat Exchanger Data Sheet	0	Pricing Issue	8/31/2018
43 12 10	Clean Dry Air System	A	PQ007-9&11	9/7/2018
43 12 10 01 _dat	Clean Dry Air System Data Sheets	A	PQ007-9&11	9/7/2018
43 12 10 01_SIT	Clean Dry Air System Submittal, Inspection and Testing (SIT) Form	A	PQ007-9&11	9/7/2018

1/30/2019

CONFIDENTIAL


	Athenex GMP Specificatio	Exhibit 2 (p. 5 of 5)

Spec No.	Name	Rev	Set Name	Issuance Date
43 21 00	Process Pumps	0	Issue for Bid	10/12/2018
43 21 00.01_dat	Centrifugal Pump Data Sheets	0	Pricing Issue	8/31/2018
43 21 00.06_dat	AODD Pump Data Sheets	0	Pricing Issue	8/31/2018
43 21 00.07_dat	Waste Transfer Unit Data Sheets	0	PQ0013-0018	9/20/2018
43 21 00.07_sit	Waste Transfer Unit Submittal, Inspection, and Testing (SIT) Form	0	PQ0013-0018	9/20/2018
43 41 16	Plastic Tanks	0	PQ0013-0018	9/20/2018
43 41 16.01 _dat	Plastic Tanks Data Sheet	0	Process Spec Review II- 1 of 2	8/1/2018
45 53 01 01	General Requirements for Biopharm Equipment	0	PQ0013-0018	9/20/2018
45 53 01 10	Submittals, Inspections, and Testing Requirements	0	PQ0013-0018	9/20/2018
45 53 12 01	Biopharm Centrifugal Pump	0	PQ0013-0018	9/20/2018
45 53 12 03_dat	Peristaltic Pump Data Sheet	A	Pricing Issue	8/31/2018
45 53 12 03_SIT	Peristaltic Pump Submittals, Inspection, and Testing (SIT) Form	A	Pricing Issue	8/31/2018
45 53 12.03	Peristaltic Pump	A	Pricing Issue	8/31/2018
45 53 15 01	Biopharm Vessels	0	PQ0013-0018	9/20/2018
45 53 15 01._SIT	Biopharm Vessels Submittals, Inspection, and Testing (SIT) Form	A	PQ007-9&11	9/7/2018
45 53 15 01.dat	Biopharm Vessels Data Sheet	1	PQ007-9&11	9/7/2018
45 53 17 11	Biopharm Magnetic Drive Mixer	A	PQ007-9&11	9/7/2018
45 53 17 11_dat	Biopharm Magnetic Drive Mixer Datasheet	A	PQ007-9&11	9/7/2018
45 53 19 01_SIT	Transfer Panels Submittals, Inspection, and Testing (SIT) Form	A	PQ007-9&11	9/7/2018
45 53 19 05	Utility Panels	A	PQ007-9&11	9/7/2018
45 53 19 05._SIT	Utility Panels Submittals, Inspection, and Testing (SIT) Form	A	PQ007-9&11	9/7/2018
45 53 19 05.dat	Utility Panels Data Sheet	1	PQ007-9&11	9/7/2018
45 53 19.01	Transfer Panels	A	PQ007-9&11	9/7/2018
45 53 19.01.dat	Transfer Panels Data Sheet	A	PQ007-9&11	9/7/2018
45 53 19.21	Mix-Proof Valve Manifold	0	PQ0013-0018	9/20/2018
45 53 19.21_dat	Mix-Proof Valve Manifold Data Sheet	0	PQ0013-0018	9/20/2018
45 53 19.21_SIT	Mix-Proof Valve Manifold Submittals, Inspection, and Testing (SIT) Form	0	PQ0013-0018	9/20/2018
45 53 21 01	Biopharm Shell and Tube Heat Exchangers	0	PQ0013-0018	9/20/2018
45 53 21 01.dat	Biopharm Shell and Tube Heat Exchangers Data Sheet	A	Process Spec Review II- 1 of 2	8/1/2018
45 53 21 01_SIT	Biopharm Shell and Tube Heat Exchangers Submittals, Inspection, and Testing (SIT) For	A	Process Spec Review II- 1 of 2	8/1/2018
45 53 21 51	Temperature Control Unit Skid Assembly	A	PQ007-9&11	9/7/2018
45 53 21 51_SIT	Temperature Control Unit Skid Assembly Submittals, Inspection, and Testing (SIT) Form	A	PQ007-9&11	9/7/2018
45 53 21.16	Biopharm Point of Use Heat Exchanger	0	Pricing Issue	8/31/2018
45 53 21.16_dat	Biopharm Point of Use Heat Exchanger Data Sheet	0	Pricing Issue	8/31/2018
45 53 21.16_SIT	Biopharm Point of Use Heat Exchanger Submittals, Inspection, and Testing (SIT) Form	0	Pricing Issue	8/31/2018
45 53 21.51.01_dat	Temperature Control Unit Skid Assembly Data Sheet	0	PQ007-9&11	9/7/2018
45 53 25 02	Hygenic Cartridge Filters	1	PQ0013-0018	9/20/2018
45 53 25 02.dat	Hygenic Cartridge Filters Data Sheet	A	Pricing Issue	8/31/2018
45 53 25 02_SIT	Hygenic Cartridge Filters Data Sheet Submittals, Inspection, and Testing (SIT) Form	A	Pricing Issue	8/31/2018
45 53 54 11	GMP Parts Washer / Dryer	0	PQ001-PQ003	8/10/2018
45 53 54 11_dat	GMP Parts Washer / Dryer Data Sheet	2	AddendumtoProcessSpecUpdates	11/26/2018
45 53 54 11_SIT	GMP Parts Washer / Dryer Data Sheet Submittals, Inspection, and Testing (SIT) Form	0	PQ001-PQ003	8/10/2018
45 53 54.01	Clean in Place Skid	0	PQ0013-0018	9/20/2018
45 53 54.01_dat	Clean in Place Skid Data Sheet	0	PQ0013-0018	9/20/2018
45 53 54.01_SIT	Clean in Place Skid Submittals, Inspection, and Testing (SIT) Form	0	PQ0013-0018	9/20/2018
45 53 55 01	GMP Autoclave	0	PQ001-PQ003	8/10/2018
45 53 55 01_SIT	GMP Autoclave Data Sheet Submittals, Inspection, and Testing (SIT) Form	0	PQ001-PQ003	8/10/2018
45 53 55.01 dat	GMP Autoclave Data Sheet	0	PQ001-PQ003	8/10/2018
45 53 61 22	WFI Vapor Compression Still	0	PQ005-PQ006	8/20/2018
45 53 61 22.dat	WFI Vapor Compression Still Data Sheet	0	PQ005-PQ006	8/20/2018
45 53 61 22_SIT	WFI Vapor Compression Still Submittals, Inspection, and Testing (SIT) Form	0	PQ005-PQ006	8/20/2018
45 53 61.31	Pure Steam Generator	0	PQ001-PQ003	8/10/2018
45 53 61.31_dat	Pure Steam Generator Data Sheet	0	PQ001-PQ003	8/10/2018
45 53 61.31_SIT	Pure Steam Generator Submittals, Inspection, and Testing (SIT) Form	0	PQ001-PQ003	8/10/2018
45 53 61.41	Compendial Water Storage and Distribution	0	PQ005-PQ006	8/20/2018
45 53 61.41_dat	Compendial Water Storage and Distribution Data Sheet	1	PQ005-PQ006	8/20/2018
45 53 61.41_SIT	Compendial Water Storage and Distribution Submittals, Inspection, and Testing (SIT) Fo	0	PQ005-PQ006	8/20/2018
45 53 65 16	Water Pretreatment Skid	0	PQ005-PQ006	8/20/2018
45 53 65 16.dat	Water Pretreatment Skid Data Sheet	0	PQ005-PQ006	8/20/2018
45 53 65 16_SIT	Water Pretreatment Skid Submittals, Inspection, and Testing (SIT) Form	0	PQ005-PQ006	8/20/2018
45 53 97.60	pH Neutralization System	0	PQ0013-0018	9/20/2018
45 53 97.60_dat	pH Neutralization System_Data Sheet	0	PQ0013-0018	9/20/2018
45 53 97.60_SIT	pH Neutralization System Submittals, Inspection, and Testing (SIT) Form	0	PQ0013-0018	9/20/2018

1/30/2019

CONFIDENTIAL


	Athenex GMP Drawing List	Exhibit 3 (p. 1 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-CS-001	GENERAL PROJECT COVER SHEET - VOLUME 1	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-CS-002	GENERAL PROJECT DRAWING LIST - VOLUME 1	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-CS-003	GENERAL PROJECT COVER SHEET - VOLUME 2	2	Bulletin0021-MechanicalUpdates	Dec 14, 2018 12:00 AM
1-CS-004	GENERAL PROJECT DRAWING LIST - VOLUME 2	2	Bulletin0021-MechanicalUpdates	Dec 14, 2018 12:00 AM
1-CS-005	GENERAL PROJECT COVER SHEET - VOLUME 3	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-CS-006	GENERAL PROJECT DRAWING LIST - VOLUME 3	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-CS-007	GENERAL PROJECT COVER SHEET - VOLUME 4	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-CS-008	GENERAL PROJECT DRAWING LIST - VOLUME 4	2	Bulletin0024-Electrical	Jan 11, 2019 12:00 AM
1-CS-010	GENERAL PROJECT SITE AND BUILDING LOCATION PLANS	2	Bulletin0024-Electrical	Jan 11, 2019 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 2 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-G-010	GENERAL PHASING DIAGRAM - FIRST FLOOR	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-020	GENERAL PHASING DIAGRAM - SECOND FLOOR	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-100	GENERAL BUILDING CODE ANALYSIS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-110	GENERAL LIFE SAFETY AND BUILDING CODE COMPLIANCE PLANS - FIRST	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-115	GENERAL LIFE SAFETY AND BUILDING CODE COMPLIANCE PLANS -	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-120	GENERAL LIFE SAFETY AND BUILDING CODE COMPLIANCE PLANS - SECOND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-130	GENERAL TRAVEL DISTANCE DIAGRAM - FIRST FLOOR NORTH	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-131	GENERAL TRAVEL DISTANCE DIAGRAM - FIRST FLOOR SOUTH	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-132	GENERAL TRAVEL DISTANCE DIAGRAM - SECOND FLOOR NORTH	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-133	GENERAL TRAVEL DISTANCE DIAGRAM - SECOND FLOOR SOUTH	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-310	GENERAL SECOND FLOOR FRAMING PLAN - FIREPROOFING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-G-320	GENERAL ROOF FRAMING PLAN - FIREPROOFING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 3 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
C-000	GENERAL NOTES, LEGEND AND SHEET LAYOUT	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-100	EXISTING CONDITIONS DEMOLITION SITE PLAN	-	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-200	OVERALL SITE PLAN	14	Bulletin 0022 - Struct & Civil	Jan 3, 2019 12:00 AM
C-201	PROPOSED SITE PLAN	14	Bulletin 0022 - Struct & Civil	Jan 3, 2019 12:00 AM
C-202	PROPOSED SITE PLAN	14	Bulletin 0022 - Struct & Civil	Jan 3, 2019 12:00 AM
C-203	PROPOSED GRADING PLAN	12	Bulletin 0015 - Civil Update	Nov 1, 2018 12:00 AM
C-204	PROPOSED GRADING PLAN	12	Bulletin 0014 - Civil & Structural	Oct 29, 2018 12:00 AM
C-205	PROPOSED UTILITY PLAN	12	Bulletin 0014 - Civil & Structural	Oct 29, 2018 12:00 AM
C-206	PROPOSED UTILITY PLAN	12	Bulletin 0014 - Civil & Structural	Oct 29, 2018 12:00 AM
C-207	PROPOSED UTILITY PLAN	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-208	PROPOSED SANITARY SEWER SITE PLAN AND PROFILE VIEW	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-209	PROPOSED PERIMETER DRIVEWAY ALIGNMENT	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-210	PROPOSED PERIMETER DRIVEWAY PROFILES	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-211	PROPOSED STORM MANAGEMENT FACILITY PONDS	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-212	PROPOSED LIGHTING PLAN	-	Civil-Addendum Info_R7	Mar 8, 2018 12:00 AM
C-300	GENERAL NOTES, LEGEND AND SHEET LAYOUT	0	Civil-FrozenScope/Town	Jan 19, 2018 12:00 AM
C-301	MISCELLANEOUS DETAILS	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-302	MISCELLANEOUS DETAILS	12	Bulletin 0014 - Civil & Structural	Oct 29, 2018 12:00 AM
C-303	MISCELLANEOUS DETAILS	11	Bulletin 0011	Oct 12, 2018 12:00 AM
C-304	MISCELLANEOUS DETAILS	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-305	MAINTENANCE AND PROTECTION OF TRAFFIC	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
C-306	LANDSCAPE DETAILS	0	Bulletin 0006 - R10	Sep 12, 2018 12:00 AM
Survey	Topographic Survey	J	Civil-Site Plan Submission_R5	Feb 9, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 4 of 21 )

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-S-101	STRUCTURAL GENERAL NOTES	1	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-102	STRUCTURAL GENERAL NOTES CONTINUED	0	Structural Steel Issue	May 23, 2018 12:00 AM
1-S-103	STRUCTURAL SCHEDULE OF SPECIAL INSPECTIONS FOR BUILDING	0	Structural Steel Issue	May 23, 2018 12:00 AM
1-S-104	STRUCTURAL SECOND FLOOR FRAMING PLAN - DESIGN LOADS	1	Structural Steel Issue	May 23, 2018 12:00 AM
1-S-105	STRUCTURAL ROOF PLAN - DESIGN LOADS	1	Structural Steel Issue	May 23, 2018 12:00 AM
1-S-106	STRUCTURAL FRAMING PLAN STEEL AND DECK PAINTING	0	Structural Steel Issue	May 23, 2018 12:00 AM
1-S-210A	STRUCTURAL FOUNDATION PLAN - SECTOR A	9	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-210B	STRUCTURAL FOUNDATION PLAN - SECTOR B	4	Bulletin 0007 - Structural Revisions	Jul 27, 2018 12:00 AM
1-S-210C	STRUCTURAL FOUNDATION PLAN - SECTOR C	5	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-210D	STRUCTURAL FOUNDATION PLAN - SECTOR D	7	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-210E	STRUCTURAL FOUNDATION PLAN - SECTOR E	5	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-210F	STRUCTURAL FOUNDATION PLAN - SECTOR F	3	Bulletin 0007 - Structural Revisions	Jul 27, 2018 12:00 AM
1-S-210G	STRUCTURAL FOUNDATION PLAN - SECTOR G	5	Bulletin 0010 - Structural Updates	Sep 20, 2018 12:00 AM
1-S-210H	STRUCTURAL FOUNDATION PLAN - SECTOR H	7	Bulletin 0010 - Structural Updates	Sep 20, 2018 12:00 AM
1-S-210J	STRUCTURAL FOUNDATION PLAN - SECTOR J	9	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-211	STRUCTURAL FOUNDATION PLAN - EQUIPMENT YARD	1	Bulletin 0016 - Structural Revisions	Nov 9, 2018 12:00 AM
1-S-212	STRUCTURAL FOUNDATION PLAN - TRUCK RAMPS	0	Bulletin 0016 - Structural Revisions	Nov 9, 2018 12:00 AM
1-S-214A	STRUCTURAL FIRST FLOOR KNEE WALL PLAN - SECTOR A	0	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-215	STRUCTURAL INTERSTITIAL FLOOR FRAMING PLAN	2	Bulletin 0008 - Structural Revisions	Aug 15, 2018 12:00 AM
1-S-220A	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR A	6	Bulletin 0023 - Structural Updates Sector A	Jan 09, 2019 12:00AM
1-S-220B	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR B	3	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-220C	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR C	3	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-220D	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR D	5	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-220E	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR E	5	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-220F	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR F	3	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-220G	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR G	1	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-220H	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR H	3	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-220J	STRUCTURAL SECOND FLOOR FRAMING PLAN - SECTOR J	5	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-221	STRUCTURAL PIPE RACK FRAMING PLAN	2	Bulletin 0007 - Structural Revisions	Jul 27, 2018 12:00 AM
1-S-222	STRUCTURAL HUNG PIPE RACK FRAMING PLAN	0	Bulletin 0005 - Foundation	Jun 19, 2018 12:00 AM
1-S-231	STRUCTURAL ROOF FRAMING PLAN - SECTOR A, B, E, F, G	8	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-232	STRUCTURAL ROOF FRAMING PLAN - SECTOR C, D, H, J	5	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-233	STRUCTURAL PARTIAL ROOF FRAMING PLANS	6	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-234	STRUCTURAL LOBBY ROOF FRAMING PLAN AND SECTIONS	4	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-235	STRUCTURAL VESTIBULE ROOF FRAMING PLAN AND SECTIONS	2	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-236	STRUCTURAL VESTIBULE ROOF FRAMING PLAN, SECTIONS AND DETAILS	1	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-237	STRUCTURAL VESTIBULE ROOF FRAMING PLAN, SECTIONS AND DETAILS	2	Bulletin 0023 - Structural Updates Sector A	Jan 09, 2019 12:00AM
1-S-301	STRUCTURAL FOUNDATION SECTIONS AND DETAILS	4	Bulletin 0007 - Structural Revisions	Jul 27, 2018 12:00 AM
1-S-302	STRUCTURAL FOUNDATION SECTIONS AND DETAILS	3	Bulletin 0005 - Foundation	Jun 19, 2018 12:00 AM
1-S-303	STRUCTURAL FOUNDATION SECTIONS AND DETAILS	5	Bulletin 0010 - Structural Updates	Sep 20, 2018 12:00 AM
1-S-304	STRUCTURAL FOUNDATION SECTIONS AND DETAILS	7	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-401	STRUCTURAL CMU WALL PLAN - SECTOR A,B,E,F,G	1	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-402	STRUCTURAL CMU WAL PLAN - SECTOR C,D,H,J	1	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-403	STRUCTURAL MASONRY WALL SECTIONS	1	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-404	STRUCTURAL MASONRY WALL SECTIONS AND DETAILS	0	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-501	STRUCTURAL BRACED FRAME ELEVATIONS	2	Bulletin 0008 - Structural Revisions	Aug 15, 2018 12:00 AM
1-S-502	STRUCTURAL BRACED FRAME ELEVATIONS	2	Bulletin 0012 - Structural Updates	Oct 3, 2018 12:00 AM
1-S-503	STRUCTURAL COLUMN SCHEDULE	1	Bulletin 0005 - Foundation	Jun 19, 2018 12:00 AM
1-S-504	STRUCTURAL BASE PLATE DETAILS AND SCHEDULES	1	Bulletin 0010 - Structural Updates	Sep 20, 2018 12:00 AM
1-S-505	STRUCTURAL FRAMING SECTIONS AND DETAILS	3	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-506	STRUCTURAL EXTERIOR WALL FRAMING ELEVATIONS	1	Bulletin 0013 - Girt Framing at Sector E	Oct 22, 2018 12:00 AM
1-S-507	STRUCTURAL EXTERIOR WALL FRAMING SECTIONS AND DETAILS	0	Bulletin 0007 - Structural Revisions	Jul 27, 2018 12:00 AM
1-S-508	STRUCTURAL EXTERIOR WALL FRAMING SECTIONS AND DETAILS	2	Bulletin 0007 - Structural Revisions	Jul 27, 2018 12:00 AM
1-S-509	STRUCTURAL FRAMING SECTIONS AND DETAILS	4	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-510	STRUCTURAL FRAMING SECTIONS AND DETAILS	2	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-511	STRUCTURAL EXTERIOR WALL FRAMING SECTIONS AND DETAILS	0	Bulletin 0009 - Structural Revisions	Aug 29, 2018 12:00 AM
1-S-512	STRUCTURAL EXTERIOR WALL FRAMING SECTIONS AND DETAILS	3	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-513	STRUCTURAL FRAMING SECTIONS AND DETAILS	2	Bulletin 0018 - Structural Updates	Nov 28, 2018 12:00 AM
1-S-514	STRUCTURAL FRAMING SECTIONS AND DETAILS	2	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-515	STRUCTURAL LOBBY STAIR FRAMING PLAN, SECTIONS AND DETAILS	0	Bulletin 0012 - Structural Updates	Oct 3, 2018 12:00 AM
1-S-516	STRUCTURAL FRAMING SECTIONS AND DETAILS	1	Bulletin 0022 - Struct & Civil Updates	Jan 01, 2019 12:00AM
1-S-517	STRUCTURAL FRAMING SECTIONS AND DETAILS	0	Bulletin 0017 - Structural Update	Nov 13, 2018 12:00 AM
1-S-518	STRUCTURAL FRAMING SECTIONS AND DETAILS	0	Bulletin 0023 - Structural Updates Sector A	Jan 09, 2019 12:00AM


	Athenex GMP Drawing List	Exhibit 3 (p. 5 of 21)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-A-000	ARCHITECTURAL FLOOR PLAN NOTES, LEGENDS, AND ABBREVIATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-100	ARCHITECTURAL SITE PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-210	ARCHITECTURAL FIRST FLOOR PLAN - EDGE OF SLAB	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-211	ARCHITECTURAL FIRST FLOOR PLAN - BUILDING ENVELOPE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-212	ARCHITECTURAL FIRST FLOOR PLAN - BUILDING ENVELOPE - NORTH	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-213	ARCHITECTURAL FIRST FLOOR PLAN - BUILDING ENVELOPE - SOUTH	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214	ARCHITECTURAL FIRST FLOOR PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214 Defer	ARCHITECTURAL FIRST FLOOR PLAN 1-A-214_RJ_Notes_25OCT18	0	Deferred Scope Mark-up	Oct 25, 2018 12:00 AM
1-A-214A	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214B	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR B	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214C	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR C	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214D	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR D	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214E	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR E	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214F	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR F	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214G	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR G	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214H	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-214J	ARCHITECTURAL FIRST FLOOR PLAN - SECTOR J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-215	ARCHITECTURAL INTERSTITIAL LEVEL ONE PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-215F	ARCHITECTURAL INTERSTITIAL LEVEL ONE PLAN - SECTOR F	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-215H	ARCHITECTURAL INTERSTITIAL LEVEL ONE PLAN - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-215J	ARCHITECTURAL INTERSTITIAL LEVEL ONE PLAN - SECTOR J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-220	ARCHITECTURAL SECOND FLOOR PLAN - EDGE OF SLAB	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-221	ARCHITECTURAL SECOND FLOOR PLAN - BUILDING ENVELOPE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-222	ARCHITECTURAL SECOND FLOOR PLAN - BUILDING ENVELOPE - NORTH	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-223	ARCHITECTURAL SECOND FLOOR PLAN - BUILDING ENVELOPE - SOUTH	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224	ARCHITECTURAL SECOND FLOOR PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224 Defer	ARCHITECTURAL FIRST FLOOR PLAN 1-A-224_RJ_Notes_22OCT18	0	Deferred Scope Mark-up	Oct 22, 2018 12:00 AM
1-A-224A	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224B	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR B	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224C	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR C	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224D	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR D	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224E	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR E	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224F	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR F	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224G	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR G	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224H	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-224J	ARCHITECTURAL SECOND FLOOR PLAN - SECTOR J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-225H	ARCHITECTURAL INTERSTITIAL LEVEL TWO PLAN - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-230	ARCHITECTURAL ROOF PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-231	ARCHITECTURAL ROOF PLANS - LOBBY, STAIRS AND ENTRANCE CANOPIES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-301	ARCHITECTURAL EXTERIOR ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-302	ARCHITECTURAL ENLARGED EXTERIOR ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-310	ARCHITECTURAL METAL PANEL TYPE PLAN DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-311	ARCHITECTURAL METAL PANEL TYPE 1 LAYOUT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-311A	ARCHITECTURAL METAL PANEL TYPE 1 LAYOUT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-312	ARCHITECTURAL METAL PANEL TYPE 2 LAYOUT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-313	ARCHITECTURAL METAL PANEL TYPE 3 LAYOUT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-314	ARCHITECTURAL METAL PANEL TYPE 3 LAYOUT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-320	ARCHITECTURAL CURTAIN WALL TYPES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-321	ARCHITECTURAL CURTAIN WALL TYPES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-322	ARCHITECTURAL CURTAIN WALL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-323	ARCHITECTURAL CURTAIN WALL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-324	ARCHITECTURAL CURTAIN WALL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-325	ARCHITECTURAL STOREFRONT TYPES AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-326	ARCHITECTURAL LOUVER TYPES AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-327	ARCHITECTURAL EXTERIOR DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-400	ARCHITECTURAL STAIR PLANS AND SECTIONS - AS1 & BS1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-401	ARCHITECTURAL STAIR PLANS AND SECTION - DS1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-402	ARCHITECTURAL STAIR PLANS AND SECTION - DS2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-403	ARCHITECTURAL STAIR PLANS AND SECTION - ES1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-404	ARCHITECTURAL STAIR PLANS AND SECTION - ES2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-405	ARCHITECTURAL STAIR PLANS AND SECTION - HS1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-406	ARCHITECTURAL STAIR PLANS AND SECTION - JS1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-407	ARCHITECTURAL STAIR PLANS AND SECTION - JS2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-408	ARCHITECTURAL STAIR PLANS AND SECTIONS - GROUND FLOOR	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-409	ARCHITECTURAL STAIR PLANS, SECTIONS AND DETAILS - EXTERIOR STAIRS AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-410	ARCHITECTURAL STAIR AND RAIL DETAILS	0	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-411	ARCHITECTURAL STAIR PLANS AND SECTIONS - INTERSTITIAL LEVEL & SECOND FLOOR	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-412	ARCHITECTURAL STAIR AND RAIL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-420	ARCHITECTURAL ENLARGED LOBBY PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-421	ARCHITECTURAL LOBBY STAIR SECTIONS AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-422	ARCHITECTURAL ENLARGED LOBBY REFLECTIVE CEILING PLAN & DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-430	ARCHITECTURAL PASSENGER ELEVATOR PLANS, SECTIONS AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-431	ARCHITECTURAL FREIGHT ELEVATOR PLANS, SECTIONS AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-432	ARCHITECTURAL ELEVATOR DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-440	ARCHITECTURAL ENLARGED VESTIBULE PLANS, SECTIONS AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-450	ARCHITECTURAL ENLARGED TOILET ROOM PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-451	ARCHITECTURAL ENLARGED TOILET ROOM PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-452	ARCHITECTURAL ENLARGED TOILET ROOM PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-453	ARCHITECTURAL ENLARGED TOILET ROOM PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-454	ARCHITECTURAL ENLARGED TOILET ROOM PLANS, ELEVATIONS AND SCHEDULE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM


	Athenex GMP Drawing List	Exhibit 3 (p. 6 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-A-460	ARCHITECTURAL ENLARGED LOCKER ROOM PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-461	ARCHITECTURAL ENLARGED LOCKER ROOM PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-462	ARCHITECTURAL ENLARGED LOCKER ROOM PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-470	ARCHITECTURAL ENLARGED GOWNING ROOM PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-471	ARCHITECTURAL ENLARGED GOWNING ROOM PLANS, ELEVATION AND SCHEDULE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-480	ARCHITECTURAL ENLARGED DENSITY STORAGE PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-500	ARCHITECTURAL LAB STANDARDS AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-501	ARCHITECTURAL LAB STANDARDS AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-502	ARCHITECTURAL OVERHEAD UTILITY PANELS DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-510	ARCHITECTURAL ENLARGED LAB FLOOR PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-511	ARCHITECTURAL ENLARGED LAB FLOOR PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-512	ARCHITECTURAL ENLARGED LAB FLOOR PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-513	ARCHITECTURAL ENLARGED LAB FLOOR PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-514	ARCHITECTURAL ENLARGED LAB FLOOR PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-515	ARCHITECTURAL ENLARGED LAB, STORAGE FLOOR PLANS AND ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614A	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614B	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR B	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614C	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR C	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614D	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR D	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614E	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR E	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614F	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR F	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614G	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR G	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614H	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-614J	ARCHITECTURAL FIRST FLOOR REFLECTED CEILING PLAN - SECTOR J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624A	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624B	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR B	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624C	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR C	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624D	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR D	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624E	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR E	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624F	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR F	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624G	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR G	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624H	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-624J	ARCHITECTURAL SECOND FLOOR REFLECTED CEILING PLAN - SECTOR J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-710	ARCHITECTURAL PARTITION TYPES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-712	ARCHITECTURAL PARTITION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-713	ARCHITECTURAL PARTITION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-714	ARCHITECTURAL PARTITION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-715	ARCHITECTURAL WALL PROTECTION AND PARTITION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-720	ARCHITECTURAL DOOR SCHEDULE AND DETAILS - BUILDING ENVELOPE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-721	ARCHITECTURAL DOOR SCHEDULE - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-722	ARCHITECTURAL DOOR SCHEDULE - SECTOR B, C, D	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-723	ARCHITECTURAL DOOR SCHEDULE - SECTOR E, F, G	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-724	ARCHITECTURAL DOOR SCHEDULE - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-725	ARCHITECTURAL DOOR SCHEDULE - SECTOR J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-726	ARCHITECTURAL DOOR DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-727	ARCHITECTURAL DOOR DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-728	ARCHITECTURAL INTERIOR STOREFRONT SYSTEM ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-730	ARCHITECTURAL INTERIOR DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-731	ARCHITECTURAL INTERIOR DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-740	ARCHITECTURAL FINISH SCHEDULE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-741	ARCHITECTURAL FINISH SCHEDULE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-742	ARCHITECTURAL FINISH LEGEND AND DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-750	ARCHITECTURAL FIRST FLOOR FINISH PLAN - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-751	ARCHITECTURAL FIRST FLOOR FINISH PLAN - SECTOR D, E, F, J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-752	ARCHITECTURAL SECOND FLOOR FINISH PLAN - SECTOR A, H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-760	ARCHITECTURAL FIRST FLOOR FURNITURE PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-761	ARCHITECTURAL FIRST FLOOR FURNITURE PLAN - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-762	ARCHITECTURAL FIRST FLOOR FURNITURE PLAN - SECTOR D, E, F, G, J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-770	ARCHITECTURAL SECOND FLOOR FURNITURE PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-771	ARCHITECTURAL SECOND FLOOR FURNITURE PLAN - SECTOR A, D, H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-810	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-811	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-812	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-813	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-814	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-815	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-816	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-817	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-818	ARCHITECTURAL WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-820	ARCHITECTURAL WALL SECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-821	ARCHITECTURAL WALL SECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-822	ARCHITECTURAL WALL SECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-823	ARCHITECTURAL WALL SECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-824	ARCHITECTURAL WALL SECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-825	ARCHITECTURAL WALL SECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-827	ARCHITECTURAL WALL SECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-830	ARCHITECTURAL EXTERIOR PLAN DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-831	ARCHITECTURAL EXTERIOR PLAN DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM


	Athenex GMP Drawing List	Exhibit 3 (p. 7 of 20)

Athenex GMP Drawing List

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-A-832	ARCHITECTURAL EXTERIOR PLAN DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-833	ARCHITECTURAL EXTERIOR PLAN DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-834	ARCHITECTURAL EXTERIOR PLAN DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-835	ARCHITECTURAL EXTERIOR PLAN DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-841	ARCHITECTURAL ROOF DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-911	ARCHITECTURAL INTERIOR WALL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-920	ARCHITECTURAL MILLWORK DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-921	ARCHITECTURAL MILLWORK DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-922	ARCHITECTURAL MILLWORK DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-923	ARCHITECTURAL MILLWORK DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-924	ARCHITECTURAL INTERIOR ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-925	ARCHITECTURAL INTERIOR ELEVATIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-A-940	ARCHITECTURAL INTERIOR SIGNAGE DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM


	Athenex GMP Drawing List	Exhibit 3 (p. 8 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-M-001	MECHANICAL COVER SHEET	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011	MECHANICAL FIRST FLOOR PLAN - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011A	MECHANICAL FIRST FLOOR PLAN - SECTOR A - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011B	MECHANICAL FIRST FLOOR PLAN - SECTOR B - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011C	MECHANICAL FIRST FLOOR PLAN - SECTOR C - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011D	MECHANICAL FIRST FLOOR PLAN - SECTOR D - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011E	MECHANICAL FIRST FLOOR PLAN - SECTOR E - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011F	MECHANICAL FIRST FLOOR PLAN - SECTOR F - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011G	MECHANICAL FIRST FLOOR PLAN - SECTOR G - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011H	MECHANICAL FIRST FLOOR PLAN - SECTOR H - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-011J	MECHANICAL FIRST FLOOR PLAN - SECTOR J - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-012	MECHANICAL SECOND FLOOR PLAN - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-012A	MECHANICAL SECOND FLOOR PLAN - SECTOR A - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-012D	MECHANICAL SECOND FLOOR PLAN - SECTOR D - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-012H	MECHANICAL SECOND FLOOR PLAN - SECTOR H - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-012J	MECHANICAL SECOND FLOOR PLAN - SECTOR J - AHU ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021	MECHANICAL FIRST FLOOR PLAN - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021A	MECHANICAL FIRST FLOOR PLAN - SECTOR A - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021C	MECHANICAL FIRST FLOOR PLAN - SECTOR C - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021D	MECHANICAL FIRST FLOOR PLAN - SECTOR D - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021E	MECHANICAL FIRST FLOOR PLAN - SECTOR E - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021F	MECHANICAL FIRST FLOOR PLAN - SECTOR F - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021G	MECHANICAL FIRST FLOOR PLAN - SECTOR G - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021H	MECHANICAL FIRST FLOOR PLAN - SECTOR H - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-021J	MECHANICAL FIRST FLOOR PLAN - SECTOR J - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-022	MECHANICAL SECOND FLOOR PLAN - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-022A	MECHANICAL SECOND FLOOR PLAN - SECTOR A - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-022B	MECHANICAL SECOND FLOOR PLAN - SECTOR B - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-022D	MECHANICAL SECOND FLOOR PLAN - SECTOR D - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-022E	MECHANICAL SECOND FLOOR PLAN - SECTOR E - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-022H	MECHANICAL SECOND FLOOR PLAN - SECTOR H - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-022J	MECHANICAL SECOND FLOOR PLAN - SECTOR J - EXHAUST ZONING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-031A	MECHANICAL FIRST FLOOR PLAN - SECTOR A - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-031B	MECHANICAL FIRST FLOOR PLAN - SECTOR B - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-031C	MECHANICAL FIRST FLOOR PLAN - SECTOR C - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-031D	MECHANICAL FIRST FLOOR PLAN - SECTOR D - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-031F	MECHANICAL FIRST FLOOR PLAN - SECTOR F - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-031G	MECHANICAL FIRST FLOOR PLAN - SECTOR G - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-031H	MECHANICAL FIRST FLOOR PLAN - SECTOR H - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-031J	MECHANICAL FIRST FLOOR PLAN - SECTOR J - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-032D	MECHANICAL SECOND FLOOR PLAN - SECTOR D - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-032H	MECHANICAL SECOND FLOOR PLAN - SECTOR H - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-032J	MECHANICAL SECOND FLOOR PLAN - SECTOR J - PRESSURIZATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210	MECHANICAL FIRST FLOOR PLAN - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210A1	MECHANICAL FIRST FLOOR PLAN - SECTOR A1 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-210A2	MECHANICAL FIRST FLOOR PLAN - SECTOR A2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210A3	MECHANICAL FIRST FLOOR PLAN - SECTOR A3 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-210A4	MECHANICAL FIRST FLOOR PLAN - SECTOR A4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210B1	MECHANICAL FIRST FLOOR PLAN - SECTOR B1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210B2	MECHANICAL FIRST FLOOR PLAN - SECTOR B2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210C1	MECHANICAL FIRST FLOOR PLAN - SECTOR C1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210C2	MECHANICAL FIRST FLOOR PLAN - SECTOR C2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210C4	MECHANICAL FIRST FLOOR PLAN - SECTOR C4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210D1	MECHANICAL FIRST FLOOR PLAN - SECTOR D1 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-210D2	MECHANICAL FIRST FLOOR PLAN - SECTOR D2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210D3	MECHANICAL FIRST FLOOR PLAN - SECTOR D3 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-210D4	MECHANICAL FIRST FLOOR PLAN - SECTOR D4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210D5	MECHANICAL FIRST FLOOR PLAN - SECTOR D5 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-210D6	MECHANICAL FIRST FLOOR PLAN - SECTOR D6 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210E1	MECHANICAL FIRST FLOOR PLAN - SECTOR E1 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-210E2	MECHANICAL FIRST FLOOR PLAN - SECTOR E2 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-210F1	MECHANICAL FIRST FLOOR PLAN - SECTOR F1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210F2	MECHANICAL FIRST FLOOR PLAN - SECTOR F2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210F3	MECHANICAL FIRST FLOOR PLAN - SECTOR F3 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210F4	MECHANICAL FIRST FLOOR PLAN - SECTOR F4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210G1	MECHANICAL FIRST FLOOR PLAN - SECTOR G1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210G2	MECHANICAL FIRST FLOOR PLAN - SECTOR G2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210H1	MECHANICAL FIRST FLOOR PLAN - SECTOR H1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210H2	MECHANICAL FIRST FLOOR PLAN - SECTOR H2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210H3	MECHANICAL FIRST FLOOR PLAN - SECTOR H3 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210H4	MECHANICAL FIRST FLOOR PLAN - SECTOR H4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210J1	MECHANICAL FIRST FLOOR PLAN - SECTOR J1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210J2	MECHANICAL FIRST FLOOR PLAN - SECTOR J2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210J3	MECHANICAL FIRST FLOOR PLAN - SECTOR J3 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-210J4	MECHANICAL FIRST FLOOR PLAN - SECTOR J4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220	MECHANICAL SECOND FLOOR PLAN - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220A1	MECHANICAL SECOND FLOOR PLAN - SECTOR A1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220A2	MECHANICAL SECOND FLOOR PLAN - SECTOR A2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220A3	MECHANICAL SECOND FLOOR PLAN - SECTOR A3 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220B1	MECHANICAL SECOND FLOOR PLAN - SECTOR B1 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220B2	MECHANICAL SECOND FLOOR PLAN - SECTOR B2 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220C1	MECHANICAL SECOND FLOOR PLAN - SECTOR C1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220C2	MECHANICAL SECOND FLOOR PLAN - SECTOR C2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220C3	MECHANICAL SECOND FLOOR PLAN - SECTOR C3 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220C4	MECHANICAL SECOND FLOOR PLAN - SECTOR C4 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220D2	MECHANICAL SECOND FLOOR PLAN - SECTOR D2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 9 of 20)

1-M-220D3	MECHANICAL SECOND FLOOR PLAN - SECTOR D3 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220D4	MECHANICAL SECOND FLOOR PLAN - SECTOR D4 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220D5	MECHANICAL SECOND FLOOR PLAN - SECTOR D5 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220D6	MECHANICAL SECOND FLOOR PLAN - SECTOR D6 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220E1	MECHANICAL SECOND FLOOR PLAN - SECTOR E1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220E2	MECHANICAL SECOND FLOOR PLAN - SECTOR E2 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220F1	MECHANICAL SECOND FLOOR PLAN - SECTOR F1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220F2	MECHANICAL SECOND FLOOR PLAN - SECTOR F2 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220F3	MECHANICAL SECOND FLOOR PLAN - SECTOR F3 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220F4	MECHANICAL SECOND FLOOR PLAN - SECTOR F4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220G1	MECHANICAL SECOND FLOOR PLAN - SECTOR G1 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220G2	MECHANICAL SECOND FLOOR PLAN - SECTOR G2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220H1	MECHANICAL SECOND FLOOR PLAN - SECTOR H1 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220H2	MECHANICAL SECOND FLOOR PLAN - SECTOR H2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220H3	MECHANICAL SECOND FLOOR PLAN - SECTOR H3 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220H4	MECHANICAL SECOND FLOOR PLAN - SECTOR H4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220J1	MECHANICAL SECOND FLOOR PLAN - SECTOR J1 - DUCTWORK	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-220J2	MECHANICAL SECOND FLOOR PLAN - SECTOR J2 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220J3	MECHANICAL SECOND FLOOR PLAN - SECTOR J3 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-220J4	MECHANICAL SECOND FLOOR PLAN - SECTOR J4 - DUCTWORK	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-230	MECHANICAL ROOF PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310	MECHANICAL FIRST FLOOR PLAN - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310A1	MECHANICAL FIRST FLOOR PLAN - SECTOR A1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310A2	MECHANICAL FIRST FLOOR PLAN - SECTOR A2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310A3	MECHANICAL FIRST FLOOR PLAN - SECTOR A3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310A4	MECHANICAL FIRST FLOOR PLAN - SECTOR A4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310B1	MECHANICAL FIRST FLOOR PLAN - SECTOR B1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310B2	MECHANICAL FIRST FLOOR PLAN - SECTOR B2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310C1	MECHANICAL FIRST FLOOR PLAN - SECTOR C1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310C2	MECHANICAL FIRST FLOOR PLAN - SECTOR C2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310C3	MECHANICAL FIRST FLOOR PLAN - SECTOR C3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310C4	MECHANICAL FIRST FLOOR PLAN - SECTOR C4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310D1	MECHANICAL FIRST FLOOR PLAN - SECTOR D1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310D2	MECHANICAL FIRST FLOOR PLAN - SECTOR D2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310D3	MECHANICAL FIRST FLOOR PLAN - SECTOR D3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310D4	MECHANICAL FIRST FLOOR PLAN - SECTOR D4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310D5	MECHANICAL FIRST FLOOR PLAN - SECTOR D5 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310D6	MECHANICAL FIRST FLOOR PLAN - SECTOR D6 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310E1	MECHANICAL FIRST FLOOR PLAN - SECTOR E1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310E2	MECHANICAL FIRST FLOOR PLAN - SECTOR E2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310F1	MECHANICAL FIRST FLOOR PLAN - SECTOR F1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310F2	MECHANICAL FIRST FLOOR PLAN - SECTOR F2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310F3	MECHANICAL FIRST FLOOR PLAN - SECTOR F3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310F4	MECHANICAL FIRST FLOOR PLAN - SECTOR F4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310G1	MECHANICAL FIRST FLOOR PLAN - SECTOR G1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310G2	MECHANICAL FIRST FLOOR PLAN - SECTOR G2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310H1	MECHANICAL FIRST FLOOR PLAN - SECTOR H1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310H2	MECHANICAL FIRST FLOOR PLAN - SECTOR H2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310H3	MECHANICAL FIRST FLOOR PLAN - SECTOR H3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310H4	MECHANICAL FIRST FLOOR PLAN - SECTOR H4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310J1	MECHANICAL FIRST FLOOR PLAN - SECTOR J1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310J2	MECHANICAL FIRST FLOOR PLAN - SECTOR J2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310J3	MECHANICAL FIRST FLOOR PLAN - SECTOR J3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-310J4	MECHANICAL FIRST FLOOR PLAN - SECTOR J4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320	MECHANICAL SECOND FLOOR PLAN - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320A1	MECHANICAL SECOND FLOOR PLAN - SECTOR A1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320A2	MECHANICAL SECOND FLOOR PLAN - SECTOR A2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320A3	MECHANICAL SECOND FLOOR PLAN - SECTOR A3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320B1	MECHANICAL SECOND FLOOR PLAN - SECTOR B1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320B2	MECHANICAL SECOND FLOOR PLAN - SECTOR B2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320C1	MECHANICAL SECOND FLOOR PLAN - SECTOR C1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320C2	MECHANICAL SECOND FLOOR PLAN - SECTOR C2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320C3	MECHANICAL SECOND FLOOR PLAN - SECTOR C3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320C4	MECHANICAL SECOND FLOOR PLAN - SECTOR C4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320D3	MECHANICAL SECOND FLOOR PLAN - SECTOR D3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320D4	MECHANICAL SECOND FLOOR PLAN - SECTOR D4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320D5	MECHANICAL SECOND FLOOR PLAN - SECTOR D5 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320D6	MECHANICAL SECOND FLOOR PLAN - SECTOR D6 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320E1	MECHANICAL SECOND FLOOR PLAN - SECTOR E1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320E2	MECHANICAL SECOND FLOOR PLAN - SECTOR E2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320F1	MECHANICAL SECOND FLOOR PLAN - SECTOR F1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320F2	MECHANICAL SECOND FLOOR PLAN - SECTOR F2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320F3	MECHANICAL SECOND FLOOR PLAN - SECTOR F3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320F4	MECHANICAL SECOND FLOOR PLAN - SECTOR F4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320G1	MECHANICAL SECOND FLOOR PLAN - SECTOR G1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320G2	MECHANICAL SECOND FLOOR PLAN - SECTOR G2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320H1	MECHANICAL SECOND FLOOR PLAN - SECTOR H1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320H2	MECHANICAL SECOND FLOOR PLAN - SECTOR H2 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320H3	MECHANICAL SECOND FLOOR PLAN - SECTOR H3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320H4	MECHANICAL SECOND FLOOR PLAN - SECTOR H4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320J1	MECHANICAL SECOND FLOOR PLAN - SECTOR J1 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320J3	MECHANICAL SECOND FLOOR PLAN - SECTOR J3 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-320J4	MECHANICAL SECOND FLOOR PLAN - SECTOR J4 - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-401	MECHANICAL ENLARGED FIRST FLOOR PLAN - EQUIPMENT YARD	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-402	MECHANICAL ENLARGED SECOND FLOOR PLAN - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-403	MECHANICAL ENLARGED ROOF PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-411	MECHANICAL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-412	MECHANICAL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 10 of 20)

1-M-413	MECHANICAL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-414	MECHANICAL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-415	MECHANICAL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-416	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-417	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-418	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-419	MECHANICAL SECTIONS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-501	MECHANICAL AIR FLOW DIAGRAM - AHU 100, 110, 120, 130, 140, 150	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-502	MECHANICAL AIR FLOW DIAGRAM - EF-100, 110, 120, 130, 300, 310, 200, 210, 220,	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-520	MECHANICAL AIR FLOW DIAGRAM - AHU 230	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-521	MECHANICAL AIR FLOW DIAGRAM - AHU 231	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-522	MECHANICAL AIR FLOW DIAGRAM - AHU 233	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-523	MECHANICAL AIR FLOW DIAGRAM - AHU 241	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-524	MECHANICAL AIR FLOW DIAGRAM - AHU 243, 245, 247, 249	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-525	MECHANICAL AIR FLOW DIAGRAM - AHU 250	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-526	MECHANICAL AIR FLOW DIAGRAM - AHU 251	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-527	MECHANICAL AIR FLOW DIAGRAM - AHU 260	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-528	MECHANICAL AIR FLOW DIAGRAM - AHU 262, 264	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-530	MECHANICAL AIR FLOW DIAGRAM - AHU 300	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-531	MECHANICAL AIR FLOW DIAGRAM - AHU 300 (CONTINUED), 302	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-532	MECHANICAL AIR FLOW DIAGRAM - AHU 301	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-533	MECHANICAL AIR FLOW DIAGRAM - AHU 301 (CONTINUED)	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-540	MECHANICAL AIR FLOW DIAGRAM - AHU 401, 402, 403, 420	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-541	MECHANICAL AIR FLOW DIAGRAM - IQC LAB	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-542	MECHANICAL AIR FLOW DIAGRAM - AHU 430, 500	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-550	MECHANICAL AIR FLOW DIAGRAM - AHU 510	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-551	MECHANICAL AIR FLOW DIAGRAM - AHU 520	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-552	MECHANICAL AIR FLOW DIAGRAM - AHU 541	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-553	MECHANICAL AIR FLOW DIAGRAM - AHU 540	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-554	MECHANICAL AIR FLOW DIAGRAM - AHU 540 (CONTINUED)	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-555	MECHANICAL AIR FLOW DIAGRAM - AHU 550, 551	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-556	MECHANICAL AIR FLOW DIAGRAM - AHU 570, 571, 580	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-557	MECHANICAL AIR FLOW DIAGRAM - MECHANICAL AND ELECTRICAL ROOMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-558	MECHANICAL AIR FLOW DIAGRAM - FAN COIL UNITS AND MISCELLANEOUS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-601	MECHANICAL PIPING DIAGRAM - CONDENSER WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-602	MECHANICAL PIPING DIAGRAM - PRIMARY CHILLED WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-611	MECHANICAL PIPING DIAGRAM - PRIMARY CHILLED WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-621	MECHANICAL PIPING DIAGRAM - SECONDARY CHILLED WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-631	MECHANICAL PIPING DIAGRAM - PROCESS CHILLED WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-641	MECHANICAL PIPING DIAGRAM - PROCESS CONDENSER WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-651	MECHANICAL PIPING DIAGRAM - BOILER 401 - STEAM GENERATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-652	MECHANICAL PIPING DIAGRAM - BOILER 401 - FUEL SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-653	MECHANICAL PIPING DIAGRAM - BOILER 402 - STEAM GENERATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-654	MECHANICAL PIPING DIAGRAM - BOILER 402 - FUEL SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-655	MECHANICAL PIPING DIAGRAM - BOILER 403 - STEAM GENERATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-656	MECHANICAL PIPING DIAGRAM - BOILER 403 - FUEL SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-657	MECHANICAL PIPING DIAGRAM - SURGE TANK ST-401	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-658	MECHANICAL PIPING DIAGRAM - DEAERATOR DA-401	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-659	MECHANICAL PIPING DIAGRAM - BOILER BLOWDOWN SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-661	MECHANICAL PIPING DIAGRAM - STEAM DISTRIBUTION	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-662	MECHANICAL PIPING DIAGRAM - STEAM DISTRIBUTION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-663	MECHANICAL PIPING DIAGRAM - STEAM DISTRIBUTION	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-664	MECHANICAL PIPING DIAGRAM - STEAM DISTRIBUTION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-671	MECHANICAL PIPING DIAGRAM - HEATING HOT WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-681	MECHANICAL PIPING DIAGRAM - GLYCOL HEATING HOT WATER SYSTEM -	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-682	MECHANICAL PIPING DIAGRAM - GLYCOL HEATING HOT WATER SYSTEM -	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-691	MECHANICAL HUMIDIFICATION STEAM SYSTEM - DISTRIBUTION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-701	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-702	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-703	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-704	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-705	MECHANICAL DETAILS	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-706	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-707	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-708	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-709	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-720	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-721	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-722	MECHANICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-801	MECHANICAL SCHEDULES	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-802	MECHANICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-803	MECHANICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-804	MECHANICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-805	MECHANICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-810	MECHANICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-811	MECHANICAL SCHEDULES	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-812	MECHANICAL SCHEDULES	2	Bulletin 0021 - Mechanical Updates	Dec 18, 2018 12:00 AM
1-M-901	MECHANICAL I&C COVER SHEET	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-902	MECHANICAL I&C DIAGRAM - BMS NETWORK RISER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-910	MECHANICAL I&C DIAGRAM - TYPICAL CENTRAL AIR SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-920	MECHANICAL I&C DIAGRAM - TYPICAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-921	MECHANICAL I&C DIAGRAM - TYPICAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-922	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-923	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-924	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-925	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-926	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-927	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 11 of 20)

1-M-928	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS GMP AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-930	MECHANICAL I&C DIAGRAM - TYPICA AIR SYSTEMS OFFICE AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-931	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS OFFICE AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-932	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS OFFICE AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-933	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS OFFICE AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-940	MECHANICAL I&C DIAGRAM - TYPICAL AIR SYSTEMS WAREHOUSE AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-941	MECHANICAL I&C DIAGRAM - TYPICAL SUPPORT AIR SYSTEM AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-942	MECHANICAL I&C DIAGRAM - TYPICAL SUPPORT AIR SYSTEM AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-943	MECHANICAL I&C DIAGRAM - TYPICAL SUPPORT AIR SYSTEM AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-950	MECHANICAL I&C DIAGRAM - AIR SYSTEMS SPINE CORRIDOR AREA	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-951	MECHANICAL I&C DIAGRAM - AIR SYSTEMS LAB SUPPORT AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-952	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL CHEMISTRY LAB AIR SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-953	MECHANICAL I&C DIAGRAM - CHEMISTRY LAB AIR SYSTEMS SUPPORT AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-954	MECHANICAL I&C DIAGRAM - TYPICAL AIR SYSTEMS SUPPORT AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-955	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS SUPPORT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-956	MECHANICAL I&C DIAGRAM - TYPICAL AIR SYSTEMS SUPPORT AREAS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-957	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS SUPPORT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-958	MECHANICAL I&C DIAGRAM - TYPICAL TERMINAL AIR SYSTEMS SUPPORT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-959	MECHANICAL I&C DIAGRAM - CHILLER ROOM TERMINAL AIR SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-960	MECHANICAL I&C DIAGRAM - FAN COIL UNIT CONTROLS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-961	MECHANICAL I&C DIAGRAM - MISCELLANEOUS MONITORING AND CONTROLS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-970	MECHANICAL I&C DIAGRAM - CONDENSER WATER SYSTEM - GENERATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-971	MECHANICAL I&C DIAGRAM - CONDENSER WATER SYSTEM - DISTRIBUTION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-972	MECHANICAL I&C DIAGRAM - PRIMARY CHILLED WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-973	MECHANICAL I&C DIAGRAM - PROCESS CHILLED WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-974	MECHANICAL I&C DIAGRAM - SECONDARY CHILLED WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-975	MECHANICAL I&C DIAGRAM - PROCESS CONDENSER WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-980	MECHANICAL I&C DIAGRAM - BOILER PLANT CONTROLS NETWORK INTERFACE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-981	MECHANICAL I&C DIAGRAM - BOILER 401, 402, & 403 - STEAM GENERATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-982	MECHANICAL I&C DIAGRAM - BOILER 401, 402, & 403 - FUEL SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-983	MECHANICAL I&C DIAGRAM - SURGE TANK ST-401	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-984	MECHANICAL I&C DIAGRAM - DEAERATOR DA-401	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-985	MECHANICAL I&C DIAGRAM - HEATING HOT WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-M-986	MECHANICAL I&C DIAGRAM - GLYCOL HEATING HOT WATER SYSTEM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 12 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-E-000	ELECTRICAL COVER SHEET	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-001	ELECTRICAL SITE PLAN - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-002	ELECTRICAL SITE PLAN - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-002A	ELECTRICAL SITE PLAN - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-003	ELECTRICAL SITE PLAN - GROUNDING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-004	ELECTRICAL SITE PLAN - 115KV SUBSTATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-005	ELECTRICAL SITE PLAN - 115KV SUBSTATION - GROUNDING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210A	ELECTRICAL FIRST FLOOR PLAN - SECTOR A - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210B	ELECTRICAL FIRST FLOOR PLAN - SECTOR B - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210C	ELECTRICAL FIRST FLOOR PLAN - SECTOR C - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210D	ELECTRICAL FIRST FLOOR PLAN - SECTOR D - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210E	ELECTRICAL FIRST FLOOR PLAN - SECTOR E - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210F	ELECTRICAL FIRST FLOOR PLAN - SECTOR F - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210G	ELECTRICAL FIRST FLOOR PLAN - SECTOR G - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210H	ELECTRICAL FIRST FLOOR PLAN - SECTOR H - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-210J	ELECTRICAL FIRST FLOOR PLAN - SECTOR J - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-215F	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR F - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-215H	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR H - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-215J	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR J - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220A	ELECTRICAL SECOND FLOOR PLAN - SECTOR A - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220B	ELECTRICAL SECOND FLOOR PLAN - SECTOR B - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220C	ELECTRICAL SECOND FLOOR PLAN - SECTOR C - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220D	ELECTRICAL SECOND FLOOR PLAN - SECTOR D - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220E	ELECTRICAL SECOND FLOOR PLAN - SECTOR E - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220F	ELECTRICAL SECOND FLOOR PLAN - SECTOR F - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220G	ELECTRICAL SECOND FLOOR PLAN - SECTOR G - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220H	ELECTRICAL SECOND FLOOR PLAN - SECTOR H - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-220J	ELECTRICAL SECOND FLOOR PLAN - SECTOR J - LIGHTING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310A	ELECTRICAL FIRST FLOOR PLAN - SECTOR A - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310B	ELECTRICAL FIRST FLOOR PLAN - SECTOR B - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310C	ELECTRICAL FIRST FLOOR PLAN - SECTOR C - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310D	ELECTRICAL FIRST FLOOR PLAN - SECTOR D - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310E	ELECTRICAL FIRST FLOOR PLAN - SECTOR E - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310F	ELECTRICAL FIRST FLOOR PLAN - SECTOR F - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310G	ELECTRICAL FIRST FLOOR PLAN - SECTOR G - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310H	ELECTRICAL FIRST FLOOR PLAN - SECTOR H - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-310J	ELECTRICAL FIRST FLOOR PLAN - SECTOR J - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-315F	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR F - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-315H	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR H - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-315J	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR J - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320A	ELECTRICAL SECOND FLOOR PLAN - SECTOR A - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320B	ELECTRICAL SECOND FLOOR PLAN - SECTOR B - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320C	ELECTRICAL SECOND FLOOR PLAN - SECTOR C - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320D	ELECTRICAL SECOND FLOOR PLAN - SECTOR D - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320E	ELECTRICAL SECOND FLOOR PLAN - SECTOR E - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320F	ELECTRICAL SECOND FLOOR PLAN - SECTOR F - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320G	ELECTRICAL SECOND FLOOR PLAN - SECTOR G - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320H	ELECTRICAL SECOND FLOOR PLAN - SECTOR H - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-320J	ELECTRICAL SECOND FLOOR PLAN - SECTOR J - POWER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-330	ELECTRICAL ROOF PLAN - NORTH - POWER & SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-331	ELECTRICAL ROOF PLAN - SOUTH - POWER & SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410A	ELECTRICAL FIRST FLOOR PLAN - SECTOR A - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410B	ELECTRICAL FIRST FLOOR PLAN - SECTOR B - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410C	ELECTRICAL FIRST FLOOR PLAN - SECTOR C - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410D	ELECTRICAL FIRST FLOOR PLAN - SECTOR D - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410E	ELECTRICAL FIRST FLOOR PLAN - SECTOR E - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410F	ELECTRICAL FIRST FLOOR PLAN - SECTOR F - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410G	ELECTRICAL FIRST FLOOR PLAN - SECTOR G - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410H	ELECTRICAL FIRST FLOOR PLAN - SECTOR H - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-410J	ELECTRICAL FIRST FLOOR PLAN - SECTOR J - FIRE ALARM AND SYSTEMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-411	ELECTRICAL FIRST FLOOR PLAN - NORTH - RACEWAY	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-412	ELECTRICAL FIRST FLOOR PLAN - SOUTH - RACEWAY	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-415F	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR F - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-415H	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR H - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-415J	ELECTRICAL INTERSTITIAL FLOOR PLAN - SECTOR J - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-420A	ELECTRICAL SECOND FLOOR PLAN - SECTOR A - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-420B	ELECTRICAL SECOND FLOOR PLAN - SECTOR B - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-420C	ELECTRICAL SECOND FLOOR PLAN - SECTOR C - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-420D	ELECTRICAL SECOND FLOOR PLAN - SECTOR D - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-420E	ELECTRICAL SECOND FLOOR PLAN - SECTOR E - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-420F	ELECTRICAL SECOND FLOOR PLAN - SECTOR F - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-420G	ELECTRICAL SECOND FLOOR PLAN - SECTOR G - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-420H	ELECTRICAL SECOND FLOOR PLAN - SECTOR H - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 13 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-E-420J	ELECTRICAL SECOND FLOOR PLAN - SECTOR J - FIRE ALARM AND	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-421	ELECTRICAL SECOND FLOOR PLAN - NORTH - RACEWAY	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-422	ELECTRICAL SECOND FLOOR PLAN - SOUTH - RACEWAY	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-501	ELECTRICAL SINGLE LINE DIAGRAM - UTILITY SUBSTATION	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-502	ELECTRICAL SINGLE LINE DIAGRAM - RELAY SCHEME	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-503	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR D - MECH CUP	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-504	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR D - MECH CUP	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-505	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR D - PROCESS CUP	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-506	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR D - PROCESS CUP	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-507	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR D - PROCESS CUP	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-508	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR D - PROCESS CUP	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-509	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR J - PROCESS 1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-510	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR J - PROCESS 1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-511	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR J - PROCESS 1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-512	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR J - PROCESS 1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-513	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR E - ADMIN PROCESS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-514	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR E - ADMIN PROCESS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-515	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR E - ADMIN PROCESS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-516	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR B - PROCESS 2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-517	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR B - PROCESS 2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-518	ELECTRICAL SINGLE LINE DIAGRAM - SECTOR B - PROCESS 2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-600	ELECTRICAL ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-601	ELECTRICAL ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-602	ELECTRICAL ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-603	ELECTRICAL ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-604	ELECTRICAL ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-605	ELECTRICAL ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-606	ELECTRICAL ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-607	ELECTRICAL ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-701	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-701A	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-702	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-703	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-704	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-705	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-706	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-707	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-708	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-709	ELECTRICAL DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-710	ELECTRICAL HAZARDOUS BOUNDARY DIAGRAM	0	Bulletin0024-Electrical	Jan 11, 2019 12:00 AM
1-E-801	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-802	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-803	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-804	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-805	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-806	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-807	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-808	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-809	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-810	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-811	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-812	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-813	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-814	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-815	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-816	ELECTRICAL SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-901	ELECTRICAL WIRING DIAGRAMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-902	ELECTRICAL WIRING DIAGRAMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-903	ELECTRICAL WIRING DIAGRAMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-904	ELECTRICAL WIRING DIAGRAMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-905	ELECTRICAL WIRING DIAGRAMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-E-906	ELECTRICAL WIRING DIAGRAMS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 14 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-P-000	PLUMBING COVER SHEET	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-200	PLUMBING UNDERGROUND PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210	PLUMBING FIRST FLOOR - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210A	PLUMBING FIRST FLOOR PLAN - SECTOR A - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210B	PLUMBING FIRST FLOOR PLAN - SECTOR B - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210C	PLUMBING FIRST FLOOR PLAN - SECTOR C - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210D	PLUMBING FIRST FLOOR PLAN - SECTOR D - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210E	PLUMBING FIRST FLOOR PLAN - SECTOR E - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210F	PLUMBING FIRST FLOOR PLAN - SECTOR F - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210G	PLUMBING FIRST FLOOR PLAN - SECTOR G - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210H	PLUMBING FIRST FLOOR PLAN - SECTOR H - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-210J	PLUMBING FIRST FLOOR PLAN - SECTOR J - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220	PLUMBING SECOND FLOOR PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220A	PLUMBING SECOND FLOOR PLAN - SECTOR A - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220B	PLUMBING SECOND FLOOR PLAN - SECTOR B - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220C	PLUMBING SECOND FLOOR PLAN - SECTOR C - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220D	PLUMBING SECOND FLOOR PLAN - SECTOR D - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220E	PLUMBING SECOND FLOOR PLAN - SECTOR E - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220F	PLUMBING SECOND FLOOR PLAN - SECTOR F - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220G	PLUMBING SECOND FLOOR PLAN - SECTOR G - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220H	PLUMBING SECOND FLOOR PLAN - SECTOR H - UTILITY PIPING	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-220J	PLUMBING SECOND FLOOR PLAN - SECTOR J - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300	PLUMBING UNDERGROUND PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300A	PLUMBING UNDERGROUND PLAN - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300B	PLUMBING UNDERGROUND PLAN - SECTOR B	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300C	PLUMBING UNDERGROUND PLAN - SECTOR C	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300D	PLUMBING UNDERGROUND PLAN - SECTOR D	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300E	PLUMBING UNDERGROUND PLAN - SECTOR E	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300F	PLUMBING UNDERGROUND PLAN - SECTOR F	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300G	PLUMBING UNDERGROUND PLAN - SECTOR G	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300H	PLUMBING UNDERGROUND PLAN - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-300J	PLUMBING UNDERGROUND PLAN - SECTOR J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310	PLUMBING FIRST FLOOR PLAN - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310A	PLUMBING FIRST FLOOR PLAN - SECTOR A - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310B	PLUMBING FIRST FLOOR PLAN - SECTOR B - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310C	PLUMBING FIRST FLOOR PLAN - SECTOR C - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310D	PLUMBING FIRST FLOOR PLAN - SECTOR D - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310E	PLUMBING FIRST FLOOR PLAN - SECTOR E - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310F	PLUMBING FIRST FLOOR PLAN - SECTOR F - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310G	PLUMBING FIRST FLOOR PLAN - SECTOR G - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310H	PLUMBING FIRST FLOOR PLAN - SECTOR H - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-310J	PLUMBING FIRST FLOOR PLAN - SECTOR J - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320	PLUMBING SECOND FLOOR PLAN - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320A	PLUMBING SECOND FLOOR PLAN - SECTOR A - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320B	PLUMBING SECOND FLOOR PLAN - SECTOR B - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320C	PLUMBING SECOND FLOOR PLAN - SECTOR C - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320D	PLUMBING SECOND FLOOR PLAN - SECTOR D - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320E	PLUMBING SECOND FLOOR PLAN - SECTOR E - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320F	PLUMBING SECOND FLOOR PLAN - SECTOR F - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320G	PLUMBING SECOND FLOOR PLAN - SECTOR G - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320H	PLUMBING SECOND FLOOR PLAN - SECTOR H - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-320J	PLUMBING SECOND FLOOR PLAN - SECTOR J - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-330	PLUMBING ROOF PLAN - DRAINAGE PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-420	PLUMBING ENLARGED PLANS	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-421	PLUMBING ENLARGED PLANS	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-422	PLUMBING ENLARGED PLANS	2	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-423	PLUMBING EXTERIOR FLOOR PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-430	PLUMBING ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-431	PLUMBING ENLARGED PLANS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-510	PLUMBING DOMESTIC WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-511	PLUMBING DOMESTIC WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-512	PLUMBING DOMESTIC WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-513	PLUMBING DOMESTIC WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-514	PLUMBING GREY WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-515	PLUMBING NON-POTABLE WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-520	PLUMBING TEPID WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-521	PLUMBING TEPID WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-522	PLUMBING TEPID WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-530	PLUMBING PROCESS WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 15 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-P-531	PLUMBING PROCESS WATER FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-540	PLUMBING SANITARY RISER DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-541	PLUMBING SANITARY RISER DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-542	PLUMBING SANITARY RISER DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-543	PLUMBING SANITARY RISER DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-550	PLUMBING STORMWATER RISER DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-551	PLUMBING STORMWATER RISER DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-552	PLUMBING STORMWATER RISER DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-553	PLUMBING STORMWATER RISER DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-560	PLUMBING PROCESS WASTE RISER DIAGRAM - PW1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-561	PLUMBING PROCESS WASTE RISER DIAGRAM - PW1	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-570	PLUMBING PROCESS WASTE RISER DIAGRAM - PW2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-571	PLUMBING PROCESS WASTE RISER DIAGRAM - PW2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-572	PLUMBING PROCESS WASTE RISER DIAGRAM - PW2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-573	PLUMBING PROCESS WASTE RISER DIAGRAM - PW2	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-580	PLUMBING NATURAL GAS FLOW DIAGRAM	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-701	PLUMBING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-702	PLUMBING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-703	PLUMBING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-704	PLUMBING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-705	PLUMBING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-706	PLUMBING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-801	PLUMBING SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-802	PLUMBING SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-P-803	PLUMBING SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
2-P-300	PLUMBING DRAINAGE PLAN		Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 16 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-FP-000	FIRE PROTECTION COVER SHEET	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010	FIRE PROTECTION FIRST FLOOR ZONING PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010A	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR A - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010B	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR B - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010C	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR C - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010D	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR D - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010E	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR E - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010F	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR F - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010G	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR G - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010H	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR H - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-010J	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR J - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-015	FIRE PROTECTION INTERSTITIAL ZONING PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-015F	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR F - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-015H	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR H - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-015J	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR J - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020	FIRE PROTECTION SECOND FLOOR ZONING PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020A	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR A - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020B	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR B - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020C	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR C - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020D	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR D - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020E	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR E - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020F	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR F - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020G	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR G - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020H	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR H - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-020J	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR J - DENSITY PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-200	FIRE PROTECTION UNDERGROUND PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210	FIRE PROTECTION FIRST FLOOR PLAN - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210A	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR A - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210B	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR B - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210C	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR C - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210D	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR D - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210E	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR E - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210F	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR F - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210G	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR G - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210H	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR H - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-210J	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR J - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-215	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-215F	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR F - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-215H	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR H - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-215J	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR J - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220	FIRE PROTECTION SECOND FLOOR PLAN - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220A	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR A - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220B	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR B - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220C	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR C - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220D	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR D - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220E	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR E - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220F	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR F - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220G	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR G - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220H	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR H - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-220J	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR J - SPRINKLER	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310	FIRE PROTECTION FIRST FLOOR PLAN - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310A	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR A - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310B	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR B - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310C	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR C - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310D	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR D - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310E	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR E - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310F	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR F - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310G	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR G - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310H	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR H - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-310J	FIRE PROTECTION FIRST FLOOR PLAN - SECTOR J - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-315	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-315F	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR F - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-315H	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR H - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-315J	FIRE PROTECTION INTERSTITIAL FLOOR PLAN - SECTOR J - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320	FIRE PROTECTION SECOND FLOOR PLAN - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320A	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR A - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320B	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR B - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320C	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR C - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320D	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR D - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320E	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR E - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320F	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR F - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320G	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR G - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320H	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR H - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-320J	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR J - PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-420D	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR D - CLEAN AGENT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-422D	FIRE PROTECTION SECOND FLOOR PLAN - SECTOR D - CLEAN AGENT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-701	FIRE PROTECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-702	FIRE PROTECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-703	FIRE PROTECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-704	FIRE PROTECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-800A	FIRE PROTECTION SCHEDULES - SECTOR A	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 17 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-FP-800B	FIRE PROTECTION SCHEDULES - SECTOR B	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-800C	FIRE PROTECTION SCHEDULES - SECTOR C	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-800D	FIRE PROTECTION SCHEDULES - SECTOR D	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-800E	FIRE PROTECTION SCHEDULES - SECTOR E	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-800F	FIRE PROTECTION SCHEDULES - SECTOR F	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-800G	FIRE PROTECTION SCHEDULES - SECTOR G	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-800H	FIRE PROTECTION SCHEDULES - SECTOR H	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-FP-800J	FIRE PROTECTION SCHEDULES - SECTOR J	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
2-FP-010	FIRE PROTECTION FIRST FLOOR DENSITY PLAN - FIRE PUMP HOUSE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
2-FP-701	FIRE PROTECTION FIRST FLOOR PLAN - FIRE PUMP HOUSE	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
2-FP-702	FIRE PROTECTION DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 18 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
1-PR-000	PROCESS PIPING COVER SHEET	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210	PROCESS PIPING FIRST FLOOR PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210A	PROCESS PIPING FIRST FLOOR PLAN - SECTOR A - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210B	PROCESS PIPING FIRST FLOOR PLAN - SECTOR B - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210C	PROCESS PIPING FIRST FLOOR PLAN - SECTOR C - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210D	PROCESS PIPING FIRST FLOOR PLAN - SECTOR D - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210F	PROCESS PIPING FIRST FLOOR PLAN - SECTOR F - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210G	PROCESS PIPING FIRST FLOOR PLAN - SECTOR G - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210H	PROCESS PIPING FIRST FLOOR PLAN - SECTOR H - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-210J	PROCESS PIPING FIRST FLOOR PLAN - SECTOR J - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-220	PROCESS PIPING SECOND FLOOR PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-220A	PROCESS PIPING SECOND FLOOR PLAN - SECTOR A - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-220B	PROCESS PIPING SECOND FLOOR PLAN - SECTOR B - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-220C	PROCESS PIPING SECOND FLOOR PLAN - SECTOR C - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-220D	PROCESS PIPING SECOND FLOOR PLAN - SECTOR D - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-220F	PROCESS PIPING SECOND FLOOR PLAN - SECTOR F - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-220G	PROCESS PIPING SECOND FLOOR PLAN - SECTOR G - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-220H	PROCESS PIPING SECOND FLOOR PLAN - SECTOR H - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-401	PROCESS PIPING EXTERIOR FLOOR PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-402	PROCESS PIPING ENLARGED PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-403	PROCESS PIPING ENLARGED PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-404	PROCESS PIPING ENLARGED PLAN - UTILITY PIPING	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-410	PROCESS PIPING PROCESS EQUIPMENT - ARRANGEMENT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-411	PROCESS PIPING WASTE NEUTRALIZATION EQUIPMENT - ARRANGEMENT	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-451	PROCESS ENLARGED PIPING PLAN SECOND FLOOR SECTOR H	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-452	PROCESS ENLARGED PIPING PLAN SECOND FLOOR SECTOR H	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-510	PROCESS PIPING PROCESS EQUIPMENT - HOUSEKEEPING PAD PLAN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-511	PROCESS PIPING WASTE NEUTRALIZATION EQUIPMENT - HOUSEKEEPING PAD	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-551	PROCESS PIPING SECTIONS SECOND FLOOR	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-552	PROCESS PIPING SECTIONS SECOND FLOOR	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-810	PROCESS PIPING SCHEDULES	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-901	PROCESS DETAIL SHEET #1 OFF-LOAD BOX, TP-002 & TP-003	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-902	PROCESS DETAIL SHEET #2 WASTE TANKS TK-026 & TK-027	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-903	PROCESS DETAIL SHEET #3 UTILITY PANELS UP-002 & UP-003	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-904	PROCESS DETAIL SHEET #4 FORMULATION #2 & #3 PLATFORMS	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-905	PROCESS DETAIL SHEET #5 FORMULATION TANKS TK-002 & TK-003	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-906	PROCESS DETAIL SHEET #6 FORMULATION TANKS TK-002 & TK-003	0	IFC Package	Dec 7, 2018 12:00 AM
1-PR-910	PROCESS PIPING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-911	PROCESS PIPING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-912	PROCESS PIPING DETAILS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PR-920	PROCESS PIPING 3D VIEWS	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
1-PRP-210G	PROCESS PIPING PLAN FIRST FLOOR SECTOR G	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRP-210H	PROCESS PIPING PLAN FIRST FLOOR SECTOR H	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRP-220G	PROCESS PIPING PLAN SECOND FLOOR SECTOR G	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRP-220H	PROCESS PIPING PLAN SECOND FLOOR SECTOR H	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRQ-210F	EQUIPMENT ARRANGEMENT FIRST FLOOR PLAN SECTOR F	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRQ-210G	EQUIPMENT ARRANGEMENT FIRST FLOOR PLAN SECTOR G	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRQ-210H	EQUIPMENT ARRANGEMENT FIRST FLOOR PLAN SECTOR H	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRQ-210J	EQUIPMENT ARRANGEMENT FIRST FLOOR PLAN SECTOR J	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRQ-220G	EQUIPMENT ARRANGEMENT SECOND FLOOR PLAN SECTOR G	0	IFC Package	Dec 7, 2018 12:00 AM
1-PRQ-220H	EQUIPMENT ARRANGEMENT SECOND FLOOR PLAN SECTOR H	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7001	PROCESS & INSTRUMENTATION DIAGRAM LEGEND SHEET #1	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7002	PROCESS & INSTRUMENTATION DIAGRAM LEGEND SHEET #2	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7003	PROCESS & INSTRUMENTATION DIAGRAM LEGEND SHEET #3	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7011	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE & IV FORMULATION SUITE	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7012	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE & IV FORMULATION SUITE	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7014	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE & IV FORMULATION	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7016	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE & IV API DISPENSING	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7017	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE & IV FORMULATION WASH	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7020	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE FILLERS 1 & 2	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7021	PROCESS & INSTRUMENTATION DIAGRAM IV FILLERS	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7022	PROCESS & INSTRUMENTATION DIAGRAM TERMINAL STERILIZER	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7023	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE PACKAGING LINE &	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7030	PROCESS & INSTRUMENTATION DIAGRAM SMALL VOLUME 503B	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7040	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE & IV FILLER PARTS	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7041	PROCESS & INSTRUMENTATION DIAGRAM SYRINGE/IV FILLER AUTOCLAVE	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7050	PROCESS & INSTRUMENTATION DIAGRAM OINTMENT HOMOGENIZER & SACHET	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7051	PROCESS & INSTRUMENTATION DIAGRAM OINTMENT SUITE WASH	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7150	PROCESS & INSTRUMENTATION DIAGRAM CENTRAL PHARMACY DOWNFLOW	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7151	PROCESS & INSTRUMENTATION DIAGRAM MICRO LAB AUTOCLAVE	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7152	PROCESS & INSTRUMENTATION DIAGRAM ENVIRONMENTAL CHAMBERS SHEET	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7153	PROCESS & INSTRUMENTATION DIAGRAM ENVIRONMENTAL CHAMBERS SHEET	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7160	PROCESS & INSTRUMENTATION DIAGRAM PARENTERAL CIP SKID 1	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7161	PROCESS & INSTRUMENTATION DIAGRAM PARENTERAL CIP SKID 2	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7163	PROCESS & INSTRUMENTATION DIAGRAM CIP DISTRIBUTION	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7301	PROCESS & INSTRUMENTATION DIAGRAM WATER PRETREATMENT	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7320	PROCESS & INSTRUMENTATION DIAGRAM WFI GENERATORS	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7322	PROCESS & INSTRUMENTATION DIAGRAM WFI TANK & PUMPS	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7323	PROCESS & INSTRUMENTATION DIAGRAM WFI DISTRIBUTION SHEET #1	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7324	PROCESS & INSTRUMENTATION DIAGRAM WFI DISTRIBUTION SHEET #2	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7325	PROCESS & INSTRUMENTATION DIAGRAM WFI DISTRIBUTION SHEET #3	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7330	PROCESS & INSTRUMENTATION DIAGRAM ROW SYSTEM	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7401	PROCESS & INSTRUMENTATION DIAGRAM PURE STEAM GENERATOR	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7402	PROCESS & INSTRUMENTATION DIAGRAM PURE STEAM DISTRIBUTION	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7501	PROCESS & INSTRUMENTATION DIAGRAM OFCA SYSTEM	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7502	PROCESS & INSTRUMENTATION DIAGRAM OFCA DISTRIBUTION SHEET #1	0	IFC Package	Dec 7, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 19 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
PR-7503	PROCESS & INSTRUMENTATION DIAGRAM OFCA DISTRIBUTION SHEET #2	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7650	P&ID NITROGEN	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7651	P&ID HELIUM	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7652	P&ID ARGON	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
PR-7653	P&ID HYDROGEN	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
PR-7660	P&ID OIL FREE COMPRESSED AIR - LAB	1	Bulletin0020-IFCPermitIssue	Dec 14, 2018 12:00 AM
PR-7701	PROCESS & INSTRUMENTATION DIAGRAM PW2 LIFT STATION	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7702	PROCESS & INSTRUMENTATION DIAGRAM PW2 SUMP PUMP	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7703	PROCESS & INSTRUMENTATION DIAGRAM PW2 EQUALIZATION TANKS & PUMPS	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7704	PROCESS & INSTRUMENTATION DIAGRAM pH NEUTRALIZATION	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7706	PROCESS & INSTRUMENTATION DIAGRAM PW1 LIFT STATION	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7707	PROCESS & INSTRUMENTATION DIAGRAM PW1 COLLECTION TANK	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7801	PROCESS & INSTRUMENTATION DIAGRAM PROCESS COOLING TOWER WATER	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7802	PROCESS & INSTRUMENTATION DIAGRAM PROCESS CHILLED WATER	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7803	PROCESS & INSTRUMENTATION DIAGRAM PROCESS CHILLED WATER	0	IFC Package	Dec 7, 2018 12:00 AM
PR-7804	PROCESS & INSTRUMENTATION DIAGRAM PROCESS CHILLED WATER	0	IFC Package	Dec 7, 2018 12:00 AM

1/13/2019


	Athenex GMP Drawing List	Exhibit 3 (p. 20 of 20)

Sheet No.	Sheet Name	Rev	Set Name	Issuance Date
IC-201	PROCESS CONTROLS SYSTEM ARCHITECTURE PART 1	C	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-202	PROCESS CONTROLS SYSTEM ARCHITECTURE PART 2	F	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-203	PROCESS CONTROLS SYSTEM ARCHITECTURE PART 3	B	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-221	ENVIRONMENTAL MONITORING SYSTEM NETWORK ARCHITECTURE	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-301	INSTRUMENT LOCATION DRAWING FIRST FLOOR PLAN SECTOR H	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-302	INSTRUMENT LOCATION DRAWING FIRST FLOOR PLAN SECTOR G	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-303	INSTRUMENT LOCATION DRAWING FIRST FLOOR PLAN SECTOR H	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-304	INSTRUMENT LOCATION DRAWING FIRST FLOOR PLAN SECTOR J	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-305	INSTRUMENT LOCATION DRAWING SECOND FLOOR PLAN SECTOR G	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-306	INSTRUMENT LOCATION DRAWING SECOND FLOOR PLAN SECTOR H	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-307	INSTRUMENT LOCATION DRAWING ENLARGED PLAN - UTILITY PIPING SHEET 2	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-308	INSTRUMENT LOCATION DRAWING ENLARGED PLAN - UTILITY PIPING SHEET 1	A	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-321	EMS INSTRUMENT LOCATION PLAN FIRST FLOOR SECTOR D	E	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-322	EMS INSTRUMENT LOCATION PLAN FIRST FLOOR SECTOR F	C	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-323	EMS INSTRUMENT LOCATION PLAN FIRST FLOOR SECTOR G	C	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-324	EMS INSTRUMENT LOCATION PLAN FIRST FLOOR SECTOR H	C	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-325	EMS INSTRUMENT LOCATION PLAN FIRST FLOOR - SECTOR J	D	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-326	EMS INSTRUMENT LOCATION PLAN SECOND FLOOR SECTOR H	E	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-327	EMS CONTROL PANEL LAYOUT FIRST FLOOR SECTOR D	E	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-328	EMS CONTROL PANEL LAYOUT FIRST FLOOR SECTOR G	C	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-329	EMS CONTROL PANEL LAYOUT FIRST FLOOR SECTOR J	D	A101 Bid Package Documents	Oct 4, 2018 12:00 AM
IC-SK-330	EMS CONTROL PANEL LAYOUT SECOND FLOOR SECTOR J	C	A101 Bid Package Documents	Oct 4, 2018 12:00 AM

1/13/2019

Athenex GMP Staffing

EXHIBIT 4

Athenex Staffing	Exyte U.S. Inc & Pike Company
Project Number:21559	Project Name:Athenex Mnfg. Facility

Name	Role	Full or Part		Hourly Rate	Location	Unit of Time
Name	Role	Time		Effective 4/1/19	Remote/On-site	Unit of Time
Anibaldi, Joe	General Superintendent - Pike	Full Time	$	155.25	On-site	Through Completion
Atkinson, Robert J	Project Estimator L1	Part Time	$	148.17	Remote	Part time for procurement
Bauman, John	Construction Project Engineer	Full Time	$	110.00	On-site	Complete as of 1/11/19
Brennan, Niall	MEP Superintendent L3	Full Time	$	140.96	On-site	Through Completion
Brewster, Gerald	MEP Construction Manager Mgmt L1	Full Time	$	153.21	On-site	Through Completion
Cain, Andrew J (Drew)	Project Estimator L1	Part Time	$	148.17	Remote	Part time for procurement
Carlson, Carl J	Sr. Process Engineer	Part Time	$	128.70	Remote	Part time for design
Ciminelli, Gloria	Procurement Manager - Pike	Part Time	$	115.00	Remote	Part time for procurement
Clancy, Andrea	Cost Control L1 - Pike	Full Time	$	110.31	On-site	Through Completion
Clemens, Destiny	EHS Administration Support L1	Full Time	$	56.65	On-site	Through Completion
Crewdson, Benjamin H (Ben)	Construction Project Engineer	Full Time	$	110.00	On-site	Through Completion
Crowe, Timmy	Sr. Project Management	Part Time	$	213.06	Remote	Part time for design
Davis, William F (Bill)	Sr. CAD/Piping Designer	Part Time	$	128.70	Remote	Part time for design
Diaz, Juan O	Sr. Process Engineer	Part Time	$	128.70	Remote	Part time for design
Drayton, Carol	Project Acctg/Admin	Full Time	$	96.25	Remote	Through Completion
Driscoll, Michael J.	MEP Construction Manager Mgmt L1	Full Time	$	153.21	On-site	Through Completion
England, Christopher B.S. (Chris)	Process QA L3	Part Time	$	105.06	Remote	Part time for design
Falanga, Dylan	CAD/BIM Designer - Pike	Part Time	$	110.31	Remote	As-Needed
Francis, Justin	Project Director - Pike	Full Time	$	213.06	On-site	Through Completion
Holden, Gareth J	Project Estimator L1	Part Time	$	148.17	Remote	Part time for procurement
Jehring, John R.	Sr. Manager Architectural	Part Time	$	176.39	Remote	As-Needed
Jenkins, Ikea	Construction Project Engineer - Pike	Full Time	$	85.00	On-site	Through Completion
Kalb, John	Scheduler - Pike	Part Time	$	128.62	Remote	As-Needed
Kane, Toni	Project Acctg/Admin - Pike	Part Time	$	85.00	Remote	As-Needed
Kelly, Robert J (Rob)	CAD/BIM Designer	Part Time	$	110.31	Remote	Part time for design
Knight, Roger O	Project Estimator L1	Part Time	$	148.17	Remote	Part time for procurement
Kotosky, Richard (Rick)	Architectural Lead	Part Time	$	176.39	Remote	Part time for design
Kretzschmar, Jon	Project Estimator L1	Part Time	$	148.17	Remote	Part time for procurement
LaMarre, Nicole	Procurement Manager	Part Time	$	141.11	Remote	Part time for procurement
Langley, Derrick D	CAD/BIM Designer	Part Time	$	110.31	Remote	As-Needed
Licursi, Steven (Steve)	Procurement Manager	Part Time	$	141.11	Remote	Part time for procurement
Lou, Raymond	Sr. Project Management	Part Time	$	213.06	Remote	Complete as of 1/11/19
Madrigal, Luis A.	MEP Construction Manager Mgmt L1	Part Time	$	153.21	Remote	As-Needed
Maeillaro, Derek	MEP Construction Manager Mgmt L1	Full Time	$	153.21	On-site	Through Completion
Marcinak, Susan A (Susan)	Project Acctg/Admin	Full TIme	$	96.25	Remote	Through Completion
Mascho, Danelle	Project Acctg/Admin - Pike	Full Time	$	96.25	On-site	Through Completion
McGowan, Joseph	EHS Field	Full Time	$	100.84	On-site	Through Completion
Mehltretter, Peter Glenn	Sr. Manager Architectural	Part Time	$	176.39	Remote	As-Needed
Mills, Jarrod L	Construction Project Engineer	Full Time	$	110.00	On-site	Through Completion
Montoya, Tody A	MEP Construction Manager Mgmt L1	Full Time	$	153.21	On-site	Through Completion
Moyer, Paul	Project Executive - Pike	Part Time	$	213.06	Remote	As-Needed
Murray, Marc	Project Estimator L1 - Pike	Part Time	$	115.00	Remote	As-Needed
Nabaty, Fadi S	Project Estimator L1	Part Time	$	148.17	Remote	Part time for procurement
Nguyen, Kim T. (Kimmie)	Administration/Doc Control	Part Time	$	81.11	Remote	Part time for procurement
Ogle, Carrie A	Cost Control L1	Full Time	$	110.31	On-site	Through Completion
Ogle, John L III (Lee)	Sr. Project Management	Full Time	$	213.06	On-site	Through Completion
Olsen, Daniel O	Sr. Project Management	Part Time	$	213.06	Remote	As-Needed
Paolotto, Mary	Project Acctg/Admin - Pike	Part Time	$	85.00	Remote	As-Needed
Pearce, William M (Michael)	Architectural Lead	Part Time	$	176.39	Remote	As-Needed
Rajski, Dave	CSA Superintendent L3 - Pike	Full Time	$	125.00	On-site	Through Completion
Rice, Courtney	Administration/Doc Control	Full Time	$	81.11	On-site	Through Completion
Reed, Tim	Construction Project Engineer - Pike	Full Time	$	85.00	On-site	Through Completion
Retzlaff, Scott	Project Estimator L1 - Pike	Part Time	$	115.00	Remote	As-Needed
Roberts, Gerald (Jerry)	General Superintendent	Full Time	$	176.39	On-site	Through Completion
Sanders, Tommy G	MEP Superintendent L3	Full Time	$	140.96	On-site	Through Completion
Stropoli, Carmine Marco	Process Director	Part Time	$	213.06	Remote	Through Completion
Tang, Keith L	Process Engineer L2	Part Time	$	96.25	Remote	Through Completion
Thompson, David Mike (Mike)	MEP Construction Manager Mgmt L1	Part Time	$	153.21	Remote	As-Needed
Tran, Vu	Cost Control L1	Part Time	$	110.31	Remote	Transition to Scheduler 2/1/19
Tran, Vu	Scheduler	Part Time	$	148.17	Remote	Through Completion
Traylor, Joneta	CAD/BIM Designer - Pike	Part Time	$	110.31	Remote	As-Needed
Urschel, Debra D	Administration/Doc Control	Part Time	$	81.11	Remote	As-Needed
Wilson, Miles	Administration/Doc Control	Full Time	$	81.11	On-site	Through Completion
Zakroczemski, Dave	CSA Superintendent L3 - Pike	Full Time	$	125.00	On-site	Through Completion
Zurek, William A.	Project Management	Full Time	$	213.06	On-site	Through Completion

3/1/2019

CONFIDENTIAL

Exyte U.S., Inc.
March 9, 2019 Athenex Attention: Mr. Rich Nassar 1001Main Street, Suite 600 Buffalo, NY 14203					Contact LeeOgle Phone 845.775.6739 Lee , Ogle@exyte . ne t

Via email to: Rich Nassar <massar@athenex.com> RE: Athenex Project - GMP and 703 Invoice Dear Mr.Nassar

As requested, this letter is to confirm the Invoicing for the GMP, executed 3/8/19, shall be processed via the format of the attached AIA document. (Please see page 2 , "Athenex GMP -Agreed G-703 for Invoicing")

The executed GMP value of $212,594,806 shall be the basis of the Invoicing and will only change via approved change orders between Athenex and Exyte .

Please confirm Athenex agreement by signing below .

Sincerely,

Lee Ogle Exyte U.S . Inc . Project Director

Rich Nassar

Athenex

Vice President of Operations

cc : KenAnthony - Vice President Bill Zurek - Project Manager

CONTINUATION SHEET

Contractor's signed certification is attached.

In tabulations below, amounts are stated to the nearest dollar.

Use Column I on Contracts where variable retainage for line items may apply.


A	B			E		F		G
	DESCRIPTION OF WORK	Vendor
ITEM				SCHEDULED		CHANGE		REVISED
NO.				VALUE		ORDERS		SCHEDULED
	CONSULTING SERVICES AGREEMENT EXHIBIT A - CONCEPTUAL DESIGN REVIEW
1	PO 091716 - Concept Revisit - M+W	Exyte	$	251,640.00	$	0.00	$	251,640.00
2	Genesis Engineering	Genesis	$	43,360.00	$	0.00	$	43,360.00

	CSA- EXHIBIT B- LIMITED SITE SERVICES (PRELIMINARY SITE WORK)
3	PO AP091706 Early Civil Works & PO AP091707 Borings & Test Pits - CPL	CPL	$	28,100.00	$	11,000.00	$	39,100.00
4	PO AP091704 Brush Clearing	Pike	$	25,000.00	$	3,403.00	$	28,403.00
5	PO AP091708 CM Services	Pike	$	20,000.00	$	0.00	$	20,000.00
6	PO AP091708 CM Services Fee	Exyte	$	1,125.00	-$	500.00	$	625.00
7	PO 121708 Concept Revisit Design Mgmt	Exyte	$	17,000.00	$	0.00	$	17,000.00
	CSA-REVISION 1 - EXHIBIT D - BOD BRIDGING - PO 091717
8	Accelerated BOD (1,309,885.00)
9	Genesis	Genesis	$	552,659.00	$	0.00	$	552,659.00
10	Exyte	Exyte	$	657,226.00	-$	400.00	$	656,826.00
11	Ryan Biggs SE	Ryan Biggs	$	100,000.00	$	0.00	$	100,000.00
12	Exyte	Exyte	$	22,000.00	$	0.00	$	22,000.00
13	Pike	Pike	$	13,000.00	$	0.00	$	13,000.00
14	Pike	Pike	$	67,000.00	$	0.00	$	67,000.00
15	Exyte	Exyte	$	102,000.00	$	0.00	$	102,000.00
16	Fencing		$	135,000.00	-$	135,000.00	$	0.00
17	Civil EngineeringCPL	CPL	$	134,600.00	$	0.00	$	134,600.00
18	Detailed Design ServicesCPL	CPL	$	65,700.00	$	400.00	$	66,100.00
19	M+W Travel Allowance - PO 011825	Exyte	$	50,000.00	$	46,303.57	$	96,303.57
	AIA BOD FINAL PO 121715
20	Exyte Design Estimate	M+W	$	747,647.00	$	0.00	$	747,647.00
21	PAS Consulting Instrumentation	PAS	$	85,302.00	$	0.00	$	85,302.00
22	Genesis MEP	Genesis	$	552,659.00	$	0.00	$	552,659.00
23	Genesis Adds: Lab-Utilities	Genesis	$	82,500.00	$	0.00	$	82,500.00
24	Genesis Add MEP Diagrams	Genesis	$	39,158.00	$	0.00	$	39,158.00
25	Exyte Construction Estimate	Exyte	$	75,000.00	$	0.00	$	75,000.00
26	Exyte Construction Team	Exyte	$	180,000.00	$	0.00	$	180,000.00
27	Ryan Biggs SE	Ryan Biggs	$	350,000.00	$	0.00	$	350,000.00
28	Pike CSA Team	Pike	$	110,000.00	$	0.00	$	110,000.00
	AIA DETAIL DESIGN ALLOWANCE - PO 041816
29	Exyte Design	Exyte	$	2,088,956.90	$	0.00	$	2,088,956.90
30	Consulting Instrumentation	PAS	$	372,928.00	$	0.00	$	372,928.00
31	Genesis MEP Genesis	Genesis	$	2,218,318.00	$	0.00	$	2,218,318.00
32	Ryan Biggs SE		$	100,000.00	$	0.00	$	100,000.00
33	Civil Engineering	CPL	$	0.00	$	15,000.00	$	15,000.00
34	Lynn Critical	Lynn Critical	$	75,000.00	$	0.00	$	75,000.00
35	Uncommitted		$	613,961.00	-$	330,861.00	$	283,100.00
36	Exyte Printing,Postage	Exyte	$	200,000.00	$	0.00	$	200,000.00
37	Exyte Travel Allowance	Exyte	$	102,120.00	$	315,861.00	$	417,981.00
	AIA DESIGN CONSTRUCTION ADMINISTRATION PO 041816
38	Uncommitted	0	$	1,230,128.00	$	416,530.00	$	813,598.00
39	Exyte Design	Exyte	$	955,821.53	$	0.00	$	955,821.53
40	Genesis MEP	Genesis	$	159,660.00	-$	416,530.00	$	576,190.00
41	Ryan Biggs SE		$	75,000.00	$	0.00	$	75,000.00
42	Civil Engineering	CPL	$	131,100.00	$	0.00	$	131,100.00
43	Exyte Printing, Postage	Exyte	$	25,000.00	$	0.00	$	25,000.00
44	ExyteTravel Allowance	Exyte	$	15,000.00	$	0.00	$	15,000.00
	AIA EPCM SERVICES - PO 041816
45	Exyte Construction	Exyte	$	9,267,648.00	$	0.00	$	9,267,648.00
46	Pike Construction	Pike	$	2,851,378.00	$	0.00	$	2,851,378.00
	AIA EPCM GENERAL CONDITIONS - PO 041816
47	Exyte Construction	Exyte	$	560,000.00	$	0.00	$	560,000.00
48	Pike Construction	Pike	$	40,000.00	$	0.00	$	40,000.00
	Uncommitted	Exyte	$	2,097,883.00	$	0.00	$	2,097,883.00
	SUBTOTAL COSTS		$	27,687,578.43	-$	74,793.43	$	27,612,785.00
	GENERAL REQUIREMENTS
49	Division 01 - General Requirements
	Uncommitted		$	4,407,422.50	-$	14,872.01	$	4,392,550.49
	American Rated Cable	Exyte	$	145,500.00	-$	4,754.94	$	140,745.06
	Dell Marketing	Exyte	$	3,069.36	$	0.00	$	3,069.36
	Rodriquez Construction	Exyte	$	33,140.00	$	8,076.37	$	41,216.37
	Williams Scotsman	Exyte	$	228,311.96	$	9,210.00	$	237,521.96
	DFT Communications	Exyte	$	28,601.00	$	0.00	$	28,601.00
	Franz & Russell Sanitary Svc	Pike	$	1,472.18	$	0.00	$	1,472.18
	Saia Communications	Exyte	$	2,490.00	$	0.00	$	2,490.00
	S St George	S St George	$	0.00	$	2,340.58	$	2,340.58
50	Division 03 - Concrete
	Uncommitted		$	5,163,257.00	-$	1,293,675.42	$	3,869,581.58
	State Group	State Group	$	5,781,000.00	$	1,293,675.42	$	7,074,675.42
54	Division 04 - Masonry
	Uncommitted		$	2,336,042.00	$	0.00	$	2,336,042.00
51	Division 05 - Metals
	Stonebridge	Stone Bridge	$	9,044,647.97	$	1,909,089.73	$	10,953,737.70
	Mader	Mader	$	703,860.00	$	0.00	$	703,860.00


	Uncommitted		$	6,154,611.03	-$	1,909,089.73	$	4,245,521.30
52	Division 07 - Thermal Moisture Protection
	Uncommitted		$	1,699,492.00	$	0.00	$	1,699,492.00
	AW Farrell	AW Farrell	$	2,772,000.00	$	0.00	$	2,772,000.00
	Building Innovations	Building Innovations	$	2,553,083.00	$	0.00	$	2,553,083.00
53	Division 08 - Openings
	Uncommitted		$	1,272,298.00	$	0.00	$	1,272,298.00
54	Division 09 - Finishes
	Uncommitted		$	11,234,602.00	$	0.00	$	11,234,602.00
53	Division 10 - Specialties
	Uncommitted		$	602,053.00	$	0.00	$	602,053.00
55	Division 11 - Equipment
	Uncommitted		$	1,375,099.00	$	0.00	$	1,375,099.00
	Custom Vault	Custom Vault	$	12,760.00	$	0.00	$	12,760.00
53	Division 12 - Furnishings
	Uncommitted		$	753,000.00	$	0.00	$	753,000.00
56	Division 13 - Special Construction
	Uncommitted		$	4,894,067.00	$	0.00	$	4,894,067.00
57	Division 14 - Conveying Equipment
	Uncommitted		$	406,400.00	$	0.00	$	406,400.00
58	Division 21 - Fire Protection
	Uncommitted		$	2,064,600.00	$	0.00	$	2,064,600.00
	FACILITY SERVICES
59	Division 22 - Plumbing
	Uncommitted		$	3,534,337.00	$	0.00	$	3,534,337.00
	WM Spaeder	WM Spaeder	$	2,593,039.00	$	0.00	$	2,593,039.00
60	Division 23 - HVAC
	Uncommitted		$	22,812,798.00	$	0.00	$	22,812,798.00
	Superior Boiler Works, Inc	Superior Boiler Works, Inc	$	1,001,914.00	$	0.00	$	1,001,914.00
	Pro Air Plus, Inc	Pro Air Plus, Inc	$	210,000.00	$	0.00	$	210,000.00
	Modular Comfort Systems	Modular Comfort Systems	$	549,074.00	$	0.00	$	549,074.00
	Johnson Controls, Inc.	Johnson Controls, Inc.	$	606,639.00	$	0.00	$	606,639.00
61	Division 25 - Integrated Automation
	Uncommitted		$	9,129,149.00	$	0.00	$	9,129,149.00
62	Division 26 - Electrical
	Uncommitted		$	16,708,263.00	-$	611,005.67	$	16,097,257.33
	Kinsley	Kinsley	$	606,739.00	$	0.00	$	606,739.00
	Ferguson Electric - Underground	Ferguson - Pike	$	2,268,261.00	$	611,005.67	$	2,879,266.67
	Ferguson Electric - Switchyard	Ferguson - Exyte	$	6,325,000.00	$	0.00	$	6,325,000.00
61	Division 27 - Communications
	Uncommitted		$	1,551,000.00	$	0.00	$	1,551,000.00
61	Division 28 - Electronic Safety & Security
	Uncommitted		$	336,758.00	$	0.00	$	336,758.00
	SITE AND INFRASTRUCTURE
63	Division 31 - Earthwork
	S.St. George	S St George	$	5,672,148.66	$	266,544.54	$	5,938,693.20
	Uncommitted		$	595,017.34	-$	266,544.54	$	328,472.80
64	Division 32 - Exterior Improvements
	Uncommitted		$	1,400,350.12	$	1,209,100.19	$	191,249.93
	S. St. George	S St George	$	446,669.88	$	1,209,100.19	$	1,655,770.07
65	Division 33 - Utilities
	S. St. George	S St George	$	2,047,592.46	$	179,377.26	$	2,226,969.72
	Uncommitted		$	3,388,439.54	-$	179,377.26	$	3,209,062.28
66	Division 41 - Material Processing & Handling Equipment
	Uncommitted		$	14,552,248.00	$	0.00	$	14,552,248.00
	SUBTOTAL COW		$	160,008,316.00	$	0.00	$	160,008,316.00
67	CONTINGENCY
	Contingency		$	13,187,324.00	$	0.00	$	13,187,324.00
	Yet-To-Buy		$	4,804,470.00	$	0.00	$	4,804,470.00
	AIA INSURANCE COST - M+W FEE - PO 041816
68	Exyte Insurance Cost	Exyte	$	1,600,371.00	$	0.00	$	1,600,371.00
	Pike Insurance Cost	Pike	$	30,613.00	$	0.00	$	30,613.00
69	Exyte Fee	Exyte	$	4,000,927.00	$	0.00	$	4,000,927.00
	Pike Fee	Pike	$	1,350,000.00	$	0.00	$	1,350,000.00
	TOTAL PROJECT COST		$	212,669,599.43	-$	74,793.43	$	212,594,806.00

Page 1 of 1 5/8/2019 1:20 PM

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Johnson Y.N. Lau, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Athenex, Inc. (the registrant);
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant ’ s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c)	Evaluated the effectiveness of the registrant ’ s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d)	Disclosed in this report any change in the registrant ’ s internal control over financial reporting that occurred during the registrant ’ s most recent fiscal quarter (the registrant ’ s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant ’ s internal control over financial reporting; and
5.	The registrant ’ s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant ’ s auditors and the audit committee of the registrant ’ s board of directors (or persons performing the equivalent functions):
	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant ’ s ability to record, process, summarize and report financial information; and
	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant ’ s internal control over financial reporting.

Date: May 9, 2019

/s/ Johnson Y.N. Lau
Name:		Johnson Y.N. Lau
Title:		Chief Executive Officer and Board Chairman
(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Randoll Sze, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Athenex, Inc. (the registrant);
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant ’ s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c)	Evaluated the effectiveness of the registrant ’ s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d)	Disclosed in this report any change in the registrant ’ s internal control over financial reporting that occurred during the registrant ’ s most recent fiscal quarter (the registrant ’ s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant ’ s internal control over financial reporting; and
5.	The registrant ’ s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant ’ s auditors and the audit committee of the registrant ’ s board of directors (or persons performing the equivalent functions):
	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant ’ s ability to record, process, summarize and report financial information; and
	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant ’ s internal control over financial reporting.

Date: May 9, 2019

/s/ Randoll Sze
Name:		Randoll Sze
Title:		Chief Financial Officer
(Principal Financial and Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In accordance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Johnson Y.N. Lau, Chief Executive Officer and Board Chairman (Principal Executive Officer) of Athenex, Inc. (the “ registrant ” ), and Randoll Sze, Chief Financial Officer of the registrant (Principal Financial Officer), each hereby certifies that, to the best of their knowledge:

1.	The registrant ’ s Quarterly Report on Form 10-Q for the period ended March 31, 2019, to which this Certification is attached as Exhibit 32.1 (the “ Report ” ), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition of the registrant at the end of the period covered by the Report and results of operations of the registrant for the period covered by the Report.

Date: May 9, 2019

/s/ Johnson Y.N. Lau
Name:		Johnson Y.N. Lau
Title:		Chief Executive Officer and Board Chairman
(Principal Executive Officer)

/s/ Randoll Sze
Name:		Randoll Sze
Title:		Chief Financial Officer
(Principal Financial and Accounting Officer)